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Abstract 
 
Tracking cell migration in vivo by scintigraphy using cells labelled with gamma-
emitting radionuclides (especially indium-111) is a well-established clinical and 
research tool. Positron emission tomography offers improved sensitivity and 
resolution, but there are no established cell labelling methods using suitable long-
lived isotopes. The long half-life positron emitter zirconium-89 (half-life 78.4 h) is a 
strong candidate for cell labelling and cell tracking, and is becoming increasingly 
available. It has no known biological role or transport mechanisms.  
 
The aim of this research was to produce a range of candidate neutral zirconium L4 
lipophilic complexes that could be prepared under radiopharmaceutical conditions 
and used in cell labelling. This aim was achieved with the ligands; oxine, tropolone 
and ethyl maltol. The resulting complexes can be prepared in high yield from 
zirconium precursors in hydrochloric or oxalic acid solution. A deferiprone complex 
was prepared from deferiprone and zirconium tetrachloride, but was found to lack 
lipophilic properties and it was not possible to prepare the deferiprone complex 
under radiopharmaceutical conditions. 
 
Analytical techniques such as carbon, hydrogen and nitrogen elemental analysis, 
nuclear magnetic resonance spectroscopy, fourier transform infrared spectroscopy, 
and Raman spectroscopy have been used to characterise the complexes. The oxine 
and tropolone complexes were the most amenable to chromatographic 
characterisation and high performance liquid chromatography and instant thin layer 
chromatography protocols have been established to monitor radiochemical purity. 
 
Cell uptake and efflux of zirconium-89 tetrakisoxine, tropolone and ethyl maltol 
utilising the following cell lines was determined; HCT116: colon cancer, J774: 
mouse macrophage and MDA-MB-231: breast cancer. Zirconium-89 tetrakisoxine 
has emerged as a lead compound. Zirconium-89 tetrakisoxine labelled myeloma cells 
retained the radiotracer in vivo for up to 7 days.  Zirconium-89 tetrakisoxine was 
found to be a promising cell tracking agent for long term cell tracking studies. 
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CHAPTER 1 
Introduction 
 
1.1. Medical Imaging 
 
Medical imaging refers to several different technologies that are used to view the 
human body in order to diagnose, monitor, or treat medical conditions. Each type of 
technology gives different information about the area of the body being studied or 
treated, related to possible disease, injury, or the effectiveness of medical treatment. 
 
Methods of medical imaging that are based on X-ray technology include traditional 
X-ray, mammography, computed tomography (CT) fluoroscopy and angiography. 
If there is a need to enhance an X-ray image it is possible to enhance the image with 
contrast agents. These contrast agents are used in angiography examinations.1 
 
Diagnostic ultrasound methods employ high-frequency sound waves which produce 
images of internal body organs and soft tissues.2 This is a painless test which is 
commonly used to monitor the growth of an unborn child, detect abnormalities of 
heart structures and detect abnormal widening of blood vessels (aneurysms).2 
 
Magnetic resonance imaging (MRI) operates without the use of ionizing radiation 
unlike conventional X-ray, CT and Molecular Imaging. MRI uses strong magnetic 
fields to visualize internal structures of the body in more detail than X-rays. MRI 
produces no known irreversible biological effects in humans.1 
 
Nuclear imaging is a method of producing images of different parts of the body after 
a radioactive tracer material is administered. Radiation is detected and the images are 
recorded on computer and on film. In the majority of cases radioactive tracers used in 
nuclear medicine are injected intravenously.3 During a typical nuclear imaging scan 
the amount of radiation a patient receives is very low. Molecular imaging in nuclear 
medicine uses methods to visualize biological processes in the cells of organisms. 
Radioactive markers, called radiopharmaceuticals, are used for molecular imaging3, 
to study molecular biological events under their full range of conditions. 
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1.1.1 X-ray Imaging (Radiography) 
 
Medical X-rays are used in various types of diagnostic examinations and procedures. 
X-ray energy is high enough to pass through materials such as body tissues, internal 
organs and clothing4. The energy is absorbed in different amounts which is 
dependent on the density of the material they pass through. Dense materials, such as 
bone show up as white on X-rays whereas air in lungs shows up as black. Fat and 
muscle appear as varying shades of grey.5 X-ray radiography can be used to locate 
tumours, orthopaedic injuries, pneumonias and foreign objects. Experienced 
physicians can read these images to diagnose medical conditions or injuries.4 
Advantages of X-ray imaging include easy mobility of certain types of equipment, a 
lower cost compared to other imaging methods and no complicated preparation of 
the patient, resulting in quick diagnosis and high bone resolution.6 Disadvantages of 
X-ray imaging include the small potential for ionising radiation to damage living 
tissue, although only at very high levels of radiation exposure and in the minority of 
procedures6, and the possibility that a person who has been exposed to X-rays could 
develop cancer, but this risk is minimal and depends on factors such as quantity of 
radiation dose administered, sex and age of the person exposed.5 
 
1.1.2 Contrast Radiography 
 
In some cases the use of conventional radiography may not be able to provide a 
diagnosis. Bones absorb radiation efficiently which is why they show up excellently 
on X-rays.7 Other tissues and organs do not absorb radiation as effectively. Contrast 
radiography is in some cases a solution to this problem as it can be used to outline 
and highlight the exact anatomy of the area under investigation. An example of this 
technique in use is when a patient is suspected to have a bladder tumour that does not 
show up on a conventional radiograph. A contrast agent is injected into the patient 
that accumulates at the tumour thus it becomes visible.8 Kidney function can also be 
evaluated using this technique. In this case the contrast agent is administered via 
intravenous pyelography (IVP). The kidneys excrete the contrast agent and 
depending on the efficiency of the process, the functional efficiency of the kidneys 
can be determined.8 
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1.1.3 Mammography 
 
Mammography is a technique that uses X-rays to create images of breast tissue. The 
technique is undertaken to detect and evaluate any anomalies that may be found such 
as cysts and tumours.9 Two forms of mammography exist; diagnostic and screening. 
Screening mammogram are used to look for cancer when the patient has no history 
of cancer, breast surgery or symptoms. Between 2 to 4 screening mammograms out 
of every 1,000 lead to the diagnosis of breast cancer. Diagnostic mammograms are 
tailored to examine a specific area in the breast.9 The X-rays in diagnostic 
mammograms are taken at a range of angles so that a specific area can be targeted. 
Magnification views or spot comparisons can also be used to aid in a diagnosis. 
Diagnostic mammography cannot however provide a definitive diagnosis of cancer, 
it can be used to assess if any discovered anomalies have the potential of being 
benign or whether further investigative procedures should be undertaken to 
determine whether cancer is present. 
 
1.1.4 Computed Tomography 
 
Computed tomography (CT) imaging also known as computerized axial tomography 
(CAT) scanning can present a form of imaging commonly known as cross-sectional 
imaging. These cross sectional images or slices of a patient’s anatomy can be used in 
a range of diagnostic and therapeutic treatments. CT techniques are based on 
mathematical algorithms originally developed by Radon in 1917.  In the 1970s CT 
techniques were introduced to the radionuclide imaging methods of the time.10 
Radiopharmaceuticals administered to a patient decay and positrons or gamma rays 
are emitted. These emissions are recorded by detectors and can be used to provide 
cross sectional images of a patient. The technique is known as emission computed 
tomography (ECT).10 When radiopharmaceuticals are used that emit γ-rays the 
technique is known as single photon emission computed tomography (SPECT). 
When a positron emitting radiopharmaceutical is used the technique is known as 
positron emission tomography/computed tomography (PET/CT). 
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1.1.5 Angiography 
 
Angiography is a medical imaging technique which is used to image blood vessels. 
The technique utilises an X-ray contrast agent that is water soluble and ionic or non-
ionic. The water soluble agent is injected into the blood stream of arteries known as 
arteriography or veins known as venography.11 When imaging lymph vessels contrast 
agents of an oily nature are used.  This technique is used to investigate the normal 
and pathological nature of a vessel. Diseases such as tumours, sources of bleeding, 
arteriovenous inflammations and arteriovenous fistulae can be investigated 
 
 
 
 
 
 
 
 
1.1.6 Ultrasound Imaging 
 
Ultrasound imaging (sonography) is a technique that has been in use for over 20 
years. The technique uses high-frequency sound waves to view soft tissues such as 
muscles and internal organs. The images are captured in real time and as such they 
can show blood flowing through vessels and movement of internal organs.12 During 
an ultrasound exam a hand-held device (transducer) is placed against the patient’s 
skin. High frequency sound waves are sent out of the transducer and these reflect off 
various structures. The sound waves return and are displayed as an image which is 
based on the time taken for the signal to return and the frequency and strength of the 
signal. It can also be used to view a fetus in pregnancy and monitor its heart beat. 
The optical equivalent of ultrasound is Optical Coherence Tomography (OCT), and 
uses a beam of infrared shone from a laser instead of sound waves.12    
 
with this technique. Digital subtraction angiography is 
used to produce images but it is also possible to take 
single shot images with rapid film changers in a 
process known as cine angiography for coronary 
arteries. The image in figure 1.1 is of a 45 year old 
female who had the symptom of weakness in her right 
arm. Head CT both with and without contrast agent 
was performed. The computed tomography image 
illustrates a subarachnoid haemorrhage with a left 
middle cerebral arterial aneurysm.11 
 
 
 
Figure 1.1:  
Cerebral 
Angiogram11 
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1.1.7 Fluoroscopy 
 
Fluoroscopy is a technique that is used to visualize the motion of internally found 
items in the body such as fluids, structures, and devices. The X-ray images provided 
by this technique are in real time and as such are very useful in a range of 
investigatory and diagnostic procedures. The level of X-ray exposure that is required 
for a single fluoroscopic image is relatively low in comparison to radiography but a 
patient usually requires a series of images to be taken and higher total exposure can 
be the result of this. During the procedure the X-rays are moved over different areas 
of the patient.
13
 Two important factors to be considered during the procedure are 
firstly the areas that are exposed the most to the X-rays because these areas will have 
the highest absorbed doses. Secondly the total amount of radiation that the patient 
has been exposed to. This is directly related to the Kerma Area Product (KAP) or 
(PAK). Fluoroscopy is used in a wide variety of examinations and procedures to 
diagnose or treat patients. Examples of the technique in use are; viewing the 
placement of devices such as stents that open blocked or narrow vessels within the 
patient, angiograms which allow the visualization of organs and blood vessels
13
 and 
orthopaedic surgery to help guide the treatment of fractures and joint replacements. 
 
1.1.8 MRI 
 
MRI is an imaging technique that utilises strong magnetic fields and radio waves. 
This in turn can produce cross sectional images of internal structures and the organs 
of a patient. The signal detected by the MRI apparatus will vary depending on the 
amount of water contained in a particular area of the body and the magnetic 
properties of that area.14 MRI scans can produce detailed images of ligaments and 
cartilage which are not possible to be imaged using any other medical imaging 
technique. The technique is used to detect abnormalities of the brain and spinal cord, 
identify diseases of the liver and abdominal organs and diagnose uterine problems in 
women who are being evaluated for possible infertility.14 A benefit of MRI imaging 
is that it does not use ionization radiation so damage to deoxyribonucleic acid (DNA) 
can be avoided, there are also no reported harmful side effects related to exposure to 
the strong magnetic fields used in MRI scanners. 
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1.2 Nuclear Medicine and Imaging 
 
Diagnostic nuclear medicine is an area of medical imaging that utilises radionuclides 
to produce an image of the distribution of radiopharmaceuticals in vivo.15 This 
technique and resultant images can provide a range of useful information about both 
structure and function of various diseases due to the fact that it principally relies on 
the functional changes of the disease.16 It is a method used to gather medical 
information that would otherwise be unavailable, require a range of more expensive 
diagnostic tests or necessitate surgical procedures. Nuclear medicine imaging can in 
many cases identify abnormalities very early in the progress of the disease. Nuclear 
medicine determines the cause of a disease or medical issue based on the function of 
the organ. This can be achieved by using the technique to analyse metabolism, 
physiological changes and molecular alterations of the disease.16 The images 
obtained with this technique can be combined with MRI or more commonly CT to 
provide greater information regarding the lesions and tissues being assessed. Nuclear 
medicine has advantages over investigatory procedures such as surgery because it is 
non-invasive, there is the possibility to monitor the patient over a few minutes to a 
few days and quantitative information can be obtained when imaging instruments are 
in conjunction with computers.16 
 
Nuclear medicine has become invaluable to a range of medical disciplines including 
neurology, cardiology, oncology and urology. The technique is used to locate 
tumours that may be found deep in the body, assess the normal functionality of 
organs and monitor the progress of medical or surgical treatments.17 A few examples 
include; assessing the blood flow to the brain, detection of infection within bones and 
the assessment of a patients liver, cardiac or renal transplant function.17 
 
Radiopharmaceuticals can be used in the treatment of diseases by being developed to 
target a specific organ or lesion. The radiopharmaceutical will be able to deliver 
enough radiation to a target which will destroy the diseased tissue. For example the 
treatment of thyroid cancer and overactive thyroid gland hyperthyroidism.18 
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1.3 Basis of Nuclear Medicine 
 
1.3.1 Atomic structure 
 
An atom is comprised of three different types of subatomic particles. The neutron has 
no electric charge and it has mass that is almost equivalent to the mass of a hydrogen 
atom, it can be found in the nucleus.19 The proton carries a charge of +e, and is 
almost equivalent to the mass of a hydrogen atom, it is also located within the 
nucleus. The electron carries a charge of –e, has a mass that is approximately 1/1837 
of a hydrogen atom, and occupies most of the volume of the atom.19  
 
1.3.2 Isotopes 
 
 
When atoms of the same element contain different numbers of neutrons, the different 
versions of the element are known as isotopes. The most common isotope of 
hydrogen contains no neutrons, the isotope of hydrogen, deuterium has one neutron 
and tritium has two neutrons as illustrated below. 
 
 
 
        H or Hydrogen        D or Deuterium         T or Tritium 
 
Figure: 1.2 Isotopes of Hydrogen 
 
 
1.3.3 Radioisotopes 
  
A number of isotopes are radioactive and are commonly referred to as radionuclides 
or radioisotopes. Stable isotopes are those which have never been observed to 
undergo radioactive decay. For example carbon-12 and carbon-13 are stable isotopes 
of the element carbon. Carbon-12 is the more common of the two accounting for 
98.89% of carbon. Carbon-14 is a radioactive form of carbon and is used as a 
radiopharmaceutical to monitor a patient’s absorption of glucose.19 
Electron Electron Electron 
Proton   Proton  Proton 
Neutron  Neutrons 
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1.4 Radiopharmaceuticals 
 
Radiopharmaceuticals are drugs that are used for a range of examinations via the use 
of gamma cameras or used for internal radiation therapy to combat a range of 
diseases.20 They are synthesised with radioactive components and these radioactive 
drugs can be specifically designed to target and accumulate in certain areas of the 
body. Gamma cameras can then be employed to detect and image the distribution of 
the radioactivity of the administered radiopharmaceutical. The radioactivity also 
allows the determination of the amount of drug that remains in the liver and other 
organs as well as the quantity that is excreted by the kidneys.16 Most 
radiopharmaceuticals are employed in the detection of diseases via diagnostic 
procedures. Around 10% of radiopharmaceuticals are used for the treatment of 
diseases.20 This is in the majority of cases, treatment of pain in cancer patients. There 
is a high level of interest in the pharmaceutical industry to develop a curative 
treatment for cancer. There are four areas of physiological measurement that 
radiopharmaceuticals are used to detect; the physiological function of organs, 
metabolism of tissues, intercellular/intracellular communications, and regional blood 
flow, cellular transport and localisation of assorted molecules.16 
 
1.5 Steps of Imaging Agent Development 
 
1.5.1 Introduction 
 
The process of imaging agent development is long and extremely costly. It can take 
approximately 10 years at a cost around 90 million pounds.21 There are several stages 
in the development ranging from the discovery of a molecule that may have potential 
to become a new radiopharmaceutical to marketing and drug monitoring.22 It should 
be noted that on average only one molecule will become a drug out of between 4000 
– 5000. The process is complex and requires specialist knowledge from a range of 
disciplines such as medicinal chemistry, molecular biology, pharmacology and 
regulatory science.23 The journey of a drug from its discovery to marketing is often 
found to be difficult and the majority of drugs will not make this journey 
successfully to completion.  
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The development of a new radiopharmaceutical requires a great deal of time and the 
investment of money.. Once a suitable compound has been developed it is then tested 
in pharmacological and preclinical studies which are undertaken in vitro.22 
Pharmacokinetics looks at the absorption, distribution, metabolism and elimination 
of the new compound. The toxicity of the compound at high and low doses is then 
determined. Three stages of clinical studies are then undertaken and if the new 
compound passes, registration can be completed. Marketing and continued 
monitoring finalises the development of a new radiopharmaceutical.22 
 
1.5.2 Discovery 
 
An imaging agent discovery project is initiated when a need or gap has been 
identified, whether it is related to a disease, clinical condition or lack of suitable 
medical compound. The primary research in the early stages of imaging agent 
discovery is usually undertaken in academia. This research results in data that are 
valuable and can be utilized in the further stages of the new compounds 
development. The need for a positron emitting radiolabel for cells was identified at 
the early stages of this PhD research.  There are positron emitters available that can 
be used to radiolabel cells such as gallium-6824 however its short half-life of 68 
minutes imposes considerable limitations. Copper-64 has a longer half-life of 12 
hours and copper complexes such as copper bis diethyldithiocarbamate25 suffer efflux 
problems over a period of hours; probably the result of biological mechanisms in 
place to control cellular copper levels, so a longer biological half-life would be 
preferable. 
89
Zr has properties that make it an ideal candidate as a cell tracking 
radionuclide. The data obtained during the discovery phase has been very promising 
and as such the Zr oxine, tropolone and ethyl maltol complexes progressed to the 
pharmalogical phase of development. 
 
1.5.3 Preclinical Testing 
During the preclinical testing stages properties of the drug candidate such as safety, 
bioactivity and efficacy are investigated.  
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The experiments designed to test these properties at this stage are developed to 
support clinical testing at later stages of development.26 An imaging agent candidate 
will first go through a series of quick tests known as screening tests. If successful it 
will progress to more substantial testing such as testing the imaging agent candidate 
on an isolated organ. Final testing at this stage involves the use of preconditioned 
animals. In the field of oncology test are conducted using mice which carry tumours 
originating from humans. 
 
1.5.4 Pharmacokinetics 
 
Pharmacokinetics is an area of research which deals with the action of drugs/imaging 
agents within the body such as; absorption, distribution, metabolism, and excretion. 
These properties are paramount in determining whether a drug candidate has the 
potential to progress through further stages of imaging agentsdevelopment 
successfully.26 Tests to determine these properties include in vitro assays which 
provide information on the drug candidate’s metabolism and permeation. If the drug 
candidate demonstrates potential it will be studied using in vivo animal models.27 Of 
the complexes reported in this thesis zirconium tetrakisoxine has demonstrated the 
properties required to progress to in vivo animal models as reported in chapter 6. 
 
1.5.6 Toxicological Analysis 
 
It is very important to identify the dose limiting organ for toxicity and radiation 
exposure of a new imaging agent candidate. Toxicity and radiation exposure from an 
imaging agent can have damaging effects to an organism as a whole, its organs or at 
a cellular level (cytotoxicity). Testing at this stage usually involves in vitro testing 
and/or in vivo tests which involve small animal studies results of which can be 
translated to humans.21 Dependant on whether any of these effects are found and the 
extent to which they occur may result in the termination of further investigation and 
development of the imaging agent candidate. 
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1.5.7 Clinical Trials 
 
New imaging agent candidates must progress through clinical trials to ascertain 
whether they are safe and function as intended. Proof of mechanism/concept and the 
issues of translation to human subjects are addressed at this stage.21 Radio tracers do 
tend to have fairly low levels of toxicity due to the small dose administered.  Proof of 
mechanism studies will demonstrate the mechanism by which the imaging agent is 
functioning. Proof of concept studies should be able to demonstrate the ability of the 
new imaging agent to compete against existing agents. PET and SPECT imaging 
agents should not/do not evoke a pharmacological response and as such measuring 
pharmacodynamics is not possible.21 To prove that the imaging agent candidate is 
reaching its intended target the amount of uptake of the imaging agent at the target 
site is determined. Uptake at other sites is also recorded to ensure that the imaging 
agent is arriving at its intended target due to discriminative binding to an intended 
target rather than by other mechanisms.21 Clinical trials are arduous and it is 
imperative that the potential imaging agent is understood and is safe. If successful 
the imaging agent candidate will move on to registration.22 
 
1.5.8 Registration 
 
If the drug candidate passes the aforementioned stages an application for registration 
with the country’s health regulative authority can be submitted. In Europe a market 
authorization application would be registered with the European Agency for the 
Evaluation of Medical Products.28 A complete description of manufacturing 
processes along with all data obtained is submitted. If successful the new drug can be 
marketed and sold under the recognized label of the regulative authority.28 
 
1.5.9 Post Marketing  
 
This phase is on-going and provides important information related to the use of the 
drug.22 Trials are conducted that ascertain the long term benefits, any risks and the 
ideal dose for patients. The trials themselves are conducted utilising thousands of 
patients and can continue for multiple years.28 
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1.6 Therapeutic Nuclear Medicine 
 
Therapeutic nuclear medicine can be used to treat a number of diseases such as 
thyroid hyperactivity, tumours in the form of lymphomas, thyroid cancer, blood 
pathologies and bone pain that is a result of metastases. Treatment in many cases 
uses single, large doses of radioactive materials and side effects do occur.  Cells that 
divide quickly as is the case with cancers are very susceptible to damage by 
radiation.22 Hence radiation may be used to irradiate areas of the body containing 
cancers and these cancers may be eradicated or inhibited.16 Therapeutic nuclear 
medicine treatments can be administered either internally or externally. Internal 
radionuclide therapy is undertaken by placing or dosing a gamma or beta emitter in 
the area requiring treatment. Internal radiotherapy is becoming more common and is 
called brachytherapy. The two types of brachytherapy are – seed implantation and 
low dose rates. Both types are used to treat prostate cancer with radiation from inside 
the prostate gland. Perhaps the most successful cancer treatment to date is the 
treatment of thyroid cancer using Iodine-131.16 External treatment uses strong beams 
of radioactivity either photons or particle radiation to destroy tumours.22 
 
1.7 Diagnostic Nuclear Medicine 
 
There are currently over 10,000 hospitals worldwide that use radioisotopes in the 
field of nuclear medicine and 89-95% of these medical procedures are diagnostic. 
Diagnostic nuclear medicine generally uses small amounts of radioisotopes, but 
certain diagnostic tests such as heart scans need to use much higher doses. In order to 
target a specific organ or type of disease a radioisotope, or tracer, is combined with a 
chemical that is known to accumulate at that specific organ or disease. This 
compound is known as a radiopharmaceutical agent. The most common radioisotope 
is technetium-99m with over 30 million diagnostic procedures conducted with this 
radioisotope worldwide annually. Radiopharmaceutical agents are administered to a 
patient either orally, intravenously or by inhalation. The photons emitted from the 
isotope are detected by cameras and this information can be fed to a computer and 
specific software can generate an image of the area of interest. 
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1.8 Scintigraphy 
 
Scintigraphy is a technique which detects and measures gamma radiation released 
from the body as a radiopharmaceutical decays. The radiopharmaceutical becomes 
concentrated in certain tissues; hence the tissues themselves become the source of the 
radiation.22 The technique is used commonly in medicine for anatomical research and 
to assess organ function. The majority of organs can be analysed using this technique 
and most importantly their function or structure can be investigated without the need 
to perform surgery or a biopsy.22 The images produced from this technique may be 
dynamic, providing information about function, or static, providing information 
about structure. 
 
An example of scintigraphy is reported in the Journal of Physiology which reports 
the effects of dynamic and isometric muscle contractions on the lymph flow in 
human skeletal muscle.29 The studies were conducted using scintigraphy and 
99m
Tc 
was used to radio label human serum albumin. The findings suggest that lymph 
propulsion by working muscle is most efficient when the muscle is able to shorten 
close to its minimum length.29 Other examples of scintigraphy techniques include: 
Gastroesophageal Scintigraphy a technique used to investigate the oesophagus and 
stomach. Once a radioisotope had been introduced into the stomach, scintillation 
measurements are taken over both the oesophagus and the stomach. This can be used 
to determine the level of gastroesophageal reflux. Myocardial perfusion scintigraphy 
is undertaken by utilising a radiotracer (normally thallium-201)30 which negotiates 
the myocardial capillary system and enters myocardial cells. Myocardial blood flow 
and the viability of cells can be determined utilising delayed and real-time images.30 
Research undertaken by Junjie Li et al31 compared the necrosis seen in vivo by 
contrast-enhanced MRI against the hot spots found on planar scintigraphy.31 
 
 
 
 
 
 
      
 
 
Figure 1.331 illustrates in vivo MRI (A) and planar 
gamma imaging (B) of necrosis in tumour models. 
Planar gamma scintigraphy radiography exposed a 
hotspot in the necrotic regions of the liver (B). 
Findings show that radioiodinated hypericin is a 
promising tracer of necrosis utilising scintigraphy.31  
 
 
Figure 1.3: In Vivo Liver 
Necrosis31 
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1.9 Single Photon Emission Computed Tomography (SPECT) 
 
Single Photon Emission Computed Tomography (SPECT) is a type of nuclear 
imaging technique that has a range of uses including imaging blood flow to tissues 
and organs in the body. It is advantageous over other imaging techniques such as X-
rays because it has unlimited depth penetration and intrinsic sensitivity.10 SPECT 
analysis requires the combination of two different technologies, a radiotracer and CT.  
The radiotracer emits gamma rays that are detected by a scanner; in the majority of 
instances two to three of these revolve around the patient. SPECT is an excellent, 
proven technique for analysing areas of the body22 that are limited in size or less well 
defined, such as the brain.22 A computer collects the information and produces two 
dimensional cross sectional images which can be reconstructed together to produce a 
3D image. The acquisition time to obtain images in SPECT is relatively long and as 
such organs that are in motion such as the heart are significantly difficult to image 
and interpret. A method to overcome this problem is to take images of the heart 
according to its rhythm.22 The time period between two beats is divided into thirty 
separate sequences and the gamma impacts detected within each of these sequences 
are collected separately. This results in thirty different images of the heart 
corresponding to a precise moment of the heartbeat. They are then displayed in the 
correct sequence and looped in a technique known as gated SPECT.22 Commonly 
used radiotracers in SPECT include: technetium-99m (
99m
Tc), iodine-123 (
123
I), 
fluorine-18 (
18
F), thallium-201 (
201
TI) and xenon-133 (
133
Xe). A range of compounds 
and drugs can be labelled with these isotopes forming a range of 
radiopharmaceuticals. The type of radiopharmaceutical used in a diagnostic exam is 
dependent on the area of interest. For example 
18
F can be used to radiolabel 
fludeoxyglucose (FDG) forming 
18
F-FDG; a radiopharmaceutical that can be used to 
analyse the glucose metabolism of tumours.22  The SPECT nuclear medicine 
technique differs from another technique that utilises gamma rays; positron emission 
tomography (PET).16 PET utilises positron decay which produces two gamma rays 
which results in the ability to locate the radiopharmaceuticals more accurately than 
SPECT which only tracks a single photon. SPECT however is more readily available 
and cheaper to conduct.16  
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1.10 Positron Emission Tomography (PET) 
1.10.1 Early History  
 
Carl David Anderson was an American physicist who discovered the positron in 
1932. He received the 1936 Nobel Prize in Physics for this outstanding discovery. 
Shortly after this discovery Jean Frédéric Joliot and Irène Curie produced the first 
positron emitting nuclide.32 This was a achieved by bombarding aluminium-27 (
27
Al) 
with alpha partcals resulting in the formation of phosphorus-30 (
30
P)33, a positron 
emitter with a half-life of 2.5 minutes.34 Ernest Orlando an American physicist 
invented the first cyclotron, an instrument that accelerates nuclear particles to very 
high velocities without the use of high voltages.  Using his newly invented cyclotron 
Ernest Orlando produced nitrogen-13 (half-life <10 minutes) and carbon-11 (half-life 
24 minutes) within the same year. These discoveries led to the production and 
utilization of positron emitting tracers.34 
 
The first commercial PET scanners were developed at the end of the 1960s and 
utilized analogue electronics which in turn generated tomographic images. In 1968 
The Royal Adelaide Hospital investigated this technology for bone scanning.35 
Results showed that the technique was too slow and inefficient for clinical use. It was 
determined that the fluorine-18 (
18
F) isotope was unusable with rectilinear scanners 
and gamma cameras. At the time it was also difficult to source the isotope.35  At the 
beginning of the 1970s at Washington University’s school of medicine Michel Ter-
Pogossian, Michael E. Phelps and Edward J. Hoffman developed the principles by 
which modern PET imaging systems are based. At the end of the 1970s detectors 
with greater sensitivities and better tomographic properties began to appear, capable 
of brain imaging and imaging the torsos of narrow patients.36 The 1980s saw the 
commercial availability of whole body PET tomographs leading to research into the 
application of this technology to analyse organs such as the heart and extra cranial 
neoplasms. The 1990s saw a generation of full ring commercial tomographs 
introduced that were capable of whole body clinical applications.36 Today’s modern 
PET tomographs continue to develop and image time continues to be reduced with 
improved image quality. 
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1.11 Positron Emitters for use in PET 
 
There are a large number of radiotracers available to clinicians to aid in the diagnosis 
of diseases. Common examples of these are reported below.  
 
1.11.1 Oxygen-15 
 
Oxygen-15 (
15
O) half-life (t ½ =2 minutes) is used to quantify regional cerebral blood 
flow (rCBF) 10. This information can be used to characterise altered brain perfusions 
in patients who are suffering from cerebrovascular disease.37 Regional myocardial 
blood flow (rMBF) can be quantified using 
15O in patients’ studies of myocardial 
perfusion in various pathological and physiological conditions.38 
 
1.11.2 Rubidium-82 Chloride  
 
Rubidium-82 Chloride (
82
RbCl) commonly known as CardioGen-82 is used in PET 
for the diagnosis of myocardial infarction. This PET radiotracer is used to distinguish 
between normal and abnormal regions of myocardial perfusion in patients with 
suspected myocardial infarction.39 It is also used to diagnose coronary artery disease 
and determine the extent and severity of this disease in the patient.40 
 
1.11.3 Fluorine-18 Fluorodeoxyglucose 
 
18
F half-life (t ½ = 109.8 minutes) is a commonly used radioisotope in nuclear 
medicine. Fluorine has very favorable properties such as its ability to replace other 
atoms that are in an active compound with relative ease, without altering the 
biological properties of these compounds.22  Cancer cells require high levels of 
glucose and will consume higher quantities than normal cells. Hence radiolabeling 
glucose can aid in the identification of cancerous cells. Once injected in to a patient 
(dose ~ 350 megabecquerel (MBq)) Fluorine-18 Fluorodeoxyglucose (
18
F-FDG) will 
accumulate at cells which are under a state of rapid growth and proliferation such as 
tumours and their metastases.22  As the brain and heart also have a high level of 
glucose uptake 
18
F-FDG can be used to image these organs as well. 
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1.11.4 Carbon-11 Methionine 
 
Carbon-11 methionine is also used in oncology where it acts as a marker for protein 
synthesis. The metabolism of methionine is altered in cancer and it is possible to use 
methionine labelled with 
11
C to image brain, lung, and breast cancer and 
lymphomas.41 It has been reported that head and neck cancer can be effectively 
imaged with
 
carbon-11 methionine and its use in PET imaging could be useful in 
measuring cancers for therapy treatment plans.41 Carbon-11 methionine has also been 
studied in the detection and PET imaging of chordoma, a rare malignant bone 
tumour.42 The findings of the studies indicated that carbon-11 methionine PET is 
viable for the imaging of this pathology and can provide valuable information on the 
therapeutic treatment of chordoma after carbon-ion radiotherapy (CIRT).42 
 
1.11.5 Nitrogen-13 Ammonia 
 
Nitrogen-13 ammonia (
13
N-NH3) has a half-life of 10 minutes and has been 
evaluated as a tracer for myocardial perfusion (the flow of blood to the heart). Using 
this tracer in a PET scan can provide information that can result in the diagnosis of 
coronary heart disease or aid in the decision of whether a patient would benefit from 
coronary bypass surgery.43 Results of work undertaken by Warren F. Walsh et al44 
show that the uptake (in animal studies) of this tracer is proportional to regional 
tissue perfusion. Clearance of this radiotracer once administered intravenously is 
rapid and excretion occurs via the liver, lungs, myocardium, kidney and bladder.44 
 
1.11.6 Iodine-124 
 
Iodine-124 (
124
I) is a positron emitting halogen and is a popular long lived 
radionuclide used for the design and synthesis of new PET radiotracers. With a half-
life of 4.2 days it is possible to use longer radio synthesis methods and longer PET 
imaging studies.45 The labelling methods and chemistry are well established for 
124
I 
and there is a large range of compounds that have used 
124
I for imaging techniques.45 
An example of 
124
I in use in PET is in the form of iodide salt (
124
I)NaI that can be 
used to image the thyroid. 
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1.12 Physical Principles of PET 
 
The main principles of imaging tissue function in vivo with PET are illustrated and 
summarised in figure 1.4 below. There are multiple steps involved in the PET 
process to produce an image that can be used for diagnostic purposes. 
 
 
Figure 1.4: The PET Scanning Process46 
 
Firstly the patient is positioned on a flat-bed which is moved into the large circular 
scanner at one end when the procedure is ready to be conducted. The patient needs to 
be placed into the field of view of the PET detectors which can detect and register 
incident gamma rays.22 A positron (β+) emitting radionuclide is administered to the 
patient and the radionuclide component of the radio tracer decays and the resulting 
positrons (β+)  travel a short distance ~ 1 mm in the body. After traveling this short 
distance the positrons will combine with electrons (e
-
) in the absorbing matter 
causing annihilation to occur10 and produce two 511 kilo electron volt (keV)22 
photons that travel in opposite directions of each other. The detectors surrounding the 
patient detect these photons and they are linked so that two events distinctly 
occurring within a specific time frame are known as a coincident and it can be said 
that these photons originated from the same annihilation. The coincident events can 
be stored in arrays and reconstructed using a form of digital image processing.16 The 
resulting images show the tracer distribution throughout the patient. 
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1.13 PET Detector 
 
The detection system is an indispensable component of any imaging apparatus. It is 
key that the properties of the detection are fully understood to devise an appropriate 
operating protocol that allows the collection of quantitative information. Since the 
introduction of PET the design and performance of the utilized detectors have 
evolved and improved dramatically. The overall axial field view has increased from 
2 cm to 20 cm and the total number of detector elements has increased from 20 to 
20,000.
47
 The spatial resolution is the capacity of an imaging system to determine the 
difference between two adjacent high-contrast objects. There has been a drastic 
improvement to the PET detectors properties increasing the spatial resolution from 
25 mm to 5 mm alongside over a thousand fold increase in sensitivity.
47
 Scintillation 
detection systems are used in nearly all PET tomographs. The conversion of high-
energy photons into visible light occurs due to an interaction with a scintillating 
material.
48
 First a photon incident creates an energetic electron on the scintillator, 
then the electron travels along through the scintillator and as it excites other electrons 
it loses its energy. The electrons that have been excited give off light as they decay 
back to their ground state. The scintillator is optically connected to a photomultiplier 
tube (PMT). Once light makes contact with the PMT an electrical signal is 
generated.
10
 An array is used to generate a timing signal then used in the coincidence 
circuitry. Due to finite time resolution of the detector and the computational fluid 
dynamics (CFD) system there is usually a time difference between the two timing 
pulses generated by a coincident. To combat this timing pulses are transferred to a 
gate generator, creating an electronic pulse.
48
 Properties required for camera 
configuration in PET that lead to the production of high resolution images include 
the detected localisation of annihilation protons achieved by utilising small detectors. 
Dead time is the time period after each coincident and in which a PET system is not 
able to record another event, meaning some events will be missed. At high count-
rates these losses, known as dead-time losses can become very significant. Every 
coincident event that is detected during an imaging session is recorded by the PET 
computer as raw data sets.  
 
 
  
20 
 
 
In both PET and SPECT the coincident data is reconstructed with computer software 
resulting in cross-sectional images in the coronal, sagittal and tranverse plains.
48 
These planes are illustrated in the diagram below.
49
 
 
 
 
 
Figure 1.5: Coronal, Sagittal and Transverse Plains
49
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1.14 Application of PET 
 
1.14.1 Oncology 
 
PET has a variety of distinctive uses in clinical fields such as cancers; lymphoma, 
melanoma and colon cancer, and strokes. A common PET radiotracer is 
18
F -
fluorodeoxyglucose (
18
F-FDG) which is used to image a wide range of malignant 
tumours. The specify and sensitivity of this radiotracer is in the majority of instances 
in the high 90s %. 
18
F-FDG50 has been used to detect and image tumours located in 
the head and neck, musculoskeletal system, neuroendocrine system, ovaries and 
breasts. In oncology PET is an extremely reliable method for differentiating between 
benign and malignant primary tumours as well as recurring pathologies.50 Staging 
(extent of spread) of the disease depends on several factors. PET can be used to 
determine the presence or absence of metastasis, the amount that the disease has 
spread to the lymph nodes in the region, the number of tumours (this includes the 
primary tumour and the presence of metastatic tumours, or metastases) the tumour 
grade (how closely the cancer cells and tissue resemble normal cells and tissue) and 
the actual size of the primary neoplasm.51 Staging is extremely important because it 
can be used to estimate a patient’s prognosis, assist in the development of a treatment 
plan and identify suitable clinical trials for which the patient may be eligible.51 
Researchers are also able to exchange information using a common terminology 
using the information obtained by the use of PET.16 
 
1.14.2 Cardiology 
 
PET is the most common form of diagnostic testing used in cardiology. 
18
F-FDG is a 
glucose analogue that is widely used as a metabolic imaging tracer in clinical 
oncology. The radionuclide Nitrogen-13 (
13
N) can be used to image myocardial 
perfusion utilising a dynamic scanning protocol to calculate the absolute blood flow 
within a patient.
52
 PET cardiology viability imaging determines the extent of heart 
muscle damaged by heart disease or a heart attack. If a patient is suspected to be 
suffering from either a stunned or hibernating myocardium PET scans can help to 
identify this.
52
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1.14.3 Neurology 
 
In the field of neurology PET is employed to differentiate recurrent brain tumours 
from radiation fibrosis or necrosis, which is essential for neurological studies.
53
 
Radionuclides such as 
15
O which are produced from nitrogen (
15
N2) can be used to 
measure the flow of blood to the main or upper sections of the brain. The carbon 
isotope 
11
C which is produced from nitrogen (
14
N2) can be used as a PET radiotracer 
to scan, image and subsequently study both normal and abnormal brain functions.
53
 
This method has been successfully used to identify areas of the brain which are 
affected by epileptic seizures. 
 
1.14.4 Neuropsychology and Cognitive Neuroscience 
 
In the medical field of neuropsychology and cognitive neuroscience PET can be 
employed to investigate a range of psychiatric disorders.  It can be used to evaluate 
neurological activity in patients suffering with amnesia.54 Research has been 
undertaken that links direct visualisation of blunted brain responses to serotonin 
release with major depression sufferers. PET has been used to investigate Fahr’s 
disease, an inherited neurological disorder that has the symptom of unnatural calcium 
deposits in the areas of the brain that control movement. 
18
F-FDG has been used to 
investigate this disease, findings showed that there was a reduced glucose uptake in 
the areas of calcium deposits and in the temporal and parietal cortices.55 
 
1.14.5 Pharmacology 
 
During pre-clinical trials PET can be employed to provide researchers with the 
information required to produce radiolabeled drugs. Radiotracers such as 
18
F-3- 
fluorothymidine (
18
F-FLT) can be used to assess specific synthetic rates of DNA, in 
turn functional state or integrity of a tissue can be assessed.
56
 Pharmalogical activity 
of a newly developed radiotracer for potential use in PET depends on the free 
concentration that can be achieved in the target tissue. This can be assessed in vivo 
utilising PET after a molecule has been labelled with a positron emitting isotope that 
does not change the properties of the chemical structure of the molecule.
56
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1.15 PET Vs SPECT 
 
The two dominant molecular imaging techniques in the field of nuclear medicine are 
positron emission tomography (PET) and single photon emission computed 
tomography (SPECT). Both techniques have strengths and limitations in hardware 
and software design and the actual radiotracers that are used with these techniques. 
Both of these techniques have suffered from setbacks over the years with 
radiopharmaceutical supply problems such as the supply shortage of the most 
commonly used nuclear medicine radioisotope precursor for 
99m
Tc; molybdenum-99 
(
99
Mo).57  
 
PET imaging has a far greater sensitivity than SPECT and this is around ~ 2 to 3 
times greater. There is a difference in the ability of the techniques to detect and 
record a higher percentage of emitted events during a procedure. Physical collimators 
are needed in SPECT to reject photons that are not within an acceptable small 
angular range. If this is not done it will not be possible to determine the angle of 
incidence.58 SPECT is more available, widely utilized and cheaper than PET. The 
overall cost of PET equipment is much more expensive than SPECT equipment. 
SPECT tracers are a lot cheaper than PET tracers and are more widely available but 
this is changing.59 SPECT has problematic issues such as long scan times, low 
resolution images and susceptibility to interference from artifacts and attenuation. It 
is easy to misdiagnose artifacts such as perfusion defects when using SPECT and the 
technique does not allow the amount of blood flow to be measured, while PET does. 
 
There have been significant advances in the development of Rubidium-82 (
82
Rb) 
technology which has enabled new levels of excellence in the assessment of 
myocardial perfusion against which the next generation of cardiac imaging agents 
can be tested for their specificity and sensitivity.60 The data that are being produced 
from studies involving 
82
Rb are expected to illustrate the cost-effectiveness of 
cardiac PET over SPECT. PET also has other advantages over SPECT such as higher 
spatial resolution and the ability to perform quantitative measurements.61 PET scan 
times are around 30-40 minutes quicker than the two or more hours required for a 
SPECT scan. 
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1.16 Immuno PET 
 
Immuno-positron emission tomography (immuno-PET) is a non-invasive imaging 
technique utilising intact antibodies labelled with a positron emitter. The technique 
can provide information in target therapy such as where the target is and where the 
antibody is located. Immuno PET has the potential to have an important role in 
cancer staging and can improve the diagnostic characterisation of tumours.62 
 
The combination of immuno-PET with mABs can be used to provide support and 
improve a range of treatment areas. It can be used to determine the most favourable 
dose for radio immunotherapy treatment or to determine the most efficient times to 
administer mAB doses.62 The efficiency of drug delivery across the blood brain 
barrier and methods to improve this can also be determined using this technique. 
Biodistribution and quantification of mABs at target locations can be visualised 
using immuno-PET.62 
 
Immuno-PET scans can be tremendously predictive of colorectal disease and slightly 
less so with recurrent ovarian cancers.63 The requirements of immuno-PET are a 
suitable positron emitter with a half-life that is relatable to the time required to 
achieve optimal tumour to non-tumour ratios and be able to latch onto the targeting 
compound securely.64 Zirconium-89 (
89
Zr) has the potential to fulfil these 
requirements. 
 
The combination of imaging and drug targeting can be used to pre select patients and 
tailor treatment plans accordingly.65 This process is the way forward for the 
development of personalised medicine. Personalised medicine itself is the 
customisation of healthcare whereby medical practices, decisions and products are 
developed for the individual which leads to greater levels of successful treatments.65  
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1.17 Cell Tracking in Cancer 
 
Cancer treatment in the form of cell based therapies provides a range of methods that 
have great potential.66 Non-invasive tracking and imaging of a range of therapeutic 
cells that have been labelled non-destructively such as stem cells and T cells can 
provide valuable information on the mechanisms of cancer development.66 The 
technique can provide information such as the location, viability, cell lineage 
expansion and response to drugs, movement, or other behaviours of cancers in vivo.  
 
There are two methods for the tracking of cells, direct and indirect. In the direct 
method of tracking, therapeutic cells are labelled directly with tags that can be 
detected67, for example radioisotopes as is the case with PET and SPECT. Direct cell 
labelling methods are cost effective, widely available and are easier to conduct when 
compared to indirect cell labelling methods. The indirect method of tracking cells 
involves cell labelling utilising reporter genes67 and immune cells such as T Cells.66 
The indirect method allows for a greater level of sensitivity and specificity.  
 
 
      Figure 1.6: Cell Tracking Methods68 
 
Another example of a direct cell labelling complex is 64-Cu-pyruvaldehydebis (N
4
-
methylthiosemicarbazone which can be used to label cells non-invasively to image 
tumours using PET. The compound has a strong binding affinity to human serum and 
is being studied as potential marker of perfusion.69 Perfusion is an important factor in 
the physiology of tumours. Perfusion can have serious implications in the diagnosis, 
prognosis, planning and responses of treatments.69  
Figure 1.5 illustrates direct imaging 
involving the labelling of stem cells 
with PET or MRI tracers, 111-In 
oxine and super paramagnetic iron 
oxide (SPIO) respectively.61 In 
Indirect imaging a detectable signal 
is the product of reporter genes 
encoding a reporter protein that 
metabolizes a substrate.61 
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1.18 Indium-111 Oxine and Indium-111 Tropolone 
 
White blood cells have been labelled with success for many years to detect areas of 
infection and inflammation. Complexes such as indium-111 oxine (
111
In-oxine) and 
indium-111 tropolone (
111
In-tropolone) have been used in scintigraphy for this 
purpose.70 Although they are being replaced by radiotracers such as 
99m
Tc-
hexamethylpropyleneamine oxime
 
(
99m
Tc-HMPAO).71 
99m
Tc-HMPAO is preferred to 
image abscesses in the gastrointestinal tract but 
111
In-oxine and 
111
In-tropolone are 
still used to image patients at a number of facilities.70 
111
In-oxine is known to be 
superior to 
99m
Tc-HMPAO when imaging a range of clinical indicators including 
lung infections, diabetic foot, postoperative abscesses and bowel disease.70 
 
1.18.1 Indium-111 Oxine 
 
111
In oxine has been used to track radiolabelled lymphocytes in cancer patients, this 
radiotracer has been approved by the FDA since 1988.66  It is known that Indium (In) 
forms a complex with oxine in the ratio of 1:3.72 The resulting complex is lipid 
soluble and neutral and as such it is able to enter cells via penetration of the cell 
membrane.73 Once the complex has entered a cell indium becomes irreversibly 
attached to cytoplasmic constituents within the cell.72 The oxine is released from the 
complex and leaves the cell. The probable mechanism of labelling cells with 
111
In 
oxine involves an exchange reaction between subcellular constituents that chelate 
indium more actively than oxine.73 
 
1.18.2 Indium-111 Tropolone 
 
111
In tropolone has properties very similar to that of 
111
In oxine. However 
111
In 
tropolone is soluble in isotonic saline whereas 
111
In oxine is not. It has also been 
reported that less time is required for the labelling of lymphocytes when using 
111
In 
tropolone.74 
111
In tropolone has the advantage that it can label lymphocytes in plasma 
whereas 
111
In oxine cannot. This is due to the fact that indium is found to bind more 
strongly to the transferrin contained within the plasma than oxine.71 
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1.19 Zirconium 
 
1.19.1 An Introduction to Zirconium 
The element zirconium (Zr) has an atomic mass of 91.224 amu and an atomic 
number of 40. It is a strong transition metal which is both malleable and ductile with 
properties similar to that of titanium. It is greyish/white in appearance and is resistant 
towards corrosion due to an oxide film on its surface. It is found to be solid at room 
temperature and becomes brittle at lower purity levels.
75
 
Zr ore (commonly known as zircon, ZrSiO4) is a by-product of the mining and 
processing of tin and the titanium minerals rutile and ilmenite, and is the most 
important form of Zr in use. Zircons main use is that of a refractor and an opacifier. 
It is also used in alloys such as zircaloy.76 Zr has an important role in nuclear 
applications because it has low thermal neutron absorption cross section (NAC) 
properties. This coupled with the fact that it possesses high thermal stability, does not 
readily absorb neutrons and has anti corrosive properties, makes it an ideal candidate 
to be used as cladding material for nuclear fuel rods. Zr is known to form a range of 
organometallic and inorganic compounds, for example zirconocene dichloride and 
zirconium dioxide. Impure Zr and baddeleyite are utilized in lab crucibles and other 
well-known uses of Zr include furnace bricks, percussion caps and catalytic 
converters.76 
 
Zr has no known biological properties or transport mechanisms and in most cases its 
salts have low systemic toxicity. The estimated average daily dietary intake in 
humans is 50 µg and absorption by the gut does not occur. Any Zr which is absorbed 
on average accumulates at a slightly greater percentage in the skeleton than in any 
other tissue.76 Zr is very biocompatible with minimal biological availability and 
electro catalytic activity in the human body. This is due to Zr’s passive oxide layers 
with very low solubility and exceptional protective properties.77 Because of the 
tolerance of human tissues to Zr, it makes the metal suitable for use in some artificial 
joints and limbs.  
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1.20 Zirconium Chemistry 
 
1.20.1 Zirconium Coordination Chemistry 
 
When Zr is in a compound it is normally in the oxidation state IV, compounds where 
Zr is in lower oxidation states such as III, II or I are less common.78 Compounds of 
Zr tend to commonly display coordination numbers and shapes of the following; 4 
(tetrahedral), 6 (octahedral), 7 (pentagonal pyramidal) and 8 (dodecahedral).79 Zr 
exhibits tetrahedral coordination in compounds such as gaseous ZrCl4.
80 In solid state 
molecular compounds the coordination number is commonly be found to be 6 or 
above. Octahedral Zr complexes include solid ZrCl4 and Rb2ZrCl6.
81 Zr complexes of 
coordination number 6 such as dimethyl benzamidinate Zr (Zr anchored via 
benzamidate ligands) have been reported to have catalytic properties that can be used 
in the polymerization of α-olefins.82 An example of a pentagonal pyramidal Zr 
complex of coordination number 7 is ZrF7
3−
 in (NH4)3ZrF7.
83
 Dodecahedral Zr 
complexes of coordination number 8 include ZrF4.H2O, a halide whereby the 
coordination around the Zr(IV) atom is comprised of six F atoms and two water 
molecules.84 Coordination numbers of 7 or 8 can be found in crystalline structures 
with capped trigonal prismatic and square antiprismatic conformations which have 
respectively been reported.81 The relatively high charge and large size of the Zr(IV) 
ion results in the preference for compounds of a higher coordination number.  Zr’s 
4d
0 
configuration is the reason for the range of coordination geometries as 
stereochemical inclination due to a partly filled d-shell does not exist in Zr(IV).85 
 
Zr is commonly known to form ionic bonds. The majority of Zr ions have a charge of 
+4 and will form a neutral complex when a bond with one or more ions totals a 
charge of -4 as is the case with the formation of zirconium tetrafluoride.86 Zr 
complexes also exhibit dative covalent bonding such as in the platinum Zr adduct 
[(Cy3P)2Pt–ZrCl4].
87 
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1.21 Zirconium Isotopes 
 
1.21.1 Zirconium Isotopes 
 
Zr is known to have four naturally occurring isotopes which are stable. It also has 
one extremely long lived naturally occurring radioisotope zirconium-96 with a half-
life of 3.9×10
20
 years.88 The properties of these isotopes are reported below. 89
,
 90 
 
Isotope Atomic Mass  
No of 
Neutrons 
Natural 
Abundance 
Nuclear 
Spin 
Magnetic 
Moment (µ/µN) 
90
Zr 89.905 50 51.45 0 N/A 
91
Zr 90.906 51 11.22 5/2 -1.304 
92
Zr 91.905 52 17.15 0 N/A 
94
Zr 93.906 54 17.38 0 N/A 
Table 1.1 
1.21.2 Zirconium Radioisotopes 
 
Apart from 
96
Zr, radioisotopes of Zr are synthesised.86 Currently twenty seven of 
these exist and the majority of them have half-lives of less than one day.86 Properties 
and uses of two common radioisotopes; 
89
Zr and 
93
Zr are reported below. 91
, 92, 93 
 
Isotope Atomic Mass  Half Life 
Decay 
mode 
Decay 
Energy  
Daughter 
Nuclide 
89
Zr 89.9089 3.27 Days β+ 396.9 keV 89Y 
93
Zr 92.9064 1.5 Million Years Β 91.24 keV 93Nb 
Table 1.2 
 
93
Zr is commonly found in used nuclear fuel (UNF) cladding, U.S. light water reactor 
fuel assemblies, spent nuclear fuels and reprocessed wastes.94 It is a concern to the 
Department of Energy (DOE) of America because of its 1.5 million year half-life.95 
89
Zr
 
has properties that are extremely useful in the field of PET imaging. Its half-life 
of 3.27 days is a good fit to the circulation half-lives of antibodies which are also in 
the magnitude of days.96 
89
Zr has been of interest in the field of PET for a number of 
years particularly in the area of labelling monoclonal antibodies.97 
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1.22 The Synthesis and Uses of 
89
Zr in PET 
 
1.22.1 
89
Zr Production 
 
The most common method of 
89
Zr production uses a low-energy cyclotron utilising 
the nuclear process; [
89
Y (p, n) 
89
Zr].
98
 This method involves the bombardment of 
89
Y with deuterons or protons.
99
 
89
Y is the preferred target material due to it being 
one of 26 chemical elements having only a solitary stable isotope (known as 
monoisotopic) hence its isotopic abundance is 100%.
98
 The use of 
89
Y avoids 
processes involving the preparation and enrichment of other isotopes for conversion 
into 
89
Zr. These processes can be costly and problematic
98
 and are involved in 
neutron activation for the synthesis of 
89
Zr
100
 and the alpha catalysed nuclear 
synthesis of 
89
Zr.
98
 
 
1.22.2
 89
Zr PET Tracers 
 
Currently PET medical imaging based around 
89
Zr has been explored in regards to a 
range of cancer related targets. Examples include epidermal growth factor receptor 2 
(HER2) which is related to cell survival, metastasis, angiogenesis, differentiation and 
proliferation.101 There is a direct correlation of the over expression of HER2 and a 
variety of human cancers96 and because of this it is an important target for cancer 
diagnosis and treatment. Zirconium-89 trastuzumab has been designed as a PET 
imaging agent, used to determine and localize HER2 over expressing tumours with 
excellent results.102 Prostate specific membrane antigen (PMSA) is one of the 
foremost characterised targets in the field of oncology.96 
89
Zr-labeled anti-PSMA 
mAb, J591 has been reported to quantify PMSA expression in vivo.103 Research has 
shown that this radiotracer has excellent potential for the imaging of PMSA.103  
 
89
Zr has been used to successfully label antibodies, proteins and peptides for 
diagnostic purposes in the field of medical imaging utilising PET for some time. 
However non-biological ligands have not been used in complexes with the 
89
Zr 
radioisotope in the attempt to label cells. It may be more cost effective and efficient 
to utilise non-biological ligands to label 
89
Zr for diagnostic purposes in PET. 
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1.23 Bodily Clearance of Yttrium-89 
 
89
Zr decays into the stable isotope yttrium-89, which has no decay products. Yttrium 
(Y) is found in a variety of common household equipment such as colour televisions, 
energy saving light bulbs and fluorescent lamps. Yttrium cannot be found in nature 
as a free element. It is in the majority of cases found in rare earth minerals and in 
uranium ores.104 The element is at its most dangerous in the working environment 
because it can be inhaled with air as gasses or danger-associated molecular pattern 
molecules105 which can be the direct cause of lung embolisms, even more so if a 
person is exposed long term.  
 
No biological role has yet to be determined for this element yet it can be found in 
most living organisms.  Human breast milk contains a concentration of 4 ppm and 
plants that are commonly eaten by humans have a range of between 20 -100 ppm. 
 
Y is a known cause of cancer and causes the chance of cancer to increase if inhaled. 
It can also be very damaging to the liver if it accumulates in the body in significant 
quantities. Research has been under taken and findings show that yttrium is poorly 
absorbed in the gastrointestinal tract and 90% of ingested or absorbed Y is excreted 
via the faeces in rats however guinea pigs excreted 0% in the faeces. Exposure to 
mice and rats of the element resulted in an uptake of 25% and 50% respectably via 
inhalation. Human studies results show 11 – 55% retention after inhalation.104  
 
Y injected intravenously into rats resulted in an accumulation in the liver lung and 
spleen. Half-life time clearance of the Y via the liver was 144 days. Experimental 
results also indicated that there is a limited maximum level uptake in the bones, 
excretion from the bones is slow and the accumulation in the bones is considerably 
less than other organs.104 These findings demonstrate that that 
89
Zr has the potential 
to be useful in PET applications. 
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1.24 Properties Required for New Zirconium Radiopharmaceuticals 
 
There are currently over 100 PET radioisotopes but the larger part of these lack 
properties that are required for use in the field of cell tracking by PET imaging. 
Problems include high production costs, low availability and lack of established 
radiochemistry. Additionally many isotopes have half-lives that do not match the 
required times for cell tracking applications.96 
89
Zr may be a solution to these 
problems and there has been a recent increase in the availability of positron emitters 
such as 
89
Zr (78.4hours/3.26 days).96 
89
Zr offers new possibilities for PET isotopes as 
it has properties that are ideal for cell tracking and possibly immunoPET.  
 
1.24.1 Half Life 
 
The half-life of 
89
Zr (3.26 days) is an excellent fit for the time required for intact 
monoclonal antibodies (mAbs) to obtain an ideal tumour to non-tumour ratio.97 The 
problem with this is the lack of methods available to couple 
89
Zr to mAbs with high 
stability.97 Established PET methods may be able to use 
89
Zr for longer study times. 
 
1.24.2 Biological Properties 
 
The action and transport mechanisms of Zr in biological systems are unknown. It is 
retained firstly within soft tissues and then gradually within the bone.106 In 
cytological and histological investigations, Zr has been shown to have low levels of 
toxicity.107 Zr is able to cross the blood brain barrier and become deposited within the 
brain.106 Human uptake of Zr has been reported to be as high as 125 mg per day.106 
 
1.24.3 Diffusion into Cells and Stability 
 
Small neutral polar molecules, such as water and urea can easily diffuse across the 
lipid bilayer of a cell.108 The ligands chosen to complex with Zr must be uninegative 
and bidentate so that they can form a neutral complex with the zirconium ion as its 
charge will be +4. When the 89Zr complexes are within the cells they must be able to 
dissociate in a manner analogous to well established 111In complexes.73 
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1.25 An Overview of the Zirconium Precursor Complexes 
 
When the radioactive Zr isotope is received from the supplier it arrives in the form of 
potassium zirconium tetrakisoxalato in oxalic acid. The Zr isotope can also be in the 
form of zirconium tetrachloride in hydrochloric acid. Because of this it was 
important to understand the chemistry of these precursor compounds. As the Zr 
isotope behaves chemically exactly the same as the stable form of Zr it was possible 
to investigate these complexes without the need for radiation safety procedures. 
 
1.25.1 Zirconium Tetra Chloride 
 
Zirconium tetrachloride, (ZrCl4) is a white crystalline solid. Commonly used as a 
source of pure zirconium in analytical chemistry it is also used to make water 
repellent textiles. ZrCl4 is easily decomposed by water and is very corrosive to 
metals and living tissue when in the presence of moisture. It has been used as a 
chemoselective catalyst compound under mild reaction conditions for the 
acetalization of carbonyl.109  
 
1.25.2 Zirconium Tetrakisoxalato 
 
Zirconium tetrakisoxalato, known as its potassium salt, tetra potassium zirconium 
tetra oxalate or potassiumoxalatozirconate (IV) has a chemical formula of C8O16 Zr 
.4 K. The 
89
Zr isotope is supplied from manufacturers, such as iba Molecular, in the 
form of the potassium salt of zirconium-89 tetrakisoxalato in 1M oxalic acid 
solution. This form of the 
89
Zr complex is due to the process of isolating high purity 
and high specific-activity 
89
Zr complex using a small cyclotron.110
 89
Zr is isolated in a 
high level of both radiochemical and radionuclidic purity in the form of zirconium-
89 oxalate by employing the use of a solid-phase hydroxamate resin which results in 
>99.5% recovery of the radioactivity.110 
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1.26 An Overview of the Ligands to be Complexed with Zirconium 
 
1.26.1 Introduction 
 
The ligands, oxine, tropolone, deferiprone and ethyl maltol were chosen to form 
complexes with the 
89
Zr ion. It is desirable to have neutral lipophilic complexes and 
this can be achieved by combining Zr(IV) with four bidentate uninegative ligands. 
The ligands chosen can form lipophilic complexes and it is necessary to surround the 
zirconium metal ion with such ligands as it is a goal of this work to label cells with 
89
Zr and as such the 
89
Zr metal isotope must be able to cross cell membranes. 
 
1.26.2 Oxine 
 
Oxine has the chemical formula C9H7NO and is an organic compound. It is a known 
derivative of the heterocycle quinoline by the employment of an OH group on the 
number eight carbon. 
 
OH
1
2
3
4
5
6
7
8
 
Figure 1.7: Structure of Oxine 
 
Synthesis of oxine can be achieved either by the use of its precursor quinoline or by 
Skraup synthesis.111 Skraup synthesis methods are known to be volatile and have 
been reported to lead to explosions even when inhibitors are employed such as boric 
acid. The reaction between 2-aminophenol (i) and glycerol (ii) in figure 1.7. The 
reactants are heated with sulphuric acid (H2SO4) and nitrobenzene (PhNO2) which 
results in the formation of oxine (iii).112 This process is expensive due to the cost of 
the raw materials involved and the low yields obtained.111 
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HO
HO
 
Figure 1.8: Skraup Synthesis of Oxine112 
 
In a neutral solution the hydroxyl is found to be in the protonated form (pKa=9.89) 
and the nitrogen itself is not protonated (pKa=5.13). A zwitterionic isomer (also 
known as inner salts) in the excited state is reported to exist.  In this case the H
+ 
is 
transferred from the oxygen (resulting in an oxygen anion) to the nitrogen (resulting 
in a protonated nitrogen cation) 113 illustrated below. 
O-
 
Figure 1.9: Zwitterionic Isomer of Oxine 
 
Once oxine or its derivatives have lost a proton, it is possible for them to form 
complexes with a large variety of main group and transition metal ions.114 Oxine and 
its related compounds have parasitical, bactericidal and fungicidal properties. Recent 
research has also been undertaken to utilise oxine in the manufacture of 
electroluminescent devices.114 The complexes of oxine have also been used as a 
contraceptive (quinosol) and in a solution of alcohol it can be used as a liquid 
bandage.111 In the past there was an interest in the compound for use as a 
chemotherapeutic. For example there was an interest in Mannich bases of oxine as 
possible anticancer drug candidates.115 The interest in these complexes resulted from 
the fact that experimental results have shown them to express a high potency against 
human cancer cells. Further research has found that some of the derivatives of oxine 
such as 7-diethylaminomethyl-oxine exhibit considerable cytotoxic activity against 
leukaemia. Another oxine derivative, clioquinol has been used to identify cellular 
targets for zinc ionophores.116 
i ii iii 
H2SO4 
PhNO2 
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1.26.3 Tropolone 
Tropolone (Figure 1.9) IUPAC name 2-Hydroxy-2, 4, 6-cycloheptatrien-1-one has 
the chemical formula; C7H6O2 is a derivative of tropone that has hydroxyl group in 
the number 2-position.117 It was first characterized in 1945 by M.J.S Dewar and 
published in Nature.118 The compound is one from the group of α-hydroxyl ketones 
that are known to undergo a tautomeric hydrogen shift. The two degenerate forms of 
tropolone in solution only require low activation energy for the hydrogen transfer to 
occur. This tautomeric proton transfer illustrated in figure 1.9 is extremely fast and as 
such NMR spectra only show the averaged signal results for both of the forms.119 
 
 
 
 
 
 
Figure 1.10: Tropolone and its Tautomeric Proton Transfer119 
 
It can be synthesized by either acyloin condensation of the ethyl ester of pimelic acid 
and then oxidising with bromine, or bromination of 1, 2-cycloheptanedione using N-
bromosuccinimide and then the use of elevated temperatures resulting in 
dehydrohalogenation.117 Tropolone has resonance structures with various 
characteristics that are similar to polyones and polyenes but it does not have any 
aromatic characteristic which is unusual due to its structure. The compound is a 
viable starting material for greater ring structures such as steroids and has been used 
in Diels Alder reactions.117 Some of the family of tropolones have anti-bacterial 
properties and may have the potential for use in antimalarial treatments. Tropolone 
has been shown to be bacteriostatic and bactericidal for a wide range of bacterial 
species.119 Colchicine is an alkaloid compound with a tropolone ring and it 
demonstrates strong antitumour properties. Cancer cells undergo increased mitosis, 
hence they are more susceptible to colchicine poisoning than normal cells. The 
therapeutic properties of colchicine against cancer are limited by its toxicity to 
normal cells.120 
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1.26.4 Ethyl Maltol 
 
Ethyl maltol, IUPAC name; 2-Ethyl-3-hydroxy-4-pyranone has the chemical formula 
C7H8O3. Ethyl maltol was discovered in the 1970s.
121 It was originally isolated from 
larch tree bark and is produced through fermentation-organic  
 
 
 
 
 
 
to cover up the bad taste of chemicals and is found in wine, chocolate, sweets, 
cosmetics, medicines, fruit flavored drinks and tobacco.121 It has been reported that 
the pyrones, maltol (3-hydroxy-2-methyl-4-pyrone, Hma) and ethylmaltol (2-ethyl-3-
hydroxy-4-pyrone, Hema), are extremely proficient in increasing the bio-availability 
and absorption of metal complexes. This is because they deprotonate very easily.  A 
low pKa value indicates that the compound is acidic and will easily give up its proton 
to a base, and the pKa value for maltol is 8.46 and the pKa value for ethyl maltol is 
8.53.121, 122 Ethyl maltol is a non-toxic anionic bidentate uninegative ligand which can 
form thermodynamically stable metal complexes with various metal ions that have 
the required charge necessary for chelation and formation of neutral complexes.123 
Six membered heterocycles such as ethylmaltol have one readily ionisable proton 
from its hydroxyl group which gives it a zwitter-ionic aromatic type property.  These 
formed ethylmaltol complexes are stable at pH ranges that are found in a 
physiological environment. Ethyl maltol has been chelated to a number of metals 
including iron, aluminium, indium molybdenum and gallium.122 The compound has 
had its biocompatibility thoroughly studied and findings show a positive toxicity 
profile.123 Ethyl maltol has been chelated to iron with high affinity and selectivity, the 
resulting complex has been investigated in firstly the iron absorption from rats small 
intestines124 and secondly investigated within patients to restore iron balance in 
anaemia.123 Requirements for an iron ligand in the treatment of anemia are; high 
affinity for Fe
3+
, highly aqueous, giving good solubility of the complex, and non-
toxicity of the ligand. Ethyl maltol fulfills these requirements.123 
 
 
Figure 1.11: 
Ethyl Maltol 
synthesis. It is possible to extract ethyl maltol crystals from 
natural products or they can be produced by semi synthetic or 
synthetic methods. Synthetic and industrial production of ethyl 
maltol causes serious pollution to the environment; it has low 
production yields with a high cost of production.121It is 
commonly used as a flavour enhancer because it has the ability 
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1.26.5 Deferiprone 
 
Deferiprone, IUPAC name; 3-hydroxy-1, 2-dimethylpyridin-4(1H)-one, common 
trade name Ferriprox has the chemical formula C7H9NO2. Deferiprone is an iron 
chelator that is orally active.125 The compound was first designed 
 
 
 
 
 
 
per day and to the iron load of the patient. However it is possible that deferiprone can 
cause the number of white blood cells made by bone marrow to decrease 
(Agranulocytosis) occurring in approximately 1% of patients.125 Deferiprone is stable 
in conditions that exist in the human digestive system. It can successfully remove 
iron from patients suffering from iron overload from a range of organs and locations 
within the body including the heart and liver. Iron is needed for life to exist in the 
majority of species but conditions of primary iron overload such a hemochromatosis 
can lead to a build-up of this element.126 There is no excretory pathway for iron and a 
build-up of this element can result in free radical damage which can lead to disease 
and death.126 The complex has excellent binding properties with iron, and research 
has shown a high degree of relative specificity for the tris form of the deferiprone 
complex. Deferiprone has a molecular weight of 139 Da and is water soluble so it is 
able to move through cell membranes throughout the body without resistance. The 
complex is quickly eliminated from the body and has a half-life of about 2 hours with 
around 90% of the complex excreted in the urine.126 It can also be used to detoxify 
patients that have been exposed to other metals such as plutonium and uranium and 
remove excess aluminum in hemodialysis patients. Deferiprone exhibits potent 
cyclotoxic activity in human hepatoblastoma cell line HepG2 and neuroblastoma cell 
line HL-60.127 Tested against human oral tumour cells results showed that 
deferiprone exhibited tumour specific cyclotoxicity against cell line HSC-2 however 
the sensitivity of deferiprone in the experiments against the different cell lines 
differed remarkably from cell to cell.127 
and synthesised in 1978 at Professor R.C. Hider's laboratories 
at the University of Essex. Subsequent studies of the complex 
showed that deferiprone was capable of achieving effective 
short-term iron chelation125. Iron excretion was found to be 
directly related to the dose of deferiprone administered to the 
patient within the range of of 25 to 100 mg/kg body weight 
per day and 
H
H3C
CH3
 
Figure 1.12: 
Deferiprone 
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1.27 Zirconium Complexes 
There is a distinct lack of information in regards to the mechanisms of ligand 
coordination and interchange for Zr complexes. The published papers used 
throughout this thesis tend to focus on the characterisation of a specific complex 
rather than discuss the reasons behind the various methods used to synthesise the Zr 
compounds themselves. The extent of controlling the reaction to synthesise a two, 
three or four coordinated complex is not discussed in any of the published papers. 
Stoichiometric ratios of the metal and ligand involved in the synthesis process are a 
key factor in controlling the resulting coordination complex. 
 
Zr can form stable complexes with hydroxamates. For immono-PET purposes Zr 
Desferrioamine is used in the radiolabelling of antibodies128. However there seems to 
be in vivo stability problems with this complex and research has been conducted to 
provide data that will help to develop new improved hydroxamate based ligands for 
chelation to 
89
Zr.128 
 
1.27.1 Zirconium Tetrakisoxine 
 
The first Zr complex to be synthesised used the monoprotic bidentate chelating agent 
oxine. It is a colourless compound that is also commonly known as 8-quinolinol and 
oxyquinoline.129 There is very little information available in regards to the zirconium 
tetrakisoxine complex at present. The first paper reporting findings on this complex 
was published by David F. Lewis and Robert C. Fay in 1974.130 The paper reports 
that the stereochemistry of dodecahedral complexes of the transition metal type 
M(AB)4 is found to be dependent upon the electronic configuration of the transition 
metal involved, in this case Zr. 
 
A stereochemical rule was proposed by L. E. Orgel in 1960 that was related to the 
geometry of eight coordinated d
0
, d
1
 and d
2
 transition metal complexes.131 The rule 
states that complexes of the form MX4Y4 (M = a d
0
, d
1
 or metal ion and X, Y = 
monodentate ligands) are compelled to assume dodecahedral stereochemistry.132  
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Structures of dodecahedral M(AB)4 complexes which have asymmetric bidentate 
ligands such as zirconium tetrakisoxine have been used to confirm Orgel’s proposal 
for d
0 
and d
2 
complexes.130  
 
Advances were made to this proposed rule133 and the revised rule states that the 
structures of dodecahedral complexes of the form M(AB)4 can be predicted because 
of  the way in which the ligands can be sorted into their applicable co-ordination sites 
according to the electronic configuration of the central transition metal ion and the 
relative  π donor acceptor properties of the ligands.133 The structure of zirconium 
tetrakisoxine (prepared by a method not reported) was determined by the use of X-
ray diffraction. It is reported that the Zr atom occupies a position at the intersection 
of three twofold axes. The complex itself assumes a dodecahedral geometry.  
 
 
 
Figure 1.13: Zirconium Tetrakisoxine 
 
The paper concludes that the structures of zirconium tetrakis (oxine) and the previous 
reported structure of [W(5-bromo-quinoline-8-olate) 4]
133 provide conclusive 
evidence that the actual choice of stereoisomer for a dodecahedral molecule can be 
governed by the electronic configuration of the metal ion.130  
 
When there is a lack of unreasonable steric interactions Orgel's hypothesis can be 
used as a guide to the stereochemistry of eight coordinated d
0
 and d
2
 transition metal 
complexes.131 
NO
N
O
N O
N
O
Zr
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The third paper was published by Poopathy Kathrigamanathan and 
Sivagnanasundram Surenendrakumar in the Journal of Materials Chemistry more 
recently in 2010.134  The paper reports the findings of experimental work under taken 
resulting in two phases of zirconium tetrakisoxine. The research focuses on the 
possible uses of this complex in new organic light emitting diode (OLED) 
technology.  
 
The research team had been working on charge transporting material for OLED’s for 
over a decade and their research has shown that zirconium tetrakisoxine has excellent 
properties that are required for OLED instruments.  
 
It should be noted that the oxine ligand was used by C W Tang and S A Van Slyke in 
1987 to produce the first OLED135, in the form tris oxine aluminium and is a green 
light emmiter.136 The properties of the ziconium tetrakisoxine complex include good 
electron transport which also lowers the operating voltage and increases the lifespan 
and performance of OLED instruments when compared to the similar compound tris 
(8-hydroxyquinolinolate) aluminium.136  
 
1.27.2 Zirconium Tropolone Complexes 
 
There is very little information available in regards to the zirconium tetrakistropolone 
complex at present. The first paper reporting findings on this complex was published 
by Alan R. Davis and Frederick W. B. Einstein in 1978.137  
 
1.27.3 Zirconium Ethyl Maltol Complexes 
 
There is very little information or published work available in regards to the 
complexing of Zr to 2-ethyl-3-hydroxy-4-pyrone (ethyl maltol) in a ratio of 1:4 
forming a zirconium tetrakisethyl maltol complex at present. 
 
However research has been published that investigates dichlorobis (2-ethyl-3-
hydroxy-4-pyrone) Zr (IV) as a new catalyst for the polymerisation of ethylene.138  
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The paper reports that the complex has four isomers and the cis configuration occurs 
most often with it being the most stable of the four. This paper is the only found 
report of Zr being complexed with ethyl maltol.138 Ethyl maltol has also been 
chelated to tin and titanium in the form bis-ethylmaltolatodichloro-tin(IV) and bis-
ethylmaltolatodichloro-titanium(IV).139  
 
Ethyl maltol has been reported to chelate to iron with a high level of selectivity and 
affinity. The resulting complex has the ratio of 1:3 metal to ligand. It is a neutral 
complex and as such can easily cross membranes.140 
 
1.27.4 Zirconium Deferiprone Complexes 
 
There is currently no information or published work available in regards to the 
complexing of Zr to deferiprone in the form of a tetrakis complex or any other 
complex formed with this metal and ligand. 
 
This is to be expected due to the fact that deferiprone was designed for oral chelation 
therapy in patients with iron over load and has been used for this purpose in over 15 
countries in the last 7 years.141 It has also been successfully investigated in the 
treatment of aluminium overload in patients undergoing renal dialysis.141  
 
Zr is a metal which has no known biological function and as such it is to be expected 
that there would not be an excess of it within the body. Research investigating the 
effectiveness of deferiprone chelating to Zr in the body is clearly not required. The 
affinity deferiprone has with other metals such as magnesium (Mg), copper (Cu) and 
zinc (Zn) has been investigated142 but Zr has not. 
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CHAPTER 2 
Synthesis and Nuclear Magnetic Resonance Spectroscopic Characterisation of 
Zirconium Compounds 
 
2.1 Introduction 
 
Zirconium complexes with the common form of ZrL4 where L is a bidentate 
uninegative ligand are the focus in this thesis for the development of new zirconium 
radiometal complexes for the diagnosis and treatment of diseases. These complexes 
are neutral and can to diffuse into cells in a manner analogous to InL3 complexes. 
 
All of the synthesis methods reported in this chapter took place in the laboratories 
located in the Ingram building at the University of Kent at Canterbury. All 
compounds and equipment used in this chapter can be found in the appendix section. 
(Compounds: Table A1, p 225, Equipment A.1.1, p 220)  
 
NMR analysis was undertaken at the University of Kent at Canterbury utilising a 
JEOL NMR ECS-400 a 2-channel NMR console, JEOL STAC MAN auto sample 
changer and JEOL Delta v5.02 software. Full specifications and settings can be 
found in the appendix section of this thesis. 
 
CHN analysis was undertaken at firstly the University of Kent at Canterbury. 
Samples of the oxine ligand and the zirconium tetrakisoxine complex were analysed 
by Dr David Smith utilising an EMA Syst 1106 elemental analyser data system 
manufactured by Elemental Microanalysis Limited. Secondly CHN analysis was 
undertaken by Stephen Boyer at the Science Centre London Metropolitan University 
utilising a Carlo Erba Flash 2000 elemental analyser, configured for % CHN. 
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2.2 Synthesis Methods of Zr Complexes 
 
2.2.1 Synthesis of Zirconium Tetrakisoxine 
 
The reported method to synthesise zirconium tetrakis 8-hydroxyquinolinate, 
(reported as zirconium tetrakisoxine in this thesis) has been adapted from 
supplementary material relating to previously published work134 in which the 
complex has been synthesised for use in organic light emitting diodes (OLED). 
  
Oxine (5.0g; 0.0345mol) was completely dissolved in ethanol, (35 mL) in 150 mL 
glass conical flask. Zirconium tetrachloride (2.01g; 0.0085mol) was completely 
dissolved in ethanol, (25 mL) in a 150 mL glass conical flask. This solution was 
cooled to 10
o
C with an ice water bath. The solution of oxine (5.0 g; 0.0345 mol) in 
ethanol, was added carefully to solution of zirconium tetrachloride (2.01 g; 0.0085 
mol) in ethanol, drop wise with a narrow mouth bottle pipette. The solution was then 
stirred utilising the magnetic stirrer function of an electric hotplate and an octagon 
magnetic stirrer. The solution was stirred for 20 minutes at room temperature (20
o
C). 
The solution was then heated to 50
o
C in a water bath and piperidine (10 mL; 0.10 
mol) was added drop wise with a narrow mouth bottle pipette. This addition of 
piperidine to the solution caused a yellow precipitate to form. This suspension was 
then refluxed for 1 hour and was allowed to cool to room temperature. The resulting 
precipitate was collected by the use of a Büchner funnel, filter paper and vacuum 
conical flask. The resulting product was then washed with ethanol, (15 mL), 
tetrahydrofuran, (15 mL) and diethyl ether (15 mL). The product was then dried at 
70
o
C for 1 hour in an electric oven. Crude yield 5.057 g (89%). Soxhlet extraction 
was undertaken (5.057 g) with 1,4-dioxane, purifying the compound for 8 hrs. 1, 4-
dioxane was removed by use of a rotavap. The resulting yellow precipitate was 
further dried and collected by the use of a Büchner funnel, filter paper and vacuum 
conical flask. This collected compound was washed a final time with ethanol, (15 
mL). The compound was then dried for 2 hrs in an electric oven at 50
o
C and once dry 
was immediately placed into a glass air tight screw top storage container. 
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Carbon, hydrogen and nitrogen (CHN) analysis results for: 
zirconium tetrakisoxine; C36H24N4O4Zr 
 
Formula Weight: 667.82 g/mol 
 
  Expected 1
st
 Analysis 2
nd
 Analysis 
C % 64.75 64.12 63.55 
H % 3.62 3.77 3.67 
N % 8.69 8.59 8.35 
          Table 2.2 
 
Theoretical Yield: 5.678 g, 
Actual Yield: 4.012 g 
Percentage of Theoretical Yield: 70.7% 
 
2.2.2 Synthesis of Zirconium Tetrakistropolone 
 
The reported method to synthesise zirconium tetrakistropolone has been adapted 
from published work which reports the method used to synthesise zirconium tetrakis 
isopropyltropolone.143  
 
Tropolone (3.8 g; 0.031 mol) was completely dissolved in chloroform (75 mL) in a 
250 mL glass conical flask. Zirconium tetrachloride (1.78 g; 0.0076 mol) was 
completely dissolved in chloroform (75 mL) in 250 mL glass conical flask. The 
solution of tropolone was added carefully to the solution of zirconium tetrachloride 
drop wise with a narrow mouth bottle pipette. The resulting solution was then stirred 
utilising the magnetic stirrer function of an electric hotplate and an octagon magnetic 
stirrer for 20 minutes at room temperature (~20
o
C). The solution became pale yellow 
in colour. The solution was then heated in a water bath at between 50
o
C and 55
o
C for 
2 hrs. The overall volume of the solution was reduced to ~40 mL during this period. 
The remaining chloroform was removed by use of a rotavap for 30 minutes.  
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The compound was then dried at 40
o
C for 2 hrs in an electric oven and once dry was 
immediately placed into a glass air tight screw top storage container. 
 
Carbon, hydrogen and nitrogen (CHN) analysis results for C28H20O8Zr 
 
Formula Weight: 575.34 g/mol 
 
  Expected 1
st
 Analysis 2
nd
 Analysis 
C % 58.40 53.24 53.33 
H % 3.50 3.50 3.51 
N % 0 0 0 
          Table 2.3 
 
The CHN results suggest a formula for the complex of; 
C28H20O8Zr · 0.55 CHCl3    
 
  Expected 1
st
 Analysis 2
nd
 Analysis 
C % 53.47 53.24 53.33 
H % 3.23 3.50 3.51 
N % 0 0 0 
          Table 2.4 
 
Formula Weight:   658.91 g/mol 
Theoretical Yield:   5.008 g 
Actual Yield:     4.179g 
Percentage of Theoretical Yield:  83.45 % 
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2.2.3 Synthesis of Zirconium Dichlorobis Ethyl Maltol 
 
The reported method to synthesise zirconium dichlorobis ethyl maltol has been 
adapted from published work which reports the method used to synthesise zirconium 
dichlorobis ethyl maltol for use as a catalyst for ethylene polymerization.138 
 
Tetrahydrofuran, (50 mL) was added drop wise with a narrow mouth bottle pipette to 
ethyl maltol (2-ethyl-3-hydroxy-4-pyrone), (2.00 g; 0.01428 mol) contained in a 150 
mL glass conical flask. The ethyl maltol was completely dissolved in the 
tetrahydrofuran. Tetrahydrofuran, (50 mL) was added drop wise with a narrow 
mouth bottle pipette to zirconium tetrachloride (1.66 g; 0.00712 mol) contained in a 
150 mL glass conical flask. The zirconium tetrachloride was completely dissolved in 
the tetrahydrofuran. The solution of ethyl maltol was added carefully to the solution 
of zirconium tetrachloride in drop wise with a narrow mouth bottle pipette. The 
resulting solution was then stirred utilising the magnetic stirrer function of an electric 
hotplate and an octagon magnetic stirrer for 60 minutes at room temperature (~20
o
C). 
The solution was then heated in a water bath at between 50
o
C and 55
o
C for 1.5 hrs. 
The overall volume of the solution was reduced to ~30 mL during this period. 
Hexane (30 mL) was added to the solution and a pale yellow precipitate was formed. 
The resulting precipitate was collected by the use of a Büchner funnel, filter paper 
and vacuum conical flask. The product was washed with hexane (4x15 mL) and was 
then dried at 55
o
C for 2 hrs in an electric oven. Once dry the zirconium dichlorobis 
ethyl maltol was immediately placed into a glass air tight screw top storage 
container. 
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Carbon, hydrogen and nitrogen (CHN) analysis results for:  
zirconium dichlorobis ethyl maltol; C14H14Cl2O6Zr 
 
Formula Weight: 440.39 g/mol 
 
  Expected 1
st
 Analysis 2
nd
 Analysis 
C % 38.18 38.26 38.27 
H % 3.20 3.13 3.19 
N % 0 0 0 
          Table 2.5 
 
Theoretical Yield:    3.316 g 
Actual Yield:    2.958 g 
Percentage of Theoretical Yield:  89.2% 
 
 
2.2.4 Synthesis of Zirconium Tetrakisethyl maltol 
 
The reported method to synthesise zirconium tetrakisethyl maltol has been adapted 
from published work which reports the method used to synthesise zirconium 
dichlorobis ethyl maltol for use as a catalyst for ethylene polymerization.138 The 
method reported for the synthesis of zirconium dichlorobis ethyl maltol above is 
based on the stoichiometric ratio of 2:1 where there are two ethyl maltol ligands for 
one zirconium tetra chloride molecule.  
 
The method for the synthesis of zirconium tetrakisethyl maltol has been adapted so 
that there is a stoichiometric ratio of 4:1, so that there are four ethyl maltol ligands 
for one ZrCl4 molecule. 
 
Tetrahydrofuran, (100mL) was added drop wise with a narrow mouth bottle pipette 
to ethyl maltol (2-ethyl-3-hydroxy-4-pyrone), (4.00 g; 0.02856 mol) contained in a 
250 mL glass conical flask.  
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The ethyl maltol was completely dissolved in the tetrahydrofuran. Tetrahydrofuran, 
(50 mL) was added drop wise with a narrow mouth bottle pipette to zirconium 
tetrachloride (1.66 g; 0.00712 mol) contained in a 250 mL glass conical flask. The 
zirconium tetrachloride was completely dissolved in tetrahydrofuran. The solution of 
ethyl maltol was added carefully to solution of zirconium tetrachloride drop wise 
with a narrow mouth bottle pipette. The solution was then stirred utilising the 
magnetic stirrer function of an electric hotplate and an octagon magnetic stirrer. The 
solution was stirred for 2 hrs at room temperature (~20
o
C). The solution was then 
heated in a water bath at between 50
o
C and 55
o
C for 3 hrs. The overall volume of the 
solution was reduced to ~30 mL during this period. Hexane (50 mL) was added to 
the solution and a pale yellow precipitate was formed. The resulting precipitate was 
collected by the use of a Büchner funnel, filter paper and vacuum conical flask. The 
product was washed with hexane (4x20 mL) and was then dried at 55
o
C for 3 hrs in 
an electric oven. Once dry the zirconium tetrakisethyl maltol was immediately placed 
into a glass air tight screw top storage container. 
 
Carbon, hydrogen and nitrogen (CHN) analysis results for C28H28O12Zr 
 
Formula Weight: 647.74 g/mol 
 
  Expected 1st Analysis 2nd Analysis 
C % 51.92 51.74 51.82 
H % 4.36 4.26 4.30 
N % 0 0 0 
          Table 2.6 
 
Theoretical Yield:    4.612g 
Actual Yield:     4.199g 
Percentage of Theoretical Yield:  91.0% 
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2.2.5 Synthesis of Zirconium Tetrakisdeferiprone 
 
The method used to synthesise zirconium tetrakisdeferiprone was adapted from the 
method reported by Wen-Yuan Hsieh and Shuang Liu to synthesise chromium tris 
deferiprone.144 Weights of the metal compound and ligand required were altered 
accordingly. 
 
Glassware used during the synthesis of zirconium tetrakisdeferiprone was soaked in a 
1% solution of nitric acid and 1% solution of hydrochloric acid for 24 hrs. The 
soaked glass wear was rinsed with millipore water and dried with an electric oven 
before use.  
 
Deferiprone (0.561 g; 0.004 mol) was added to a solution of methanol (70 mL) in a 
250 mL glass round bottom flask. The solution was then warmed to ~32
o
C until the 
deferiprone had completely dissolved. Zirconium tetrachloride (0.242 g; 0.001 mol) 
was completely dissolved in the solution containing deferiprone in a fume cupboard. 
The addition of zirconium tetrachloride resulted in a release of hydrogen chloride 
which was allowed to disperse. The solution was then refluxed for 5 hrs, no 
precipitate had formed at this stage.  
 
The solution was then allowed to cool to room temperature. Diethyl ether (150 mL) 
was then added to the solution and a white precipitate was immediately formed. The 
precipitate was filtered with the use of a Büchner funnel. The solid was washed with 
diethyl ether then recrystallized 3 times (methanol/diethyl ether). The compound was 
then dried for 18 hrs in a vacuum oven and once dry was immediately placed into a 
glass air tight screw top storage container. 
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Carbon, hydrogen and nitrogen (CHN) analysis results for C28H32N4O8Zr 
 
Formula Weight: 643.45 g/mol 
 
  Expected 1
st
 Analysis 2
nd
 Analysis 
C % 52.24 38.94 38.84 
H % 5.01 6.49 6.48 
N % 8.70 6.60 6.63 
          Table 2.7 
The CHN results suggest a formula for the complex of; 
C28H32N4O8Zr 
. 
12H2O 
 
  Expected 1
st
 Analysis 2
nd
 Analysis 
C % 39.02 38.94 38.84 
H % 6.57 6.49 6.48 
N % 6.50 6.60 6.63 
           Table 2.8 
 
Formula Weight:    859.99 g/mol   
Theoretical Yield:   0.859 g 
Actual Yield:    0.767 g    
Percentage of Theoretical Yield: 89.3 % 
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2.3 Results and Discussion, Synthesis 
 
The zirconium tetrakisoxine complex was synthesised by adapting a previously 
reported method.134 The synthesis method of zirconium tetrakistropolone was devised 
adapting a previously reported method stating the synthesis of zirconium tetrakis 
isopropyltropolone.143 The zirconium dichlorobis ethyl maltol complex was also 
synthesised by adapting a previously reported method.138 The method previously 
reported to synthesise zirconium dichlorobis ethyl maltol was adapted and the 
synthesis of tetrakisethyl maltol was undertaken. The method to synthesise zirconium 
tetrakisdeferiprone was developed using an amalgamation of the previously 
developed methods for the synthesis of the zirconium tetrakis complexes.  
 
The CHN analysis results of the zirconium tetrakisoxine, zirconium dichlorobis ethyl 
maltol and zirconium tetrakisethyl maltol complexes demonstrate that the expected 
percentage composition values of these three compounds were extremely close to the 
results of the analysis undertaken. The analysis result values are within ±0.3% of the 
expected results. 
 
The CHN results for the zirconium tetrakistropolone complex suggest a formula of 
C28H20O8Zr · 0.55 CHCl3. It has been previously reported
137 that a tropolone ligand 
can be disordered when in a complex between two positions due to close contact 
with a partially occupied chloroform molecule.137 This would explain the presence of 
the chloroform.  
 
The CHN results for the zirconium tetrakisdeferiprone suggest the formula 
C28H32N4O8Zr. 12H2O for the complex which shows an incorporation of water into 
the structure. Complexes of the form M tris deferiprone (M= Cr, Al, Ga, Fe, In and 
Mn) are known to be significantly hydrated incorporating 12 water molecules per 
complex in their crystal structures.144 Mass spectrometry results confirmed the 
synthesis of the zirconium tetrakisdeferiprone complex. Zirconium tetrakisethyl 
maltol and zirconium tetrakisdeferiprone are novel complexes and it has not been 
possible to find previous accounts of these two complexes. 
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2.4 Mass Spectrometric Analysis of Zirconium Tetrakisdeferiprone 
 
Zirconium tetrakisdeferiprone is a novel complex with no previously reported close 
approximations. Mass spectrometry was used to further characterise the zirconium 
tetrakisdeferiprone complex.  
 
2.4.1 Mass Spectrometry 
 
It is possible to deflect molecules by magnetic fields if the molecule has been 
converted into an ion as electrically charged particles are affected by magnetic 
fields.145 
The mass spectrometric process involves several steps. Firstly an atom is ionised by 
knocking off one or more electrons which results in a positive ion. The ions are all 
accelerated so that they all have the same kinetic energy. Depending on the mass of 
the ion it will be deflected accordingly.145 Deflection of ions also relies upon the 
magnitude of the positive charge of the ion. A higher charge equals a greater amount 
of deflection from the magnetic field. Finally the beams of ions pass through the 
apparatus and are detected electrically.146 
Two mass spectrometry techniques were used during these experiments; Matrix-
assisted laser desorption/ionization time of flight (MALDI-TOF) and electrospray. 
MALDI-TOF mass spectrometry is a technique that allows the analysis of 
compounds which are inclined to be fragile and fragment when ionized by more 
traditional ionization methods.146 Electrospray mass spectrometry was used 
employing direct infusion where by a liquid sample is introduction and continually 
flowed into a mass spectrometer ion source. The electrospray technique uses high 
voltage electricity to create an aerosol from a liquid resulting in the production of 
ions.145 
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2.4.2 Experimental Method 
  
Experimental work was carried out by Kevin Howland, Biomolecular Science 
Facility Manager, School of Biosciences, University of Kent. MALDI-TOF and 
electrospray mass spectrometry were both used to analyse the zirconium deferiprone 
compound. MALDI-TOF mass spectra was recorded on a ultraflexTOF/TOM mass 
spectrometer. Electro spray mass spectra were recorded on a Bruker micrOTOF-Q II 
mass spectrometer. The sample was injected as a 0.01 mg/mL infusion into the 
electro spray source, operating in positive ion mode, at 4.5 kV and mass spectra 
recorded from 50-1250 m/z.  Data was analysed with Bruker’s Compass Data 
Analysis software. 
  
2.4.3 Results and Discussion 
 
MALDI-TOF mass spectrometry, which is the softest ionisation technique available 
at the University of Kent resulted is a spectra showing only the zirconium tris 
deferiprone complex (figure 2.1) However a cationising agent was not used which 
may have enhanced the ionization efficiency. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: MALDI-TOF mass spec of Zirconium Deferiprone Complex 
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Electrospray mass spectrometry using direct infusion was also used to analyse the 
zirconium deferiprone complex. Results showed that the predominant ion is the 
zirconium tris deferiprone, however there is a peak at 665 m/z which could be 
explained by a zirconium tetrakisdeferiprone sodium adduct. Expansion of this 
region along with the theoretical isotope pattern for the zirconium tetrakisdeferiprone 
can be seen in figure 2.3. 
 
Figure 2.2: MALDI-TOF Spectra of Zirconium Tetrakisdeferiprone 
 
 
Figure 2.3: Actual and Predicted Spectra of Zirconium Tetrakisdeferiprone 
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2.4.4 Conclusion 
 
Both of the mass spectrometry techniques have shown that there appears to be 
zirconium complexes with either three or four deferiprone ligands attached to the 
zirconium metal.  
 
2.5 Crystal Growth and X-ray Analysis of Deferiprone Complex 
 
2.5.1 Introduction 
 
To confirm the structure of the zirconium tetrakisdeferiprome complex it was 
decided to grow crystals of a nature that could be analysed with single-crystal X-ray 
diffraction.147 
 
2.5.2 Crystal Growing 
 
A variety of methods to grow crystals was undertaken over a period of six months. 
Methods included, slow evaporation (22
o
C and 5
o
C), solvent diffusion by layering, 
vapour diffusion, reactant diffusion and sublimation.148 All of these methods failed to 
yield crystals of a quality that could be analysed with single-crystal X-ray diffraction 
apart from slow evaporation at 5
o
C. 
 
2.5.3 Method  
 
Crystals were grown in two batches. Batch 1; zirconium tetrakisdeferiprone (0.1g) 
was dissolved in the minimum amount of methanol possible until saturated (<10mL). 
Once saturated the solution was heated to dissolve the entire remaining compound. 
This was then placed in a glass test tube, and sealed with parafilm with a small 
needle sized hole to allow slow evaporation over a number of months at a 
temperature of 5
o
C. Batch 2 follows the same method with methanol exchanged for 
dimethyl sulfoxide. 
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2.5.4 Results and Discussion 
 
Two batches of crystals were grown by was slow evaporation at 5
o
C that yielded 
crystals suitable for analysis. These crystals were sent to University College London 
for Single-Crystal X-ray Diffraction analysis. 
 
2.5.5 Single-Crystal X-ray Diffraction  
 
All single-crystal X-ray diffraction experiments were undertaken by Professor Derek 
A. Tocher, deputy head, department of chemistry, University College London. 
 
2.5.6 Crystal Batch 1 
 
Two data sets were collected; the first was with a crystal from batch 1 with Cu 
radiation. This could not be solved so a second crystal form batch 1 was analysed 
with Mo radiation and was found to be the hydrochloride salt of deferiprone as the 
monohydrate, [C7H8N1(OH)2]
+
Cl
-.
H2O. Once the Mo dataset had been solved it was 
possible to use Cu radiation on another crystal from batch 1. Unit cell parameters of 
crystals were analysed and it was found with certainty that all three of the crystal 
samples from batch 1 are the same organic salt as seen in figure 2.4. 
 
 
Figure 2.4: Hydrochloride Salt of Deferiproneas a Monohydrate 
[C7H8N1(OH)2]
+
Cl
-
.H2O. 
 
  
58 
 
2.5.7 Crystal Batch 2  
 
A fragment from a crystal from batch 2 was placed on the diffractometer and showed 
no spots. A thinner sample was placed on the diffractometer with the same results. A 
larger (> 3mm long) crystal was placed on the diffractometer and there was only 
diffuse scattering. From these results it can be concluded that the crystals from batch 
2 are in fact completely amorphous. 
 
2.5.7 Conclusion 
 
All of the crystals analysed from batch 1 were found to be protonated ligand without 
any zirconium. All of the crystals from batch 2 were found to be completely 
amorphous. Results indicate that it has not been possible to grow any crystals of the 
zirconium tetrakisdeferiprone complex. As such it has not been possible to use 
single-cystal X-ray diffraction to obtain information about the structure of the 
zirconium tetrakisdeferiprone complex. 
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2.6 Nuclear Magnetic Resonance Spectroscopy 
 
Nuclear magnetic resonance (NMR) spectroscopy is a widely used analytical 
technique which can provide useful data that can be used to build models of the 
compounds being investigated. The technique depends on the magnetic properties of 
the atomic nucleus. When nuclei are deposited in a strong magnetic field, certain 
nuclei will resonate at a distinctive frequency located in the radio frequency area of 
the electromagnetic spectrum.149 When there is a difference in the resonance 
frequency it is possible to derive detailed information about the molecular structure 
in which the atom is located. This information can then be compared to simulation 
predictions to ascertain whether a predetermined hypothesis was correct. 
 
 Chemical shift data provides information about the local surroundings of the atom. 
The resonant frequency varies slightly depending on the position of an atom within a 
molecule, known as the chemical environment. Bonding electrons establish their own 
small scale magnetic field and this in turn alters the external magnetic field in the 
proximity of the nucleus, in the order of one part per million.149 
 Signal intensity, which is measured as the integral of the signal, is derived from the 
number of equivalent atoms which are present in the given environment. The 
absorption signal in the NMR spectra is in most cases proportional to the number of 
protons that are advancing into resonance at the frequency of the signal.150  Hence the 
area which is under the absorption peaks is directly proportional to the number of 
protons which have been detected.150 
 Spin-spin coupling and through-space interactions can be used to determine 
distances/spacing. In high resolution NMR spectroscopy the splitting of NMR signals 
into multiplets is due to scalar or indirect coupling of nuclear spins facilitated by 
covalent bonding.151 
NMR spectroscopy will be employed and findings will be reported in this chapter. 
The technique will be used to determine the loss of a proton from each of the ligands 
which would have occurred once binding of the ligand to the zirconium ion has 
occurred. There will be a chemical shift once the ligand has bound to the metal ion 
and the differences between the spectra of the ligand and the metal complex are 
compared and findings reported.  
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2.7 Experimental Method 
 
For 
1
H NMR analysis of the compounds the quantity of material to be dissolved was 
between about 5 to 25 mg depending on solubility of the complex into the deuterated 
solvent. For 
13
C NMR analysis of the compounds as much compound was dissolved 
as possible in to the deuterated solvent (as 
13
C is six thousand times less sensitive). 
 
The complex was dissolved in 1 mL of deuterated solvent in a clean sample vial at 
room temperature ~22
o
C. Once fully dissolved the deuterated solvent had become 
saturated with the compound and the solution was drawn up into a sterile syringe 
fitted with a sterile microlance 3 needle. Between the needle and the sterile syringe a 
ministart single use filter unit (0.45 µm) was used. The solution was then pushed 
through the filter and needle into a clean and sterile NMR tube; O.D: 5 mm, thin 
walled, length 20 cm. The height of the solution contained in the NMR tube was 
between 4.5 cm and 5.5 cm in all experiments to ensure accurate shimming of the 
apparatus.  The NMR tube cap was then securely place onto the NMR tube. 
 
The NMR tube was then placed into the sample carriage and the position number 
was noted. The JEOL Delta software (v.5.0.1) controlling the NMR spectrometer 
was set according to experimental requirements and the experiment was run. Results 
were automatically saved on to the PC controlling the NMR spectrometer. 
 
Tables of equipment, equipment settings and reagents used throughout this chapter 
can be located in the appendix section of this thesis.
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2.7.1 
1
H and 
13
C NMR of Oxine and Zirconium Tetrakisoxine 
 
Figure 2.5: 
1
H NMR of Oxine in DMSO-d6 
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Figure 2.6: 
13
C NMR of Oxine in DMSO-d6 
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Figure 2.7: 
1
H NMR of Zirconium Tetrakisoxine in DMSO-d6 
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Figure 2.8: 
13
C NMR of Zirconium Tetrakisoxine in DMSO-d6
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2.7.2 
1
H and 
13
C NMR of Tropolone and Zirconium Tetrakistropolone
 
Figure 2.9: 
1
H NMR of Tropolone in DMSO-d6 
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Figure 2.10: 
13
C NMR of Tropolone in DMSO-d
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Figure 2.11: 
1
H NMR of Zirconium Tetrakistropolone in DMSO-d6 
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Figure 2.12: 
13
C NMR of Zirconium Tetrakistropolone in DMSO-d6 
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2.7.3 
1
H and 
13
C NMR Ethyl Maltol, Zirconium Dichlorobis Diethyl Maltol and Zirconium Tetrakisethyl Maltol
 
Figure 2.13: 
1
H NMR of Ethyl Maltol DMSO-d6
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Figure 2.14: 
13
C NMR of Ethyl Maltol in DMSO-d6 
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Figure 2.15: 
1
H NMR of Zirconium Dichlorobis Ethyl Maltol in DMSO-d6 
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Figure 2.16: 
13
C NMR of Zirconium Dichlorobis Ethyl Maltol in DMSO-d6 
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Figure 2.17: 
1
H NMR of Zirconium Tetrakisethyl Maltol in DMSO-d6 
 
ab
un
da
nc
e
0
1.
0
2.
0
3.
0
4.
0
X : parts per Million : Proton
8.0 7.0 6.0 5.0 4.0 3.0 2.0 1.0
a
b
2
3
 
 CHa 
 CHb 
 CH2 
 CH3 
  
 
7
4
 
 
Figure 2.18: 
13
C NMR of Zirconium Tetrakisethyl Maltol in DMSO-d6
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2.7.4 
1
H & 
13
C NMR of Deferiprone and Zirconium Tetrakis Deferiprone
 
Figure 2.19: 
1
H NMR of Deferiprone in DMSO-d6 
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Figure 2.20: 
13
C NMR of Deferiprone in DMSO-d6 
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Figure 2.21: 
1
H NMR of Zirconium Tetrakisdeferiprone in DMSO-d6 
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Figure 2.22: 
13
C NMR of Zirconium Tetrakisdeferiprone in DMSO-d6
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2.8 Results and Discussion 
 
For NMR sample preparation all compounds were dissolved in d
6
-DMSO.  All NMR 
spectra have been referenced to a d
6
-DMSO NMR residual proton peak at 2.46 ppm 
and NMR carbon peak at 40.00 unless stated otherwise.  
 
2.8.1 Oxine 
 
The NMR results were in agreement with previously published findings.152 This 
paper reports the findings of proton nuclear magnetic resonance studies of 8-
quinolinol and several of its metal complexes. However the paper is over 40 years 
old and it reports the shifts relative to DMSO. In the cases of the spectra reported in 
this thesis the NMR spectrometer has assigned the centre of the DMSO quintet to 
2.46, hence to correct the values and compare the results reported from the paper to 
the recent experimental findings 2.46 needs to be added to all NMR values as 
illustrated in the table below. 
  Baker et al  Baker (+2.46) Current Results 
2-H 6.27 8.73 8.78 
3-H 4.95 7.41 7.47 
4-H 5.71 8.17 8.26 
5-H 4.82 7.28 7.34 
6-H 4.87 7.33 7.40 
7-H 4.58 7.04 7.06 
Table 2.8 
The assignment of the peaks is as follows: 
δH(400 MHz, d
6
-DMSO), 9.81 (1 H, br s, OH), 8.78 (1 H, d, J2,3 3.7 Hz, 2-H), 8.26 
(1 H, d, J3,4 8.3 Hz, 4-H), 7.47 (1 H, dd, J2,3 4.1  Hz , J3,4 8.3 Hz, 3-H), 7.40 (1 H, dd, 
J5,6 7.8 Hz, J6,7 7.4 Hz, 6-H) 7.34 (1 H, d, J5,6 7.8 Hz, 5-H), 7.06 (1 H, d, J6,7 7.4 Hz, 
7-H) 
 
To assign the 
13
C peaks of the analysed oxine, previously published work by J.K. 
Howie et al153 was utilized. The published work shows the DMSO peak assigned as 
40.018 which is in agreement with this research assigning the peak as 40.00. 
 
δc(100 MHz, d
6
-DMSO) 153.86 (C8), 148.66 (C2), 139.02 (C9), 136.58 (C4), 129.33 
(C10), 128.04 (C6), 122.35 (C3), 118.25 (C5), 111.83 (C7) 
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2.8.2 Zirconium Tetrakisoxine 
 
The method used to synthesise the compound was adapted from supplementary data 
provided from the previously published work by Kathirgamanathan et al.134 The 
paper claims to report the discovery of two new phases of zirconium tetrakis 8-
hydroxyquinolinate (reported in this thesis as zirconium tetrakisoxine). The 
supplementary data provided gives NMR spectra for both an alpha and beta form of 
the zirconium tetrakisoxine complex.134 However from this supplementary data it is 
not possible to identify a difference between the alpha and beta forms. The 
supplementary data provided by Kathirgamanathan et al134 only shows the proton 
chemical shifts for the alpha form of the complex and the carbon chemical shifts for 
the beta form of the complex. The proton NMR chemical shift data and allocation of 
peaks to the complex are reported below and is closely related to the supplementary 
data reported by Kathirgamanathan 134 regarding the alpha form of the complex. 
 
δH(400 MHz, d
6
-DMSO), 8.64 (1 H, b s, 2-H), 8.19 (1 H, d, J3,4 8.3 Hz, 4-H), 7.37-
7.30 (2 H, m, 5-H and 6-H), 7.06 (1 H, d, J3,4 8.2 Hz, 3-H), 6.73 (1 H, d, J6,7 7.3 Hz, 
7-H) 
 
The carbon NMR chemical shift data and allocation of peaks to the complex is 
reported below and is effectively identical to the supplementary data reported by 
Kathirgamanathan 134 in regards to the beta form of the complex. 
 
δc(100 MHz, d
6
-DMSO) 162.82 (C8), 145.88 (C2), 141.73 (C9), 138.37 (C4), 129.90 
(C10), 129.61 (C6), 122.17 (C3), 114.15 (C5), 112.37 (C7) 
 
For NMR sample preparation, tropolone and zirconium tetrakistropolone were 
dissolved in pure d
6
-DMSO. During the 
1
H analysis of the compounds the NMR 
spectrometer assigned the centre of the DMSO quintet to 2.462. 
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2.8.3 Tropolone 
 
The 
1
H and 
13
C spectra of tropolone illustrate the protons as expected for the 
complex. The 
1
H allocation of peaks for tropolone is as follows: 
 
δH(400 MHz, d
6
-DMSO), 7.41 (2H, dd, J 9.7, 11.0 Hz, H3 & 5),  7.22 (2 H, d, J2,3 J5,6 
11.0 Hz, H2 & 6), 7.04 (1 H, t, J 9.7 Hz, H4). 
 
The 
13
C allocation of peaks for tropolone is as follows; (100 MHz, d
6
-DMSO) 172.27 
(C1 &C7), 137.79 (C2 & C6), 128.41 (C4), 124.90 (C3 & C5). 
 
2.8.4 Zirconium Tetrakistropolone 
 
The 
1
H and 
13
C spectra of zirconium tetrakistropolone illustrate the protons as 
expected for the complex. The 
1
H assignment of peaks for zirconium 
tetrakistropolone is as follows:  
 
δH (400 MHz, d
6
-DMSO), 8.31 (0.125H, s, CHCl3), 7.63 (2H, dd, J 9.6 Hz, 11.0, H3 
& 5), 7.23 (2 H, d, J2,3 J5,6 11.0 Hz, H2 & 6), 7.17 (1 H, t, J 9.6 Hz, H4). 
 
The 
13
C assignment of peaks for tropolone is as follows: δc (100 MHz, d
6
-DMSO) 
181.70 (C1 &C7), 140.29 (C2 & C6), 128.26 (C4), 125.03 (C3 & C5). 
 
2.8.5 Ethyl Maltol 
 
The 
1
H spectrum of ethyl maltol illustrates the protons as expected for the complex. 
The 
1
H assignment of peaks for ethyl maltol are as follows: δH (400 MHz, d
6
-
DMSO), 8.83 (1 H, br s, OH), 8.06 (1H, d, Ja, b 5.5 Hz, CHa), 6.34 (1 H, d, Ja, b 5.5 
Hz, CHb), 2.63 (2 H, q, J 7.3 Hz, CH2), 1.09 (3 H, t, J 7.8 Hz, CH3) 
 
The 
13
C assignment of peaks for ethyl maltol is as follows: (100 MHz, d
6
-DMSO) 
173.26 (CO), 155.25 (CHa), 153.79 (C2), 142.74 (C3), 113.95 (CHb), 21.45 (CH2), 
11.39 (CH3) 
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2.8.6 Zirconium Dichlorobisethyl Maltol 
 
Published research on the synthesis of a new zirconium catalyst for ethylene 
polymerization138
,154 reports that depending of the synthesis method they have found 
four isomers of the zirconium dichlorobisethyl maltol complex and are as follows; 
 
1H-NMR (300 MHz, DMSO-d6): 8.56ppm (d, 2Ha, JHH  5 Hz, Ha - isomer A), 8.51 
(d, 2Ha, JHH 5 Hz, Ha - isomer B), 8.42 (d, 2Ha, JHH 5 Hz, Ha – isomer C), 8.36 (d, 
2Ha, JHH 5 Hz, Ha – isomer D), 6.81 (d, 2Hb, JHH 5.1 Hz, Hb - isomer B), 6.76 (d, 
2Hb, JHH 5.1 Hz, Hb - isomer A), 6.72 (d, 2Hb, JHH 5.1 Hz, Hb - isomer D), 6.63 
(d, 2Hb, JHH 5.1 Hz, Hb - isomer C);  2.68 (q, 4H, JHH 6 Hz, CH2), 2.61 (q, 4H, 
JHH 6 Hz, CH2); 1.08 (t, 6H, JHH 6 Hz, CH3), 1.04 (t, 6H, JHH 6 Hz, CH3). 
 
Experimental results are similar to the published research that relates to the third 
synthesis method138; The 
1
H assignment of peaks for dichlorobisethyl maltol are as 
follows; δH (400 MHz, d
6
-DMSO), 8.46 (1H, d, Ja,b 5 Hz, CHa), 6.79 (1 H, d, Ja,b 5 
Hz, CHb), 3.38 (2 H, q, J 7.3 Hz, CH2), 1.04 (3 H, t, J 6.9 Hz, CH3). 
 
Residual hexane from the synthesis of the compound has resulted in the following 
peaks; δH (400 MHz, d
6
-DMSO), 1.21 (6 H, m, CH3), 0.80 (8 H t, CH2). 
 
A weak isomer signal is assigned to,( 2.61 q, 4H, JHH 6, CH2). 
 
Previous published research on the synthesis of a new zirconium catalyst for ethylene 
polymerization138
,154 the 
13
C assignment of peaks for ethyl maltol are as follows: 13C-
NMR (100 MHz, DMSO-d6): 180.97 (Cc CO, isomer C), 180.19 (Cc CO, isomer 
B),179.91 (Cc CO, isomer D), 158.06(Ca), 157.08 (Ca); 156.10 (Cd), 155.22 (Cd); 
153.65 (Ce), 153.26 (Ce); 110.16 ppm (Cb), 109.88 (Cb); 21.77 (CH2), 21.63 (CH2), 
21.49 (CH2); 11.66 (CH3). 
 
Experimental results and the 
13
C assignment of peaks for zirconium dichlorobis ethyl 
maltol are as follows: (100 MHz, d
6
-DMSO) 179.78 (CO), 157.93 (CHa), 155.91 
(C2), 152.55 (C3), 109.98 (CHb), 21.58 (CH2), 11.49 (CH3). 
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2.8.7 Zirconium Tetrakisethyl maltol 
 
The 
1
H spectrum of zirconium tetrakisethyl maltol illustrates the protons as expected 
for the complex. The NMR spectra of the free ligand displays a resonance relating to 
the hydroxyl group ligand which is absent from the NMR spectra of the zirconium 
tetrakisethyl maltol complex. This indicates that there has been deprotonation of the 
free ligand because of metal insertion which was expected. Complexing of the ligand 
to Zr has also resulted in a shift of the Ha and Hb protons to a higher chemical shift.  
 
The 
1
H assignment of peaks for zirconium tetrakisethyl maltol is as follows: δH (400 
MHz, d
6
-DMSO), 8.28 (1H, d, Ja,b 5.2 Hz, Ha), 6.68 (1 H, d, Ja,b 4.8 Hz, Hb), 2.54 (2 
H, q, J 7.3 Hz, CH2), 0.95 (3 H, t, J 7.6 Hz, (CH3) 
 
The 
13
C assignment of peaks for zirconium tetrakisethyl maltol is as follows: δc(100 
MHz, d
6
-DMSO), 180.28 (CO), 155.95 (Ca), 154.34 (C2), 153.77 (C3), 109.92 (Cb), 
21.44 (CH2), 11.40, CH3) 
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2.8.9 Deferiprone 
 
For NMR sample preparation, deferiprone was dissolved in pure d
6
-DMSO. During 
the 
1
H analysis of deferiprone the NMR spectrometer assigned the centre of the 
DMSO quintet to 2.462. The exact splitting patterns are not observed because the un-
equivalent protons are very similar and the NMR spectrometer is unable to 
differentiate them clearly from each other. The NMR spectra of deferiprone do not 
show a resonance relating to the hydroxyl group. It is presumed that this is obscured 
by the other peaks in the NMR spectra. NMR prediction software was utilised 
(Copyright: Luc Patiny - Ecole Polytechnique Fédérale de Lausanne) to predict 
possible 
1
H assignments of the deferiprone complexes. These are as follows; 7.63 (1 
H), 5.65 (1 H), 3.98 (3 H), 2.07 (3 H). This information was utilised to assist in the 
assignment of the 
1
H peaks the following obtained results are within close agreement 
with previously published findings85. 
 
The 
1
H allocation of peaks for deferiprone is as follows: δH (400 MHz, d
6
-DMSO), 
7.78 (1 H, d, J  6.8 CHNMe), 6.40 (1 H, J 6.8 CHCO), 3.82 (3 H, s, NMe), 2.29 (3 H, 
s, Me)  
 
The 
13
C allocation of peaks for deferiprone is as follows: (100 MHz, d
6
-DMSO) 
172.06 (CO), 156.40 (CO), 136.60 (CH), 133.01 (C), 107.92 (CH), 42.91 (Me), 
12.36 (Me). 
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2.8.10 Zirconium Tetrakisdeferiprone  
 
The H
1
 and 
13
C spectra of zirconium tetrakisdeferiprone illustrate the protons and 
carbons as expected for the complex.  
 
The 
1
H allocation of peaks for zirconium tetrakisdeferiprone is as follows: δH(400 
MHz, d
6
-DMSO), 7.94 (1 H, br s, CHNMe), 6.79 (1 H, br s, CHCO), 3.86 (3 H, s, 
NMe), 2.37 (3 H, s, Me) 
 
The 
13
C allocation of peaks for zirconium tetrakisdeferiprone is as follows: δc(100 
MHz, d
6
-DMSO) 163.82(CO), 144.40 (CO), 138.77 (CH), 136.82 (C), 110.76 (CH), 
43.10(Me), 12.77 (Me) 
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2.9 Results and Discussion 
 
Both the 
1
H and 
13
C NMR spectra of the oxine ligand and the zirconium 
tetrakisoxine complex are in agreement with previously published work.134
,152 This 
confirms that the ligand used in the synthesis is as expected and the complex 
synthesised is zirconium tetrakisoxine. There is a notable difference when comparing 
the proton NMR spectra of the free oxine ligand (Figure 2.1) against the metal 
complex, (Figure 2.3). The broad singlet representing the H bound to O has 
disappeared in the spectrum of the complex indicating deprotonation and binding of 
the ligand to the Zr metal. The broad singlet in the spectrum of the complex is 
possible due to the result of an asymmetric isomer being present that is still 
undergoing fairly rapid interconversion of the oxine ligand sites. This is in agreement 
with work undertaken by Green et al relating to the molecular structure of indium tris 
oxine.155  
 
The exchange of free and coordinated oxine ligands is fairly slow compared to the 
NMR time scale. It should be further noted that not all of the rings are equivalent so 
there must be a fluxional process at work. 
 
The 3D images shown in figure 2.5 below were produced by utilising previously 
published single crystal X-ray crystallographic studies data
3 
and Jmol software, an 
open-source Java viewer for chemical structures in 3D.  
 
Figure 2.23: 3D Illustration of Zirconium Tetrakisoxine 
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The 3D images show that the zirconium tetrakisoxine complex has adopted the 
dodecahedral geometry. This is the most sterically efficient geometric arrangement 
for eight equivalent ligands and the complex is not symmetrical. The nitrogen atom 
on the oxine ligand in some instance is found to be close to a hydrogen atom found 
on an adjacent oxine ligand.  
 
This is not always the case and can have an effect on the NMR spectra with their 
proton forming a hump on the spectra instead of a peak due to interactions with the 
nitrogen atom. It is possible for geometric isomerism156 to come into effect. Ligand 
binding can occur at different sites through either the nitrogen or oxygen atom. 
Hence in some instances in the zirconium tetrakisoxine complex there will be pairs 
of ligands that have nitrogen atoms in close proximity to each other and in other 
instances there will be pairs of ligands which have a nitrogen and oxygen atom close 
proximity to each other.  
 
The 
1
H and 
13
C NMR spectra of the tropolone ligand and the zirconium 
tetrakistropolone complex are in agreement with predicted spectra. There is a 
distinctive shift in the spectra when comparing the tropolone ligand against the 
zirconium tetrakistropolone complex indicating binding of the ligand to the metal 
ion. The peak seen in the spectrum of the zirconium tetrakistropolone complex at 
8.27 ppm is identified as the proton in CHCl3. This is in agreement with CHN 
analysis results suggesting a formula of C28H20O8Zr · 0.55 CHCl3.  
 
Both the 
1
H and 
13
C NMR spectra of the ethyl maltol ligand and the zirconium 
dichlorobis ethyl maltol complex are in agreement with previously published work.138 
However there seems to be some confusion and the paper has allocated two peaks for 
DMSO when there should only be one. The use of Heteronuclear Multiple Quantum 
Coherence (HMQC) NMR allowed the allocation of the C2 and C3 peaks which was 
not possible with 
13
C NMR alone. The resonance of the OH group at 8.79 disappears 
on the spectra of the dichlorobis and tetrakis complex indicating deprotonation of the 
ligand due to the insertion of Zr.  
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The 
1
H and 
13
C NMR spectra of the zirconium dichlorobis ethyl maltol indicate that 
isomers are present. These isomers vary in proportion in relation to the synthesis 
method used.  
 
The 
1
H NMR spectrum for the deferiprone ligand does not show a peak for the 
proton that is bound to an adjacent oxygen in the complex. This is because the peak 
is obscured under one of the other 
1
H peaks in the spectrum. This is the proton that 
becomes deprotonated when chelation to the metal complex occurs. However there is 
a distinct shift in the peaks of the complex when compared to the free ligand 
indication ligand binding to the metal ion. 
 
2.10 Conclusion 
 
Four zirconium tetrakis complexes and zirconium dichlorobis ethyl maltol have been 
synthesised from a starting complex of zirconium tetrachloride. Zirconium 
tetrakisethyl maltol and zirconium tetrakisdeferiprone are novel complexes. NMR 
spectroscopy results are in agreement with predicted results.  
 
The four tetrakis zirconium complexes are in the general form ZrL4 where L is a 
bidentate uninegative ligand. Each of the following ligands; oxine, tropolone, ethyl 
maltol or deferiprone has been successfully chelated to the Zr ion. The ZrL4 
complexes are neutral and it is hypothesised that they will be able to diffuse into cells 
in a similar manner analogous to confirmed InL3 complexes.
157 
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CHAPTER 3 
Fourier Transform Infrared, Raman Spectroscopy Characterisation and 
Physical Properties of Zirconium Compounds  
 
3.1. Introduction 
3.1.1 Fourier Transform Infrared Spectroscopy 
Fourier Transform Infrared Spectroscopy (FTIR) has become the favoured method of 
infrared spectroscopy and is a chemically specific analytical technique. The 
technique is based on passing infrared (IR) radiation through a sample. An amount of 
this IR radiation is transmitted and another amount is absorbed.150 A PC connected to 
the apparatus uses software algorithms to produce a spectrum which directly 
represents the molecular transmission and absorbance of the sample being analysed. 
The spectrum is comprised of two regions; between 4000-1000 cm
-1
 is known as the 
functional group region, and < 1000 cm
-1
 is known as the fingerprint region.158 As 
functional groups have vibrational frequencies that are distinctive it is possible to 
identify these groups using this portion of the spectra. The fingerprint region 
consistently contains a very complicated series of absorptions. These are essentially 
due to all manner of bending vibrations within the molecule. This is unique to a 
sample and like a fingerprint no two unique molecular structures will produce the 
same infrared spectrum. Because of this infrared spectroscopy is useful for several 
types of analysis.150 
 FTIR is a non-destructive analytical technique that can be used to determine the 
consistency or quality of a sample, identify unknown materials and determine the 
quantity of components.158 This is due to the fact that the size of the peak in the 
spectrum is directly proportional to the amount of material that is present. FTIR can 
be used to positively identify via qualitative analysis a large range of materials.158 
FTIR was used during this research to firstly ensure that the spectra of the zirconium 
tetrakis complexes indicated a lack of an O-H group when compared to the spectra of 
the free ligands.  
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This would indicate a bonding between the ligand and metal ion as de-protonation 
must occur for the ligand to bind to the zirconium ion. Important functional groups of 
each of the compounds and ligands were identified using this technique. The 
fingerprint regions of the free ligand and zirconium tetrakis complexes were 
compared to ensure uniqueness between the free ligand and the complex. 
3.1.2 Raman Spectroscopy 
 
Raman spectroscopy is a technique that is based on inelastic scattering of 
monochromatic light which is provided in the majority of cases in the form of a laser 
source. Inelastic scattering occurs when the frequency of photons in monochromatic 
light is altered after interaction with a sample. It may be absorbed, reflected or 
scattered. It is the wavelength of the scatted radiation that is analysed. The change in 
wavelength of the scattered photon provides the structural and chemical information. 
 
Raman spectroscopy was used alongside FTIR spectroscopy to analyse the ligands 
and complexes. This was undertaken to help confirm functional group assignment as 
the Raman spectrum and the FTIR spectrum for a given species resemble each other 
quite closely. Hence for a certain bond type the energy shift that is observed in a 
Raman spectrum should be identical to the energies seen in its infrared absorption 
bands. This is provided that the vibrational modes involved are active in both Raman 
scattering and in infrared absorption.  During the process of Raman scattering a brief 
distortion of electrons that are distributed around a bond in a molecule occurs, 
directly followed by a discharge of radiation as the bond is restored to its normal 
state. When the molecule is distorted it is polarized for a brief amount of time, during 
which an induced dipole is established that disappears upon reemission.  In contrast 
infrared absorption depends upon a vibrational mode of the molecule to have a 
change in dipole moment or a charge distribution related to it. 
 
Raman spectroscopy has advantages over FTIR, such as water does not cause 
interference with the analysis of a species. Vibrations that may not be active in FTIR 
spectroscopy may be visible in Raman spectroscopy due to different selection 
properties. Because of this Raman spectroscopy complements FTIR spectroscopy. 
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3.2 Methods 
3.2.1 FTIR Spectroscopy 
 
Tables of equipment, equipment settings and reagents used throughout this chapter 
can be located in the appendix section of this thesis. 
 
The FTIR spectra were obtained by using a Shimadzu IRAffinity-1 FTIR 
Spectrometer with a Specac Golden Gate single reflection diamond ATR accessory. 
These were interfaced with a Viglen E7600 personal computer (PC), with Microsoft 
Windows 7 Professional installed as the operating system. Software used to collate 
and interpret the FTIR data was in the form of the licensed program: Shimadzu I 
Resolution 1.5.  
 
Before each of the precursor compounds, ligands and Zr complexes were analysed 
using the FTIR spectrometer, a background spectrum was taken which was then 
automatically subtracted from each of the spectra via the Shimadzu I Resolution 1.5 
software. A small quantity of each of the samples was placed onto the diamond 
surface of the Specac Golden Gate single reflection diamond ATR accessory 
individually. The solid samples were pressed into direct contact with the diamond 
using the pressure tower and using only minimal force. The FTIR spectrometer was 
set using Shimadzu I Resolution 1.5 software to set a parameter of 8 foreground 
scans and 8 background scans, 16 scans in total. The software was pre-set to a 
resolution of 2 cm
-1
, transmission mode T%. Preliminary scans of each sample were 
run to decide whether the sample was in acceptable contact with the Specac Golden 
Gate single reflection diamond ATR accessory. Once it was confirmed that all of the 
samples were in acceptable contact, the instrument was in each case set to collect the 
sample scans. None of the sample spectra underwent any smoothing. This was to 
ensure accurate spectra. Sensitivity was not adjusted with any of the spectra taken. 
The peak function of the Shimadzu I Resolution 1.5 software was used to identify 
any important peaks of the various spectra (known as a threshold function).  The 
spectra were then saved using the Viglen E7600 PC to be interpreted further and 
reported in this thesis. 
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3.2.2 Raman Spectroscopy 
 
The Raman spectra were obtained by utilising a Horiba LabRAM-HR Raman 
spectrometer. This was interfaced with a Dell Optiplex 780 personal computer (PC), 
with Microsoft XP Professional installed as the operating system. Software used to 
collate and interpret the Raman data was in the form of the licenced program by 
Horiba Scientific: LAB Spec 6 spectroscopic suite, version 6.1.197.  
 
Calibration of the Raman spectrometer was undertaken before any of the experiments 
were conducted by utilising the silicon line at 520.6 cm
-1
. The experiments utilised a 
laser operating at a wavelength of 784.15 nm. The Raman spectrometer has a Peltier 
cooled charge coupled device detector incorporated which operated at -70 
o
C. Edge 
filters of high quality were used to enable the analysis of the region closer to the 
excitation line. An x50 objective lens was used throughout the experiments in turn 
giving a beam of ~ 2 µm optically focused on the sample. The power of the laser 
directed at the sample was 20.1 mW with the 784.15 nm laser at full power.  The 
power of the laser was measured by utilising an ASSY LaserCheck handheld power 
meter with an accuracy of ± 5%. A neutral density filter was used during the 
experiments which blocked 25 % of the lasers intensity at the sample. A diffraction 
grating of 600 gr/mm was used in turn achieving a spectral resolution of 2 cm
-1
. The 
slit width during all experiments was 100 µm. 
 
A minimum of 3 spectra were obtained during the FTIR and Raman experiments 
from different samples/parts of the sample to ensure reproducibility.   
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3.3 FTIR and Raman Specrtroscopy of Compounds 
3.3.1 FTIR and Raman Spectroscopy of Zirconium Tetrachloride 
 
Figure 3.1: FTIR Spectrum of Zirconium Tetrachloride 
 
Figure 3.2: Raman Spectrum of Zirconium Tetrachloride 
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3.3.2 FTIR and Raman Spectroscopy of Zirconium Tetrakisoxalato 
 
Figure 3.3: FTIR Spectrum of Zirconium Tetrakisoxalato 
 
Figure 3.4: Raman Spectrum of Zirconium Tetrakisoxalato
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3.3.3 FTIR and Raman Spectroscopy of Oxine and Zirconium Tetrakisoxine 
 
Figure 3.5: FTIR Spectrum of Oxine 
 
Figure 3.6: FTIR Spectrum of Zirconium Tetrakisoxine 
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Figure 3.7: Raman Spectrum of Oxine 
 
 
  Figure 3.8: Raman Spectrum of Zirconium Tetrakisoxine 
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3.3.4 FTIR and Raman Spectroscopy of Tropolone and Zr Tetrakistropolone 
 
Figure 3.9: FTIR Spectrum of Tropolone 
  Figure 3.10: FTIR Spectrum of Zirconium Tetrakistropolone 
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Figure 3.11: Raman Spectrum of  Tropolone 
 
Figure 3.12: Raman Spectrum of Zirconium Tetrakistropolone
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3.3.5 FTIR and Raman Spectroscopy of Ethyl Maltol and Zirconium Tetrakisethyl maltol
 
Figure 3.13: FTIR Spectrum of Ethyl Maltol
 
Figure 3.14: FTIR Spectrum of Zirconium Tetrkis Ethyl Maltol 
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Figure 3.15: Raman Spectrum of Ethyl Maltol 
 
Figure 3.16: Raman Spectrum of  Zirconium Tetrakisethyl maltol
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3.3.6 FTIR and Raman Spectroscopy of  Deferiprone and Zirconium Tetrakisdeferiprone
 
Figure 3.17: FTIR Spectrum of  Deferprone 
                        Figure 3.18: FTIR Spectrum of  Zirconium Tetrakisdeferiprone 
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Figure 3.19: Raman Spectrum of  Deferiprone 
 
Figure 3.20: Raman Spectrum of  Zirconium Tetrakisdeferiprone 
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3.4 Significant Wavenumbers from FTIR and Raman Analysis of compounds        
      and Possible Functional Group Assignment 
 
3.4.1 Assignment Key 
 
The following abbreviations were used when analysing the spectral peaks of both the 
FTIR and Raman experiments: 
 
vw: very weak s: strong  sh: shoulder 
w: weak  vs: very strong v: stretching  
m: medium br broad  δ: bending 
ω: wagging τ: twisting γ: out of plane deformation 
          
3.4.2 Zirconium  Tetrachloride 
 
IR υmax (cm
−1
): 3435 br (OH), 3393 br (OH), 1590 s (OH), 792 br, 617 m, 581 m 
(ZrCl), 506 w (ZrCl)  
 
Raman υmax (cm
−1
): 1638 w, 1379 w, 1029 w, 583 w, 453 w (ZrCl), 259 w (ZrCl), 
216 w (ZrCl) 
 
3.4.3 Zirconium Tetrakisoxalato 
 
IR υmax (cm
−1
): 3537 sh (OH), 3440 br (OH), 1730 s (C=O), 1709 sh, 1679 s (C=O), 
1660 vs (C=O), 1399 s (C=O), 1280 m, 1267 sh, 905 m, 792 s (C-O), 519 s 
 
Raman υmax (cm
−1
): 1724 s (C=O), 1710 w, 1674 w, 1439 m (C-O), 1410 m, 1262 w, 
920 w v(C-C), 855 w, 554 m (Zr-O), 520 w (OCO), 367 w, 273 w, 255 w 
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3.4.4 Oxine 
 
IR υmax (cm
−1
): 3050 br (O-H), 1947 w, 1906 w, 1892 w, 1818 w, 1731 w, 1625 w 
(C=N), 1592 sh, 1579 m (υC=C), 1496 s, 1473 s (C-C ring skeleton), 1431 m, 1409 s, 
1380 s (CH ring skeleton), 1283 sh, 1272 s, 1241 sh, 1222 s, 1205 s, 1163 s, 1138 m, 
1093 m (C-O), 1057 w (υC-O), 1028 w, 896 w, 864 w, 818 m (δCH out of plane), 777 
vs (CH) , 738 s, 709 vs, 638 m, 572 m, 544 m (ring deformations). 
 
Raman υmax (cm
−1
): 1626 sh (υC=N), 1582 s(υC=C), 1473 m, 1431 s, 1404 s, 1381 s, 
1347 m (υC-C), 1274 w, 1256 w, 1226 w, 1206 w, 1185 w, 1164 w, 1141 w, 1101 
w(C-O), 1061 w (υC-O), 889 w, 864 w, 807 vw (δCH out of plane), 715 vs (ring 
breathing), 578 w, 547 w, 487 m, 473 m, 421 vw (ring deformations), 269 vw  
 
3.4.5 Zirconium Tetrakisoxine 
 
IR υmax (cm
−1
): 3045 w (υCH), 1604 m (υC=N), 1573 s (υC=C), 1495 vs, 1462 vs, 1423 
m, 1378 vs, 1318 vs (υC-C), 1274 s, 1227 m, 1173 w, 1107 vs (δCH in plane), 1054 m 
(υC-O), 1030 m, 910 w, 822 s, 806 m (δCH out of plane), 785 s, 737 vs (ring 
breathing), 643 m, 616 s, 560 w, 514 vs (ring deformations). 
 
Raman υmax (cm
−1): 1606 w (υC=N), 1589 m, 1578 m 1572 sh (υC=C), 1498 m, 1463 w, 
1421 m, 1388 vs, 1378 s, 1327 w (υC-C),  1284 m, 1209 w, 1175 w, 1143 w, 1137 w, 
1112 w (δCH in plane),  1054 w (υC-O) ,  1032 w, 907 m, 824 w, 805 m (δCH out of 
plane),  754 m, 736 w (ring breathing), 650 w, 617 m, 558 w, 524 vs (Zr-O), 500 sh, 
492 m, 469 w, 449 w (ring deformations). 
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3.4.6 Tropolone 
 
IR υmax (cm
−1
): 3521 w (OH) , 3298 w, 3188 br, 2998 sh (υCH), 2012 w, 1976 w, 
1960 w, 1924 w, 1892 w, 1837 w, 1773 w, 1750 w, 1602 s (υC=C and υC=O), 1541 m 
(υC=O  and υC=C), 1479 sh, 1463 s, 1421 sh, 1408 s, 1309 m(υC=C), 1263 m, 1231 s(υC-
O), 1202 br, 1176 sh, 1051 m (υC-C and δCH), 1005 w, 983 vw, 957 m, 918 m (υC-C), 
873 w, 860 m, 793 m, 747 m (υC-C and δCH), 702 sh (υCH), 673 vs (υC-C), 583 w, 557 
w, 531 w, 519 sh 
 
Raman υmax (cm
−1
): 1606 m (υC=C and υC=O), 1542 w (υC=O  and υC=C), 1459 vs (υC=O  
and υC=C), 1437 sh (OH and CH ) , 1422 sh (CH and υC-C), 1309 vw, 1270 m , (OH 
and CH), 1237 s (CH), 1193 w (CH), 1048 vw (υC-C), 977 sh, 960 m (υC-C), 872 w 
(υC-C), 739 m (υCH),  , 685 m, 446 w, 365 w, 337 w 
 
 
3.4.7 Zirconium Tetrakistropolone 
 
IR υmax (cm
−1
): 3013 m (υCH) , 1590 vs (υC=C and υC=O), 1516 vs (υC=O  and υC=C), 
1418 sh, 1408 vs, (υC=O, υC-C and δCH), 1349 vs (υC=C), 1223 vs (υC-O), 1079 m (υC-C 
and δCH), 968 m, 934 m, 919 m (υC-C), 875 s, 728 vs (υC-C and δCH), 712 vs (υCH), 661 
m (υC-C),  586 m, 530 vs (υZr-O) 
 
Raman υmax (cm
−1): 1593 vs (υC=C and υC=O) , 1533 w, 1521 w (υC=O  and υC=C), 1471 
m (δCH), 1422 m, 1408 m (υC=O, υC-C and δCH), 1390 w, 1350 w (υC=C), 1227 m (υC-O),  
1082 m (υC-C and δCH),  975 s (υC-C),  879 m (υC-C and δCH),  722 vs (υCH),  662 w (υC-
C), 575m, 538 m (υZr-O) 
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3.4.8 Ethyl Maltol 
 
IR υmax (cm
−1
): 3085 w, 2982 br (υCH), 2940 w (υCH), 2879 w, 2163 w, 1892 w, 1644 
s, 1606 vs (υC=O), 1557 s (υC=C), 1505 sh, 1467 w, 1450 m, 1434 w (υC-C), 1389 m, 
1376 sh, 1344 w, 1315 m, 1257 s, 1212 m, 1189 s, 1096 w, 1067 m, 1034 w, 976 m, 
947 w, 935 s, 860 w, 831 vs, 783 sh, 702 br (γ ring), 667 br, 570 sh, 650 m, 509 s (δ 
ring) 
 
Raman υmax (cm
−1
): 1648 s, 1598 m (υC=O), 1564 s (υC=O), 1451 w (υC-C), 1338 w 
(ωCH) , 1268 w (τCH), 1101 w, 1035 m (υC-O-C), 937 w, 833 w, 700 w, 627 w, 560 w, 
514 w, 484 w, 335 w 
 
3.4.9 Zirconium Tetrakisethyl maltol 
 
IR υmax (cm
−1
): 3065 w, 2986 m (υCH), 2943 w (υCH), 2885 w, 1628 sh (υC=O), 1606 
sh (υC=O), 1556  vs (υC=C) , 1519 s, 1507 sh, 1473 vs, 1456 sh, 1433 sh (υC-C), 1393 
m, 1368 m, 1331 s, 1262 vs, 1235 s, 1187 vs, 1102 w, 1087 w, 1069 w, 1050 sh, 
1040 m, 990 m, 936 m, 885 w, 859 vw, 840 vs, 828 sh, 786 w, 771 m, 624 w, 602 m, 
558 w, 522 vs s (δ ring) 
 
Raman υmax (cm
−1): 1599 vs (υC=O), 1582 sh (υC=O), 1518 s, 1476 m, 1428 w(υC-C), 
1327 w (ωCH), 1264 w (τCH), 1048 s (C-O-C), 938 w, 845 m, 769 w, 725 s, 621 w, 
603 m, 546 m, 539 m (Zr-O), 525 m, 511 m 
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3.4.10 Deferiprone 
 
IR υmax (cm
−1
): 3134 br (OH), 3011 sh (υCH aromatic ring), 2163 vw, 2015 vw, 1979 
vw, 1870 w, 1628 s (υC=O), 1563 s, 1531 w (υC=C aromatic ring), 1508 m, 1460 s, 
1444 sh (υC=C aromatic ring), 1402 w, 1380 m, 1331 s (C-N), 1208 sh, 1225 br (C-
O), 1122 m, 1054 m, 1028 m, 938 w, 899 m, 876 sh, 815 vs, 767 m (υCH),  , 738 s, 
693 sh, 669 m, 593 m, 564 m, 531 s, 512 s  
 
Raman υmax (cm
−1
): 1633 m (υC=O), 1530 s (υC=C aromatic ring), 1470 m, 1380 m, 
1329 w (C-N), 1245 sh, 1226 m (C-O), 1177 w, 1126 w, 1029 s, 901 vw, 821 vw, 
771 m (υCH) , 676 s, 599 m, 531 w, 503 m, 476 m, 349 w, 326 w, 278 w 
 
3.4.11 Zirconium Tetrakisdeferiprone 
 
IR υmax (cm
−1
): 3500-2500 br, 1610 m (υC=O), 1555 m (υC=C aromatic ring), 1491 s, 
1458 m (υC=C aromatic ring), 1438 w, 1341 m, 1283 s (υC-N), 1261 m, 1169 w, 1123 
m, 1069 m, 1034 m, 923 w, 823 m, 770 m, 710 s, 619 w, 556 m, 498 s 
 
Raman υmax (cm
−1): 1609 m (υC=O), 1556 m, 1524 m (υC=C), 1498 w, 1427 m, 1382 m 
1334 m (υC-N), 1292 w, 1262 m (υC-O), 1169 w, 1123 w, 1071 m, 1035 m, 920 w, 771 
m (υCH), 715 vs, 615 m, 574  m (Zr-O), 536 w, 499 m, 404 m, 325 m, 288 m 
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3.5 Discussion of FTIR and Raman Spectroscopy Results 
 
3.5.1 Zirconium Tetrachloride 
 
The FTIR spectrum shows broad peaks at 3435 cm
-1
 and 3393 cm
-1
 relating to an O-
H group which  is due to a small amout of moisture in the zirconium tetrachloride 
complex. The peak at 1590 cm
-1 
relates to an O-H bend. Zr to Cl bonding peaks are 
located in the fingerpring region of the spectra at 581 cm
-1
, and 506 cm
-1
. Published 
work by Taylor159 reports Zr-Cl bonding peaks in the low frequency region of  the IR 
spectra between 220 cm
-1
 and 415 cm
-1
 however the FTIR apparatus used during this 
work has a lower limit of 500 cm
-1
. The Raman spectrum of zirconium tetrachloride 
shows peaks at 453 cm
-1
, 
 
259 cm
-1 
and 216 cm
-1 
which can all be attributed to 
bonding between the Zr and Cl of the complex. The allocation of these peaks was 
based on published work by Photiadis and Papatheodorou160 investigating vibrational 
modes of zirconium tetrachloride.  
 
3.5.2 Zirconium Tetrakisoxalato 
 
The broad  peak at 3537 cm
-1
 and 3440 cm
-1
 relates to an O-H group which  is due to 
a small amout of moisture in the zirconium tetrakisoxalato complex. The values 
obtained for the zirconium tetrakisoxalate are in in agreement with those that have 
been previously described for the oxalate ligand in published work by Yan-Tuan Li 
and Cui-Wei Yan et al.161 The peaks at 1730 cm
-1
, 1679 cm
-1
, 1660 cm
-1
 and 1399 
cm
-1
 can all be attributed to C=O bonds in the zirconium tetrakisoxalato complex. 
The peak at 792 cm
-1 
can be attributed to a C-O bond in the complex. The Raman 
spectrum of the zirconium tetrakisoxalato complex shows a peaks at 1724 cm
-1 
which 
can be  can be attributed to a C=O bond. A wavenumber of 1439 cm
-1
 may be 
asssigned to a v(CO) stretching mode as reported by Frost162 when investigating 
oxalates utilising Raman spectroscopy. The bands at 920 cm
-1 
 may be attributed to a 
v(C-C) stretching mode. A symmetric OCO bending mode may be attributed to 520  
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3.5.3 Oxine and Zirconium Tetrakisoxine 
 
Previously published papers report the FTIR spectroscopic findings of the both oxine 
and complexes of a similar nature such as aluminium tris oxine163, metal complexes 
with oxine as a primary ligand and vitamin U as a secondary ligand164 and vibrational 
spectra of some solid oxine metal complexes in correlation with their coordination 
bond length and type of metal ion.165 The proposed assignment of wavenumbers to 
functional groups from the Raman analysis of the compounds was undertaken 
utilising standard correlation tables and work published by Wagner et al regarding 
vibrational spectra of Ga(III) complexes with oxine and clioquinol.166 
 
FTIR analysis of oxine and the zirconium tetrakisoxine complex shows that the 
groups/structures which are to be expected are present. The OH group which is 
located at ˜ 3045 cm
-1 
on the spectrum of oxine is not present in the spectrum of 
zirconium tetrakisoxine, due to deprotonation of the ligand at the O-H functional 
group region. Chelatation occurs via covalent linkage between the zirconium metal 
ion to the phenolic oxygen of the oxine ligand. The band at ˜ 1625 cm
-1
, assigned to 
the C=N group, has shifted slightly to 1604 cm
-1
 in the chelated complex. 
 
Raman analysis of the oxine and zirconium tetrakisoxine complexes yielded similar 
results to the FTIR analysis of both the ligand and the complex. The band at located 
at 1626 cm
-1 
is assigned to C=N in the spectrum of oxine. In the spectrum of the 
zirconium tetrakisoxine complex this has shifted to a lower energy of 1606 cm
-1
.  The 
band located at 1582 cm
-1 
assigned to C=C has also shifted to a lower energy of 1573 
cm
-1 
in oxine when compared to zirconium tetrakisoxine. There is also a notable shift 
to lower energies of the peak assigned to C-C in plane from 1347 cm
-1 
in oxine to 
1327 cm
-1
 in the zirconium tetrakisoxine complex. The assigned bands have values 
that are in close agreement with the work reported by Wagner et al.166 A band at 524 
cm
-1 
can be tentatively assigned to Zr-O. 
 
cm
-1 
and has been reported by Frost162 in regards to oxalate complexes. A band at 554 
cm
-1 
can be tentatively assigned to Zr-O. 
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3.5.4 Tropolone and Zirconium Tetrakistropolone 
 
The FTIR values obtained for the tropolone ligand are in agreement with those  
previously described in published work by Yusaku Ikegami.167 When comparing the 
spectra of both the tropolone ligand and the zirconium tetrakistropolone complex it is 
clear that the complex has a distinct lack of  a broad peak found between ˜ 3521 cm
-1 
and ˜ 2998 cm
-1  
which is found in the spectrum of the tropolone ligand. This broad 
peak is due to hydrogen bonding which alters the electron cloud and in turn alters the 
resonance frequency of the O-H bond. As the complex does not have an O-H group 
that is hydrogen bonded the broad peak is distinctly reduced. The small peak relating 
to a O-H group is due to a small amout of moisture in the zirconium tetrakistropolone 
complex. The bands found at 2998 cm
-1
 and 3013 cm
-1
 can be atributed to C-H 
stretching vibrations of both the ligand and complex respectably. The C=O and C=C 
functional groups can be attributed to 1602 cm
-1 
and 1541 cm
-1
 for the ligand. These 
values are found to be at lower energies for the zirconium tetrakistropolone complex 
with wavenumbers of 1590 cm
-1
 and 1516 cm
-1
. The band located at 1408 cm
-1 
may 
be attributed to a combination of C=O, C-C and C-H functional groups in the 
tropolone ligand and the tropolone complex.  
 
Raman analysis of the tropolone and zirconium tetrakistropolone complexes yielded 
similar results to the FTIR analysis of both the ligand and the complex. Standard 
correlation tables and work published by Jianlin et al168 were used in assigning the 
Raman spectrum to possible functional groups. When comparing the Raman spectra 
of the free tropolone ligand to the zirconium tetrakis complex it can be seen that 
there is a significant shift in frequencies of the C=O and C=C functional groups. 
Between the wavelength range of 1000 cm
-1
 to 600 cm
-1
 a number of bands were 
observed which relate to vibrational modes of the ring structure, C-C, C-H etc.  
These groups show a smaller shift between the spectra of the ligand and the complex 
as they do not bind with the Zr metal ion to form the complex.  The band at 538 cm
-1 
is unique to the complex and it is proposed that this band is due to the Zr–O 
interaction of the complex. This band has been reported by Jianlin et al 168 to be the 
interaction of the O of tropolone and a metal ion such as lanthanum. 
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3.5.5 Ethyl Maltol and Zirconium Tetrakisethyl maltol 
 
FTIR spectra were assigned utilising work by J Burgess et al169,  K Thompson et 
al170, B. S. Parajon-Casta et al 171, 172 and C Wagner et al.173 Comparison of the 
spectrum of the ligand against the complex shows the broad peak around ˜ 3085 cm 
-1 
becomes broadened
 
out significantly in the spectrum of the zirconium tetrakisethyl 
maltol complex. As is the case with oxine and tropolone this peak is due to hydrogen 
bonding which alters the electron cloud and in turn alters the resonance frequency of 
the O-H bond. As the complex does not have an O-H group that is hydrogen bonded 
the broad peak is distinctly reduced. The small peak relating to a O-H group is due to 
a small amout of moisture in the zirconium tetrakisethyl maltol complex. The bands 
found in the region of  2982 & 2940 cm
-1
 in the spectrum of the ligand and at a 
slightly higher energies in the complex at 2986 & 2943 cm
-1
 can be atributed to C-H 
stretching vibrations. The band located at 1556 cm
-1
 and 1557 cm
-1
 resemble the 
C=C vibrations in the aromatic ring in both the complex and ligand. The band 
located at 1606 cm
-1
 resemble the C=O vibrations in both the complex and ligand. 
The band located at 509 cm
-1 
& 522 cm
-1
 in the spectra of the ligand and complex 
may be attributed to the ring structure of tropolone. 
 
Raman analysis ethyl maltol and zirconium tetrakisethyl maltol yielded similar 
results to FTIR. Standard correlation tables, work published by Panicker et al174 and 
authors work used to assign FTIR functional groups were employed in assigning the 
Raman spectra to possible functional groups. When comparing the Raman spectra of 
the free ethyl maltol ligand to the zirconium tetrakisethyl maltol complex it can be 
seen that there is a shift in frequencies of the C=O and C-C functional groups. The 
bands at 1035 cm
-1
 in the ligand and at 1048 cm
-1
 in the complex can be attributed to 
symmetric C-O-C vibrations. The CH2 wagging mode can be attributed to 1338 cm
-1
 
in the free ligand and at a lower energy in the complex at 1327 cm
-1
. The CH2 
twisting mode can be attributed to 1268 cm
-1
 in the free ligand and at a slightly lower 
energy in the complex at 1264 cm
-1
. The band at 539 cm
-1 
is unique to the complex 
and it is proposed that this band is due to the Zr–O interaction of the complex as is 
the case with the tropolone complex at 538 cm
-1
.  
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3.5.6 Deferiprone and Zirconium Tetrakisdeferiprone 
 
The values obtained for the deferiprone ligand are in agreement with those that have 
been previously described in published work by Carla Queiros et al175 and M 
Mohammadpour et al.176 When comparing the spectrum of the deferiprone ligand 
against the zirconium tetrakisdeferiprone complex it is clear that the complex has a 
distinct lack of  a broad peak around ˜ 3134 cm
-1 
which is found in the spectrum of 
the deferiprone ligand. As is the case with oxine and tropolone this peak is due to 
hydrogen bonding which alters the electron cloud and in turn alters the resonance 
frequency of the O-H bond. As the complex does not have an O-H group that is 
hydrogen bonded the broad peak is distinctly reduced. The broad peak seen on the 
spectum of the zirconium tetrakisdeferiprone complex between 3500 cm
-1
 - 2500 cm
-
1 
is proposed to be related to the 12 waters of hydration incorporated into the 
complex. This is in agreement with the results of CHN anlaysis of the complex. The 
band found at 1628 cm
-1
 can be atributed to C=O stretching in the ligand and at a 
slightly lower energy of 1610 cm
-1
 in the complex. Bands at 1531 cm
-1
 / 1444 cm
-1
 in 
the ligand and at at higher energies of 1555 cm
-1
 / 1458 cm
-1
 in the complex can 
possibly be assigned to the C=C group in the aromatic ring structure of deferipropne. 
 
Raman analysis of the deferiprone ligand and zirconium tetrakisdeferiprone complex 
yielded similar results to the FTIR. Standard correlation tables and work published 
by Šebsetίk et al177 were used in assigning the Raman spectra to possible functional 
groups. The band found at 1633 cm
-1
 can be atributed to C=O stretching in the ligand 
and at a slightly lower energy of 1609 cm
-1
 in the complex. The bands seen at 1530 
cm
-1
 in the ligand and at a slightly lower energy of 1524 cm
-1
 in the complex can be 
attributed to aromatic C=C stretching. The band found at 771 cm
-1
 in the spectrum of 
the ligand and the complex at can be atributed to C-H stretching vibrations. The band 
at 574 cm
-1 
is unique to the complex and it is proposed that this band is due to Zr–O 
interaction in the complex. This assignment was based on the work reported by 
Šebsetίk et al177 stating a bending of chelating oxygens bound to iron in the iron (III) 
deferiprone complex can be assigned to a wavenumber of 573 cm
-1
.  
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3.6 Properties of the Zirconium Complexes 
 
Basic properties of the each of the synthesised Zr complexes were analysed and are 
reported in this section of the thesis.  
 
Melting points determination is straightforward technique that is provides 
characteristic information of materials. The capillary method is the standard 
technique for melting point determination. The melting points of the complexes were 
determined utilising a Stuart SMP3 melting point apparatus, full details can be found 
in the appendix section of this thesis. A thin glass capillary tube which contains a 
small amount of the complexes to be analysed was placed into the melting point 
apparatus the temperature of the apparatus was ramped at a constant rate until the 
complex in the sample tube had melted into its liquid state. Melting point 
temperatures were recorded. 
 
Complex Molecular Mass Appearance Melting Point 
Oxine 145.16 g/mol White Solid 70-73 
o
C 
Zirconium 
Tetrakisoxine 
667.82  g/mol Dark Yellow Solid 388 
o
C 134 
Tropolone 122.12 g/mol Light Yellow Solid 83-84 
o
C 
Zirconium 
Tetrakistropolone 
575.34 g/mol Light Yellow Solid >349
 o
C 
Ethyl Maltol 104.14 g/mol White Solid 91 – 95 
o
C 
Zirconium Dichlorobis 
Ethyl Maltol 
440.39 g/mol White Solid 206 – 208 oC 
Zirconium 
Tetrakisethyl maltol 
647.74 g/mol White Solid 186 -187 
o
C 
Deferiprone 139.15 g/mol White Solid 272 – 275 
o
C 
Zirconium 
Tetrakisdeferiprone 
751.90 g/mol White Solid 
292 – 293 oC 
(Decomposed) 
Table 3.16: Properties of Ligands and Complexes. 
3.7 Solubility 
 
Solubility tests were be undertaken to determine the best solvent to use for each of 
the complexes when performing chromatographic analysis and further experimental 
work. For testing solubility of the complexes a concentration of 1g / 100mL was used 
and solubility tests were all conducted at room temperature of ~22
o
C. Visual 
observations and findings are reported on page 115 of this thesis. 
  
1
1
4
 
3.8 Solubility of Ligands and Complexes 
Solubility tests were conducted at a concentration of 1 g of compound per 100 mL of solvent at a temperature of 22
o
C at 1atm pressure. 
The salinity of the water used during the solubility tests was based on salt dissolved in (g/L) 
 
Solvent Solubility with Zirconium 
Tetrakisoxine  
pH Pre Addition pH Post Addition 
    
Water (0.5g-0.30 g/L) Suspended (Possible Low Solubility) 6.00 6.90 
Water (Brine) (60 g/L) Immiscible & Partly Suspended 5.40 6.07 
Water (Purified) (<0.5 g/L) Immiscible 6.29 N/A 
Water (Saline) (30 g-50 g/L) Immiscible & Partly Suspended 6.70 7.00 
Table 3.17: Solubility of Zirconium Tetrakisoxine in Water of Various Salinities 
Solvent Solubility With Zr 
Tetrakisoxine 
Solubility with Zr 
Tetrakistropolone 
Solubility With Zr 
Tetrakisethyl maltol 
Solubility With Zr 
Tetrakisdeferiprone 
Acetone <1g/100mL Insoluble Insoluble Insoluble 
Benzene <1g/100mL Insoluble Insoluble Insoluble 
Chloroform >1g/100mL >1g/100mL >1g/100mL Insoluble 
Dichloromethane <1g/100mL Insoluble >1g/100mL <1g/100mL 
Diethyl Ether <1g/100mL Insoluble Insoluble Insoluble 
Dimethyl Sulfoxide >1g/100mL >1g/100mL >1g/100mL >1g/100mL 
Ethanol <1g/100mL <1g/100mL <1g/100mL >1g/100mL 
Hexane <1g/100mL Insoluble Insoluble Insoluble 
Methanol <1g/100mL <1g/100mL >1g/100mL >1g/100mL 
Tetrahydrofuran >1g/100mL Insoluble Insoluble <1g/100mL 
Water Insoluble Insoluble Insoluble >1g/100mL 
Table 3.18: Solubility of Zirconium Tetrakis Complexes in a Range of Solvents
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3.9 Conclusion 
 
3.9.1 FTIR and Raman Spectroscopy 
 
When comparing the spectra of the complexes and their related ligands it was shown 
that there was a difference in the fingerprint region of the spectra in all cases. In the 
functional group region of the spectra comparison of the complex to the ligand 
showed an absence of an O-H group. This is because the ligand becomes 
deprotonated to allow the chelation to the metal ion.  
 
FTIR and Raman spectra of all of the ligands and their zirconium tetrakis complex 
forms have values that are in agreement with previously published works. All of the 
spectra of the ligands and zirconium tetrakis complexes have peaks that directly 
relate to expected functional groups. The disappearance of the OH vibrational mode 
when comparing the spectra of the ligands to the complexes as well as a shift in 
various functional groups indicates the formation of a chelated complex. 
 
3.9.2 Melting Points and Solubility 
 
The experiments to determine the melting points of the ligands and complexes were 
undertaken three times to determine precision and the average of these findings are 
reported in table. All of the melting points of the ligands are in agreement with the 
suppliers (Sigma Aldrich) material safety details sheet data. Zirconium tetrakisoxine, 
tropolone and ethyl maltol complexes are coloured, solid, non-hygroscopic and 
thermally stable. The solubility tests illustrated in table 3.18 page 115 shows that the 
compounds are soluble in a range of organic solvents such as chloroform, ethanol, 
methanol and DMSO. However, the complexes are insoluble in water. This would 
suggest the possibility that the complexes have strong metal ligand bonds and are 
non-polar and lipophilic. The zirconium tetrakisdeferiprone complex is highly water 
soluble, not soluble in chloroform and as such lacks lipophilic properties. 
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CHAPTER 4 
Synthesis of Zirconium Tetrakis Complexes under Conditions Compatible with 
Radiopharmacy 
 
4.1 Introduction 
 
Chapter 4 of this thesis reports the refinement and adaption of the synthesis methods 
devised and reported in chapter 2. This work has been undertaken as it is necessary 
to synthesise the complexes under conditions that are likely to be found when dealing 
with radioactive Zr. Radioactive Zr is supplied in an excess of different acids 
depending on the form of the complex.The radioactive Zr is either supplied in the 
form of zirconium tetrachloride in an excess of hydrochloric acid or zirconium 
tetrakisoxalato in an excess of oxalic acid. Experiments have been undertaken to 
determine the possibility of exchanging the chloride and oxalate ligands under acidic 
and neutral conditions for the desired ligands reported in chapter 2 of this thesis. 
 
Tables of equipment, equipment settings and compounds used throughout this 
chapter can be located in the appendix section of this thesis All compounds used can 
be found listed in Table A2 (p226) in the appendix section. Equipment used during 
this chapter can be found in appendix, section A.1.3, (p222). 
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4.2 Synthesis of Potassium Zirconium Tetrakisoxalato 
 
Aim 
 
The synthesis of potassium zirconium tetrakisoxalato was undertaken so that further 
experiments could be conducted that would closely resemble the circumstances in 
which the 
89
Zr isotope is supplied from the manufacturer. The method was adapted 
from previously published work.178  
 
Method 
 
Zirconyl chloride (15 g; 0.048 mol) was dissolved in reverse osmosis water (300 mL) 
in a 1000 mL glass conical flask at room temperature (~20 
o
C). Potassium oxalate 
monohydrate (36 g; 0.195 mol) was dissolved in a second, separate volume of 
reverse osmosis water (100 mL) in a 1000 mL glass conical flask at room 
temperature (~20 
o
C).  To this second solution, oxalic acid dihydrate (12 g; 0.096 
mol) was added and dissolved at room temperature (~20 
o
C).  
The zirconyl chloride solution was added carefully to the solution of potassium 
oxalate and oxalic acid. This was accomplished by the use of a narrow mouth bottle 
pipette under constant stirring utilising the magnetic stirrer function of an electric 
hotplate and an octagon magnetic stirrer. The solution was observed to be cloudy and 
opaque at this stage of the synthesis process. The solution was then heated to 100 
o
C 
and was boiled for 30 minutes. During the boiling process the solution became 
totally clear. The solution was then allowed to cool to room temperature (~20 
o
C). 
Once the solution was cooled the volume of the solution was increased to 400 mL 
with reverse osmosis water. Absolute ethanol (99.9%, 400 mL) was slowly added to 
the solution to precipitate out the potassium zirconium tetra oxalato. The resulting 
precipitate was then collected by the use of a Büchner funnel, filter paper and 
vacuum conical flask. The precipitate was washed with ethanol (99.7%, 50 mL). The 
precipitate was then dissolved in reverse osmosis water (250 mL) in a 1000 mL glass 
conical flask at a temperature of 70
o 
C. The solution was cooled to 30 
o
C and 
absolute ethanol (150 mL) was added.  
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The precipitate was then was then collected by the use of a Büchner funnel, filter 
paper and vacuum conical flask. The precipitate was then washed with 3 x ethanol 
(99.7%, 25 mL) and 2 x diethyl ether (99+%, 50 mL) The precipitate was then dried 
in an electric oven at a 55 
o
C for 1 hour, cooled and stored in a glass air tight storage 
container. Visual appearance of the compound was white in colour and finely 
crystalline.   
 
Results and Discussion 
 
The synthesis of potassium zirconium tetrakisoxalato was successful and confirmed 
via the use of CHN analysis. The product was successfully used in several of the 
experiments summarised in this section of this thesis. The zirconium tetrakisoxalate 
complex is soluble in water. Once the potassium zirconium tetrakisoxalato is 
dissolved in water, the solution remains clear at concentrations of between 1 – 200 
ppm. 
 
Carbon, hydrogen and nitrogen (CHN) analysis results for potassium zirconium 
tetrakisoxalate pentahydrate 
 
Formula Weight: 689.77 g/mol 
 
  Expected 1st Analysis 2nd Analysis 
C % 13.93 14.06 14.03 
H % 1.46 1.41 1.45 
N % 0 0 0 
          Table 4.1 
 
Theoretical Yield: 33.109g  
Actual Yield: 31.509g    
Percentage of Theoretical Yield: 95.2%  
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4.3 Synthesis of Complexes under Acidic Conditions 
 
4.3.1 Synthesis of Zr Tetrakisoxine from Potassium Zirconium Tetrakisoxalato  
         Reverse Osmosis Water 
 
Aim 
 
The 
89
Zr isotope is supplied in the form of zirconium-89 tetrachloride in an excess of 
hydrochloric acid or zirconium-89 tetrakisoxalato in an excess of oxalic acid. The 
aim of this experiment was to ascertain if it is possible to exchange the ligands found 
on the zirconium tetrakisoxalato complex with 4 oxine bidentate ligands. This would 
result in the neutral zirconium tetrakisoxine complex. This synthesis was conducted 
without any of the excess acid solutions present and the reaction was under taken in 
reverse osmosis water. 
 
Method 
 
Oxine (4.330 g; 0.0298 mol) was added to reverse osmosis water (150 mL) in a 250 
mL glass conical flask, heated to 70 
o
C and constantly stirred for 30 minutes until 
completely dissolved. Once the oxine was totally dissolved, the solution was cooled 
to room temperature (~20 
o
C). Potassium zirconium tetrakisoxalato (5.000 g; 
0.00724 mol) was dissolved in reverse osmosis water (50 mL) in a 250 mL conical 
flask at room temperature. The solution of oxine was added carefully to the solution 
of potassium zirconium tetrakisoxalato drop wise with a narrow mouth bottle pipette. 
The solution was then stirred utilising the magnetic stirrer function of an electric 
hotplate and an octagon magnetic stirrer. The solution was stirred for 20 minutes at 
room temperature (~20 
o
C). Ammonium hydroxide, 1M (100 mL) was added to the 
solution and a precipitate immediately formed. The solution was then heated to 85 
o
C 
for 30 minutes to ensure the reaction was complete. The solution was then allowed to 
cool to room temperature (~20 
o
C). The solution was allowed to stand for 20 minutes 
and the resulting precipitate was then collected by the use of a Büchner funnel, filter 
paper and vacuum conical flask. 
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The precipitate was then dried in an electric oven at a 125 
o
C for 1 hour. The dried 
complex was then ground with a pestle and mortal to ensure homogeneity and was 
stored in a glass air tight storage container. 
 
Formula weight: 667.82 g/mol 
 
Visual appearance: Bright yellow, fine powder.   
 
Theoretical yield: 4.835g 
Actual Yield: 4.123 g 
Percentage of theoretical yield: 85.3 % 
 
Results and Discussion 
 
The reactants and products are illustrated below; 
 
 
K4[Zr(oxalate)4]
4-     
Zr(Oxine)4 + 4 NH4K(oxalate) + 4 H2O 
 
 
NMR results show that the ligand exchange was successful and the Zr metal favours 
the oxine bidentate ligands opposed to the oxalate bidentate ligands. Reasons for this 
are currently unknown. 
 
As these results showed that is possible to exchange the oxalate ligands for the 
required oxine ligands further experiments were undertaken to repeat this developed 
method under acidic conditions. 
 
 
 
 
 
 
4 Oxine 
4NH4OH 
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4.4 Synthesis of Zirconium Tetrakisoxalate from Zirconium Tetrakisoxine 
 
Experiments were undertaken to ascertain if it was possible to exchange the oxine 
ligands of the Zr complex for oxalate ligands. NMR analysis of the resulting 
complexes determined that it was not possible, showing that the zirconium 
tetrakisoxine complex is more stable than the zirconium tetrakisoxalate complex. 
 
4.4.1 Synthesis of Zirconium Tetrakisoxine from Zirconium Tetrachloride in  
         1M Hydrochloric Acid 
 
Aim 
 
This experiment was conducted to replicate the conditions by which the 
89
Zr isotope 
is received from the supplier in the form zirconium-89 tetra chloride in 1 M of 
hydrochloric acid (HCl). The conditions were replicated and the oxine ligand was 
added in a stoichiometric ratio of 4:1 with the Zr ion. Ammonia was added to 
neutralise excess acid.   
 
Method 
 
Oxine (2.5 g; 0.01725 mol) was added to reverse osmosis water (150 mL) in a 250 
mL glass conical flask, heated to 58 
o
C and constantly stirred for 30 minutes until 
completely dissolved. Once the oxine was totally dissolved, the solution was cooled 
to room temperature (~20 
o
C). Zirconium tetrachloride (1.005 g; 0.0042 mol) was 
dissolved in HCl (20 mL) in a 250 mL conical flask at room temperature. The pH 
was then raised to 7.60 by addition of 1M NH4OH (28 mL). The solution of oxine 
was added carefully to the solution of zirconium tetrachloride drop wise with a 
narrow mouth bottle pipette under constant stirring utilising the magnetic stirrer 
function of an electric hotplate and an octagon magnetic stirrer. The solution was 
stirred for 20 minutes at room temperature (~20 
o
C). The solution was then heated to 
boiling for 30 minutes to ensure the reaction was complete and its volume was 
reduced by 90%. The solution was then allowed to cool to room temperature (~20 
o
C).  
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The solution was allowed to stand for a further 20 minutes and the resulting 
precipitate was then collected by the use of a Büchner funnel, filter paper and 
vacuum conical flask. The precipitate was washed with ethanol (15 mL), 
tetrahydrofuran (15 mL) and diethyl ether (15 mL) and then dried in an electric oven 
at a 100 
o
C for 1 hour. The dried complex was then ground with a pestle and mortar 
to ensure homogeneity and was stored in a glass air tight storage container. 
 
 
Formula weight: 667.82 g/mol 
  
Visual Appearance: Greenish yellow, fine powder.   
 
Theoretical Yield: 2.805 g 
Actual Yield: 2.552 g 
Percentage of Theoretical yield: 90.98% 
 
Results and Discussion 
 
Where the zirconium ion is in a solution of HCl problems were encountered when 
attempting to attach the oxine to the Zr ion. This was thought to be caused by the fact 
that oxine will not de-protonate successfully because of the excess protons in the 
solution provided by the 1 M of HCl present. The addition of ammonia is thought to  
push the reactions to completion by neutralisation of the excess acid and allow the 
ligand exchange to take place. As a result of the addition of ammonia, a salt was 
produced between ammonia and HCl; ammonium chloride. The ammonium chloride 
itself may also be interfering with the reaction. 
 
NMR analysis of the complex clearly shows that the desired complex of zirconium 
tetrakisoxine has been successfully synthesised (figure: 4.1, page 124). However 
there are a number of peaks that are currently unknown and are likely to be attributed 
to any remaining HCl present. The presence of the unknown contaminants is not 
acceptable and other methods of synthesis and purification were pursued. 
 
  
 
1
2
3
 
 
Figure 4.1: 
1
H NMR of Zirconium Tetrakisoxine and contaminants in DMSO-d6 
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4.5 Synthesis of Zirconium Tetrakisoxine from Potassium Zirconium  
      Tetrakisoxalato in 1 M Oxalic Acid 
 
Aim 
 
This experiment was conducted to replicate the conditions by which the 
89
Zr isotope 
is received from the supplier in the form zirconium tetrakisoxalato in 1 M of oxalic 
acid. The conditions were replicated and the oxine ligand was added in a 
stoichiometric ratio of 4:1 with the zirconium ion.  Ammonia was added to push the 
reaction to completion by neutralisation of the excess acid. 
 
Method 
 
Oxine (0.1800 g; 0.001240 mol) was added to reverse osmosis water (150 mL) in a 
250 mL glass conical flask, heated to 58 
o
C and constantly stirred for 30 minutes 
until completely dissolved. Once the oxine was totally dissolved, the solution was 
cooled to room temperature (~20 
o
C). Potassium zirconium tetrakisoxalato (0.2000 g; 
0.000289 mol) was dissolved in aqeous oxalic acid (50 mL; 1M) in a 250 mL conical 
flask at room temperature. The solution of oxine was added carefully to solution of 
potassium zirconium tetrakisoxalato in oxalic acid drop wise with a narrow mouth 
bottle pipette. The solution was then stirred utilising the magnetic stirrer function of 
an electric hotplate and an octagon magnetic stirrer. The solution was stirred for 20 
minutes at room temperature (~20 
o
C). Ammonia (50 mL) was added to the solution 
and a precipitate immediately formed. The solution was then heated to 85 
o
C for 30 
minutes to ensure the reaction was complete. The solution was then cooled to room 
temperature (~20 
o
C). The cooling process was accelerated by placing the 250 mL 
conical flask into an ice bucket. The solution was allowed to stand for 20 minutes 
and the resulting precipitate was then collected by the use of a Büchner funnel, filter 
paper and vacuum conical flask. The precipitate was then dried in an electric oven at 
a 100 
o
C for 1 hour. The dried complex was then ground with a pestle and mortar and 
stored in a glass air tight storage container.  
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Formula Weight: 667.82 g/mol 
 
Theoretical Yield: 2.805 g  
Actual Yield: 2.552 g     
Percentage of Theoretical Yield: 90.98 %  
 
Results and Discussion 
 
Where the zirconium is in the form zirconium tetrakisoxalato in a solution of oxalic 
acid problems were encountered when attempting to attach the oxine to the 
zirconium ion. This was thought to be caused by the fact that oxine will not de-
protonate successfully because of the excess protons in the solution provided by the 1 
M of oxalic acid present. The addition of ammonia is thought to push the reactions to 
completion by neutralisation of the excess acid and and allow the ligand exchange to 
take place. As a result of the addition of ammonia, a salt was produced between 
ammonia and oxalic acid; ammonium oxalate. The ammonium oxalate itself may 
also be interfering with the reaction.  
 
NMR results show that the desired zirconium tetrakisoxine complex did not form 
under this set of synthesis conditions. There are clear indications that the unbound 
oxine ligand is present along with a quantity of what is probably the salt formed 
between ammonia and oxalic acid (ammonium oxalate).  
 
Further work was undertaken to rectify the problems during the attempted synthesis 
of zirconium tetrakisoxine from potassium tetrakisoxalato in 1 M oxalic acid 
involving a neutralisation step and is reported in the following section of this thesis.   
 
 
 
 
 
 
 
 126 
 
4.6 Neutralisation of a 1 M HCl Acid Solution Containing Zirconium 
      Tetrachloride and Subsequent Synthesis of Zirconium Tetrakisoxine 
 
Aim 
 
It was hypothesised that neutralisation of the 1 M HCl solution in which the 
zirconium tetrachloride is dissolved would rectify the problems with the synthesis of 
the desired zirconium tetrakisoxine complex previously reported in sections 4.2.3 
and 4.2.4 of this thesis.  
 
Method 
 
Oxine (2.500 g; 0.01725 mol) was finely ground using a pestle and mortar. It was 
then added to reverse osmosis water (150 mL) in a 250 mL glass conical flask, 
heated to 58 
o
C and constantly stirred for 30 minutes until completely dissolved. The 
pH of the solution was measured and was found to be a pH of 7.11. Once the oxine 
was totally dissolved, the solution was cooled to room temperature (~20 
o
C). 
Zirconium tetrachloride (1.005 g; 0.00425 mol) was dissolved in HCl (20 mL) in a 
250 mL conical flask at room temperature. This acidic solution (pH 0.79) was then 
neutralised with sodium carbonate (Na2CO3)  in aqueous solution 1M (28 mL) (pH 
12.87), The pH of the solution at this stage was measured and was found to be 
neutral (pH 7.60). The solution of oxine was added carefully to the solution of 
zirconium drop wise with a narrow mouth bottle pipette under constant stirring 
utilising the magnetic stirrer function of an electric hotplate and an octagon magnetic 
stirrer. The solution was stirred for 20 minutes at room temperature (~20 
o
C). The 
solution was then heated to 80 
o
C for 30 minutes to ensure the reaction was 
complete. To extract the compound from the solution the volume was reduced until 
the compound had precipitated out. At this point there was less than 10% of the 
original volume remaining. The solution was then cooled to room temperature (~20 
o
C). The cooling process was accelerated by placing the 250 mL conical flask into an 
ice bucket. The solution was allowed to stand for 20 minutes and the resulting 
precipitate was then collected by the use of a Büchner funnel, filter paper and 
vacuum conical flask.  
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The precipitate was then dried in an electric oven at a 100 
o
C for 10 minutes. The 
dried complex was then ground with a pestle and mortar to ensure homogeneity and 
was stored in a glass air tight storage container. 
 
Formula weight: 667.82 g/mol 
  
Visual Appearance: Greenish yellow, fine powder.   
 
Theoretical Yield: 2.838g,  
Actual Yield: 3.221g 
Percentage of Theoretical yield: 113.50 % 
 
Results and Discussion 
 
NMR analysis on the complex clearly shows that the desired complex of zirconium 
tetrakisoxine had been successfully synthesised. However the appearance of the 
compound and the yield which is higher than expected suggests that the salt being 
formed with the neutralisation step is mixed in with the desired complex. This salt 
will need to be removed to ensure a purer product. 
 
The 1 M HCl acid solution containing zirconium tetrachloride was neutralised with 
the required amount of sodium carbonate (Na2CO3) with constant stirring for the 
solution to obtain neutral pH of ~7.00. Products formed during neutralisation of the 
acid with the base was sodium chloride salt (NaCl) and water.   
 
NMR results of the resulting product from this experiment show neutralisation of the 
1 M solution containing the zirconium tetrachloride is a necessary step to ensure the 
successful chelation of the oxine ligand to the zirconium ion. However a further step 
is required to separate the desired complex from the salts formed during the synthesis 
process. 
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4.7 Neutralisation of a 1 M Oxalic Acid Solution Containing Potassium 
      Zirconium Tetrakisoxalato and Subsequent Synthesis of Zirconium  
      Tetrakisoxine 
 
Aim 
 
As is the case with the attempted synthesis of zirconium tetrakisoxine from 
zirconium tetra chloride in an excess of HCl it was hypothesised that neutralisation 
of the 1 M oxalic acid solution in which the zirconium tetrakisoxalato is dissolved, 
would rectify the problems with the synthesis of the desired zirconium tetrakisoxine 
complex previously reported in sections 4.2.3 and 4.2.4 of this thesis.  
 
Method 
 
Oxine (2.10 g; 0.01446 mol) was finely ground using a pestle and mortar. It was then 
added to reverse osmosis water (150 mL) in a 250 mL glass conical flask, heated to 
58 
o
C and constantly stirred for 30 minutes until completely dissolved. The pH of the 
solution was measured and was found to be a pH of 7.11. Once the oxine was totally 
dissolved, the solution was cooled to room temperature (~20
o
C). Potassium 
zirconium tetrakisoxalato (2.00 g; 0.002899 mol) was dissolved in oxalic acid (1 M) 
(20 mL) in a 250 mL conical flask at room temperature. This acidic solution (pH 
1.02) was then neutralised with sodium carbonate (Na2CO3) (1M) (44 mL) (pH 7.80). 
The pH of the solution at this stage was measured and was found to be neutral (pH 
7.01). The solution of oxine was added carefully to the solution of potassium 
zirconium tetrakisoxalato drop wise with a narrow mouth bottle pipette under 
constant stirring utilising the magnetic stirrer function of an electric hotplate and an 
octagon magnetic stirrer. The solution was stirred for 20 minutes at room 
temperature (~20 
o
C). The solution was then heated to 70 
o
C for 20 minutes to ensure 
the reaction was complete. The solution was then allowed to cool to room 
temperature (~20 
o
C). The solution was allowed to stand for a further 20 minutes and 
the resulting precipitate was then collected by the use of a Büchner funnel, filter 
paper and vacuum conical flask.  
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The precipitate was then dried in an electric oven at a 100 
o
C for 10 minutes. The 
dried complex was then ground with a pestle and mortar to ensure homogeneity and 
was stored in a glass air tight storage container. 
 
Formula weight: 667.82 
  
Visual Appearance: Bright yellow, fine powder.   
 
Theoretical Yield: 1.936g 
Actual Yield: 2.490g 
Percentage of Theoretical yield: 128% 
 
Results and Discussion 
 
The 1 M oxalic acid solution containing potassium zirconium tetrakisoxalato was 
neutralised with the required amount of sodium carbonate (Na2CO3) (1M) with 
constant stirring for the solution to obtain a neutral pH of ~7.00. No precipitate 
formed during neutralisation; the salt formed due to the neutralisation of the acid 
with the base (sodium oxalate) remained dissolved in the solution. Carbon dioxide 
and water were also produced during the neutralisation process whilst the zirconium 
ion remained dissolved in the solution. The yield which is higher than expected 
suggests that the salt being formed with the neutralisation step is mixed in with the 
desired complex. 
 
NMR results of the resulting product from this experiment shows that neutralisation 
of the 1 M solution containing the zirconium tetrakisoxalato is a necessary step to 
ensure the successful chelation of the oxine ligand to the zirconium ion. 
 
It has been proven possible to exchange either the monodentate bound chloride or the 
bidentate bound oxalate ligands of the zirconium complex in an excess of either acid 
with the desired ligands. However a further step is required to separate the desired 
complex from the salts formed during the synthesis process to ensure a purer 
product. 
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4.8 Neutralisation of Acidic Conditions and Complex Synthesis 
 
4.8.1 Zirconium Tetrakisoxine 
 
Aim 
 
The aim of this experiment is to exchange the oxalate ligands attached to the Zr ion 
for oxine ligands in turn producing a neutral complex and to separate the salt formed 
during the neutralisation step from the desired complex. 
 
Method 
 
Oxine was (2.10 g; 0.01446 mol) was finely ground using a pestle and mortar and 
then completely dissolved in chloroform (50 mL) in a 100mL glass conical flask. 
Potassium zirconium tetrakisoxalato (2.00 g; 0.00289 mol) was dissolved in oxalic 
acid (20 mL) in a 100 mL conical flask at room temperature. This acidic solution (pH 
1.06) was then neutralised with sodium carbonate (Na2CO3) (1M) (19 mL) (pH 7.80). 
The pH of the solution at this stage was measured and was found to be neutral (pH 
7.00). This solution was then diluted to 50 mL with reverse osmosis water. The 
solution of oxine was added carefully to the solution of potassium zirconium 
tetrakisoxalato drop wise with a narrow mouth bottle pipette under constant stirring 
utilising the magnetic stirrer function of an electric hotplate and an octagon magnetic 
stirrer. The solution was stirred for 20 minutes at room temperature (~20 
o
C). The 
solution was then transferred to a 250 mL glass separating funnel. The chloroform 
layer had become pale yellow in colour as the zirconium tetrakisoxine complex was 
extracted into the chloroform phase.  
 
The chloroform layer was separated and heated on an electric hotplate at 60
o
C until 
the zirconium tetrakisoxine complex had precipitated and the remaining chloroform 
had been evaporated. The complex was then stored in an air tight container. NMR 
analysis was then undertaken to confirm the structure of the complex and was in 
agreement with the findings reported in chapter two of this thesis. 
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Carbon, hydrogen and nitrogen (CHN) analysis results for Zirconium Tetrakisoxine. 
 
Formula Weight: 667.82 g/mol 
 
 Expected 1
st
 Analysis 2
nd
 Analysis 
C % 64.75 64.59 64.66 
H % 3.62 3.71 3.70 
N % 8.69 8.60 8.67 
 
Table 4.2: CHN Analysis of Zirconium Tetrakisoxine 
        
 
Theoretical Yield:    1.93 0g 
Actual Yield:     1.700 g 
Percentage of Theoretical Yield:  88.10 % 
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4.8.2 Zirconium Tetrakistropolone 
 
Aim 
 
The aim of this experiment is to exchange the oxalate ligands attached to the Zr ion 
for tropolone ligands in turn producing a neutral complex and to separate the salt 
formed during the neutralisation step from the desired complex. 
 
Method 
 
Tropolone (3.600 g; 0.0298 mol) was completely dissolved in chloroform (50 mL) in 
a 100 mL glass conical flask. Potassium zirconium tetrakisoxalato (5.00g; 0.00725) 
mol was dissolved in oxalic acid (20 mL) in a 100 mL conical flask at room 
temperature. This acidic solution (pH 1.06) was then neutralised with sodium 
carbonate (Na2CO3) (1M) (19 mL) (pH 7.80). The pH of the solution at this stage 
was measured and was found to be neutral (pH 7.00). This solution was then diluted 
to 50 mL with reverse osmosis water. The solution of tropolone was added carefully 
to the solution of potassium zirconium tetrakisoxalato drop wise with a narrow 
mouth bottle pipette under constant stirring utilising the magnetic stirrer function of 
an electric hotplate and an octagon magnetic stirrer. The solution was stirred for 20 
minutes at room temperature (~20 
o
C). The solution was then transferred to a 250 mL 
glass separating funnel. The chloroform layer had become pale yellow in colour as 
the zirconium tetrakistropolone complex was extracted into the chloroform phase.  
 
The chloroform layer was separated and heated on an electric hotplate at 60
o
C until 
the zirconium tetrakistropolone complex had precipitated. The complex was then 
stored in an air tight container. NMR analysis was then undertaken to confirm the 
structure of the complex and was in agreement with the findings reported in chapter 
two of this thesis. 
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Carbon, hydrogen and nitrogen (CHN) analysis results for Zirconium 
Tetrakistropolone. 
 
Formula Weight: 658.91 g/mol 
 
 Expected 1
st
 Analysis 2
nd
 Analysis 
C % 53.47 53.22 53.28 
H % 3.23 3.20 3.21 
N % 0 0 0 
 
Table 4.3: CHN Analysis of Zirconium Tetrakistropolone  
(.55 Chloroform) 
 
      
Theoretical Yield:    4.780 g 
Actual Yield:     4.640 g 
Percentage of Theoretical Yield:  97.10 % 
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4.8.3 Zirconium Tetrakisethyl maltol 
 
Aim 
 
The aim of this experiment is to exchange the oxalate ligands attached to the Zr ion 
for ethyl maltol ligands in turn producing a neutral complex and to separate the salt 
formed during the neutralisation step from the desired complex. 
 
Method 
 
Ethyl maltol (4.2042g; 0.0300 mol) was completely dissolved in chloroform (50 mL) 
in a 100 mL glass conical flask. Potassium zirconium tetrakisoxalato (5.000 g; 
0.00725 mol) was dissolved in oxalic acid (20 mL) in a 100 mL conical flask at room 
temperature. This acidic solution (pH 1.18) was then neutralised with sodium 
carbonate (Na2CO3) (1M) (24 mL) (pH 7.30). The pH of the solution at this stage 
was measured and was found to be neutral (pH 7.04). This solution was then diluted 
to 50 mL with reverse osmosis water.  
 
The solution of ethyl maltol was added carefully to the solution of potassium 
zirconium tetrakisoxalato drop wise with a narrow mouth bottle pipette under 
constant stirring utilising the magnetic stirrer function of an electric hotplate and an 
octagon magnetic stirrer. The solution was stirred for 20 minutes at room 
temperature (~22 
o
C). The solution was then transferred to a 250 mL glass separating 
funnel. The chloroform layer had become milky/cloudy as the zirconium 
tetrakisethyl maltol complex was extracted into the chloroform phase.  
 
The chloroform layer was separated and heated on an electric hotplate at 60
o
C until 
the zirconium tetrakisethyl maltol complex had precipitated and the remaining 
chloroform had been evaporated. The complex was then stored in an air tight 
container. NMR analysis was then undertaken to confirm the structure of the 
complex and was in agreement with the findings reported in chapter two of this 
thesis. 
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Carbon, hydrogen and nitrogen (CHN) analysis results for Zirconium Tetrakisethyl 
maltol. 
 
Formula Weight: 647.74 g/mol 
 
 Expected 1
st
 Analysis 2
nd
 Analysis 
C % 51.92 51.79 51.89 
H % 4.36 4.33 4.43 
N % 0 0 0 
 
Table 4.4: CHN Analysis of Zirconium Tetrakisethyl maltol 
 
      
Theoretical Yield:    4.701 g 
Actual Yield:     4.220 g 
Percentage of Theoretical Yield:  89.79 % 
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4.8.4 Zirconium Tetrakisdeferiprone 
 
Aim 
 
The aim of this experiment is to exchange the oxalate ligands attached to the 
zirconium ion for deferiprone ligands in turn producing a neutral complex and to 
separate the salt formed during the neutralisation step from the desired complex. 
 
Method 
 
Deferiprone (4.105g; 0.00295 mol) was completely dissolved in chloroform (50 mL) 
in a 100 mL glass conical flask whilst heated to 45 
o
C. Potassium zirconium 
tetrakisoxalato (5.000 g; 0.00725 mol) was dissolved in oxalic acid (20 mL) in a 100 
mL conical flask at room temperature. This acidic solution (pH 1.20) was then 
neutralised with sodium carbonate (Na2CO3) (1M) (25 mL) (pH 7.30). The pH of the 
solution at this stage was measured and was found to be neutral (pH 7.01). This 
solution was then diluted to 50 mL with reverse osmosis water.  
 
The solution of deferiprone was added carefully to the solution of potassium 
zirconium tetrakisoxalato drop wise with a narrow mouth bottle pipette under 
constant stirring utilising the magnetic stirrer function of an electric hotplate and an 
octagon magnetic stirrer. The solution was stirred for 20 minutes at room 
temperature (~22 
o
C). The solution was then transferred to a 250 mL glass separating 
funnel. The aqueous layer had become milky/cloudy indicating that the zirconium 
tetrakisdeferiprone complex was extracted into the aqueous phase.  
 
Both layers were separated and heated on an electric hotplate at 60
o
C (chloroform 
layer) 100
o
C (aqueous layer) until the zirconium tetrakisdeferiprone complex had 
precipitated and the remaining water had been evaporated. The complex was then 
stored in an air tight container. NMR analysis was then undertaken to confirm the 
structure of the complex. 
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Carbon, hydrogen and nitrogen (CHN) analysis results for Zirconium 
Tetrakisdeferiprone. 
 
Formula Weight: 859.99 g/mol 
 
 Expected 1
st
 Analysis 2
nd
 Analysis 
C % 39.02 37.31 37.39 
H % 6.57 5.58 5.64 
N % 6.50 6.11 6.19 
 
Table 4.5: CHN Analysis of Zirconium Tetrakisdeferiprone 
 
      
Theoretical Yield:    6.235 g 
Actual Yield:     6.112 g 
Percentage of Theoretical Yield:  98.03 % 
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4.9 Results and Discussion 
 
The experiments reported on pages 142-149 involve the neutralisation of a 1 M 
oxalic acid solution containing potassium zirconium tetrakisoxalato and subsequent 
synthesis of zirconium tetrakis complexes. Each of the synthesis methods involves a 
chloroform extraction to separate the desired complex from the salt formed during 
the neutralisation process 
 
The yields for all of the complexes apart from zirconium tetrakisdeferiprone are 
within acceptable values. The deferiprone complex has a higher than expected actual 
yield due to the problems separating the salt from the complex. 
 
CHN results from zirconium tetrakisoxine, tropolone and ethyl maltol are all in 
agreement with the predicted and obtained values reported in chapter 2 of this thesis 
with the exception of the deferiprone complex. For zirconium tetrakisdeferiprone to 
be separated from the salt further research and method development must be 
undertaken. 
 
NMR results of the resulting products from this set of experiments show that 
neutralisation of the 1 M solution containing the zirconium tetrakisoxalato is a 
necessary step to ensure the successful chelation of the oxine ligand to the zirconium 
ion. Furthermore the chloroform extraction step is a potential method to separate the 
desired complex from the salts formed during the neutralisation step in the synthesis. 
Zirconium tetrakisoxine, tropolone and ethyl maltol all have an affinity for the 
chloroform layer whereas the salt has an affinity for the aqueous layer so separation 
of the two is straightforward. However zirconium tetrakisdeferiprone has an affinity 
for the aqueous layer and as such makes the separation of the complex and the salt 
problematic. The CHN results for the zirconium deferiprone complex are inaccurate 
as it has not been possible to separate the salts formed during the synthesis from the 
complex itself. 
  
 
1
3
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Proposed Reactants and Products Formed During the Neutralisation of Zirconium Tetrakisoxalato and Subsequent Formation of 
Zirconium Tetrakisoxine 
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Figure 4.2: Synthesis Steps of Zirconium Tetrakioxine 
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4.10 Conclusions 
 
4.10.1 Neutralisation of Acidic Solutions 
 
A range of methods used in the attempt to synthesise the zirconium complexes from 
acidic solutions were unsuccessful. It was determined that a neutralisation step in the 
synthesis was necessary.  
 
4.10.2 Ammonium Hydroxide 
 
During the synthesis of the un-neutralised complexes, ammonium hydroxide was 
used to push the reactions to completion by neutralisation of the excess acid and 
consequently a salt is formed. The excess protons in the solution originate from the 
acidic conditions. 
 
Generally salts of ammonia are water soluble which allows any unwanted 
ammonium salts to be washed away leaving the product; zirconium tetrakisoxine 
intact. Zirconium tetrakisoxine, tropoleone and ethyl maltol are insoluble in water 
and as such none of the the yield should be lost during the washing step of the 
synthesis. However ammonia in an aqueous solution can also be expelled by boiling 
which provides another option of removing any unwanted/excess ammonia from a 
solution.  During the experiments involving the neutralisation of an excess of oxalic 
acid, ammonium oxalate, carbon dioxide and water are formed. During the 
experiments involving an excess of HCl, ammonium chloride, carbon dioxide and 
water are formed. 
 
4.10.3 Sodium Carbonate 
 
Sodium carbonate was also investigated to be utilised in the neutralisation step. As is 
the case with ammonium hydroxide the addition of sodium carbonate pushes the 
reactions to completion by neutralisation of the excess acid and consequently a salt is 
formed. With HCl it forms sodium chloride, carbon dioxide and water, with oxalic 
acid it forms sodium oxalate, carbon dioxide and water. 
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 There does not seem to be any difference in the use of either ammonium hydroxide 
or sodium carbonate to neutralise either of the acidic solutions of HCl or oxalic acid. 
Sodium carbonate was used due to availability during the experimental process. 
 
4.10.4 Synthesis of Complexes under Neutralised Conditions and Chloroform     
           Extraction 
 
Neutralisation of the acids in which the zirconium complex is supplied is essential in 
the process of synthesising the desired complexes. The neutralisation step results in a 
salt being formed which the desired compound needs to be separated from. As the 
complex has greater solubility in the chloroform phase and the salt has greater 
solubility an aqueous phase, chloroform extraction is the simplest method to separate 
the two.  
 
4.10.5 CHN Analysis of the Zirconium Complexes 
 
CHN analysis of zirconium tetrakisoxine, tropolone and ethyl maltol were all within 
agreement with the predicted results and the results reported in chapter 2. Zirconium 
tetrakisdeferiprone has been problematic when attempting to synthesise from 
potassium zirconium tetrakisoxalato, with or without an excess of acid in the 
solution. Methods to synthesis the tetrakisdeferiprone complex from potassium 
zirconium tetrakisoxalato have failed. CHN results vary greatly from each of the 
failed methods and suggest that two or three of the deferiprone ligands are attached 
to the zirconium ion with the remaining two ligands or single ligand being that of 
oxalate. It may be possible to synthesise the complex from zirconium tetra chloride 
in an excess of HCl, but as that is not the form in which the radioactive zirconium is 
currently supplied this synthesis method will not be pursued 
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CHAPTER 5 
Ultraviolet-Visible Spectroscopy and Chromatographic Analysis of the 
Zirconium Compounds and their Ligands for Quality Control Purposes 
 
5.1 Introduction 
 
Ultraviolet-visible (UV-Vis) spectroscopy is an analytical technique that allows the 
determination of the concentration of solutions of transition metals ions, biological 
macromolecules, highly conjugated organic compounds and the rate of reactions.179 d 
electrons within metal ions in solution can become excited from one electronic state 
to another causing the ions to be coloured. This colour is influenced by the presence 
of certain ligands.180 The Beer Lambert Law is commonly used in UV-Vis analysis. 
 
The Beer Lambert law is the linear relationship between the concentration and 
absorbance of an absorbing sample, usually written as A = a (λ)bc.179 A is the 
measured absorbance, a (λ) relates to a wavelength dependent absorption coefficient, 
b is the path length and c is the sample’s concentration.179 If working in concentration 
units of molarity the Beer Lambert Law is written as A = Ɛbc, Ɛ is the wavelength 
reliant molar absorptivity coefficient (units M
-1
 cm
-1
).180 The Beer-Lambert law was 
used to calculate molar absorptivity for both the ligand and the zirconium tetrakis 
complexes. 
  
Each solvent used during the high performance liquid chromatography (HPLC) 
experiments was analysed with use of UV-Vis spectroscopy to determine whether 
there was any absorbance from the solvent in an area that would interfere with the 
detection of the ligands or the zirconium complexes. The analysis of the ligands and 
zirconium tetrakis complexes was also undertaken with UV-Vis spectroscopy. This 
analytical technique provided unique spectra which allowed identification of both the 
ligands and complexes. This information is essential when setting the range of the 
UV-Vis detector on the HPLC apparatus. 
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5.2 Experimental Method 
 
Tables of equipment, equipment settings and reagents used throughout this chapter 
can be located in the appendix section of this thesis 
 
Each of the precursor compounds, ligands and zirconium complexes were dissolved 
in an appropriate solvent into a volumetric flask. Acetonitrile for oxine and 
zirconium tetrakisoxine, methanol for tropolone, zirconium tetrakistropolone, ethyl 
maltol, zirconium tetrakisethyl maltol, millipore water for deferiprone and zirconium 
tetrakisdeferiprone. Serial dilutions were prepared using a range of glass pipettes in 
to volumetric flasks resulting in a range of concentrations. Each of the solutions were 
placed into a 400 µL quartz cuvette and analysed utilising a Shimadzu UV-1800 
spectrometer. A reference quartz curvette containing the relevant solvent was run 
alongside the sample for background purposes. 
 
Microcal Origin 5.0 was used to plot calibration curves of the ligands and complexes. 
Molar absorbtivity values of the compounds include a standard error of the slope 
value. This value was automatically calculated by the software using the following 
formula: 
 
𝑆𝐸 =
√∑(𝑦𝑖 − ?̂?𝑖)-
2 /(𝑛 − 2)
√∑(𝑥𝑖 − ?̅?)2
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5.3 Results and Discussion 
 
Figure 5.1: UV-Vis Stacked Spectra of Oxine 
 
 
Figure 5.2: UV-Vis Stacked Spectra of Tetrakisoxine 
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Figure 5.3: Calibration Curve of Oxine (308 nm) 
y = 0.01383 x + 0.0476 R-Squared Value = 0.99997 
 
 
 Figure 5.4: Calibration Curve of Oxine (380 nm) 
y = 0.01419 x - 0.007779  R-Squared Value = 0.99936 
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Figure 5.5: UV-Vis Stacked Spectra of Tropolone 
 
 
 
Figure 5.6: UV-Vis Stacked Spectra of Tetrakistropolone 
250 275 300 325 350 375 400 425
0.0
0.5
1.0
1.5
2.0
2.5
 
 
Wavelength (nm)
A
bs
or
ba
nc
e
 50.80 ppm
 25.40 ppm
 12.70 ppm
 6.35 ppm
 1.27 ppm
250 275 300 325 350 375 400 425 450 475
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
 50.80 ppm
 25.40 ppm
 12.70 ppm
 6.35 ppm
 1.27 ppm
Ab
so
rb
an
ce
Wavelength (nm)
 147 
 
 
Figure 5.7: Calibration Curve of Tropolone (370 nm) 
y = 0.0304 x - 0.00194 R-Squared Value = 0.99961 
 
Figure 5.8: Calibration Curve of Tetrakistropolone (369 nm) 
y = 0.0396 x + 0.09742 R-Squared Value = 0.99986
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Figure 5.9: UV-Vis Stacked Spectra of Ethyl Maltol 
 
Figure 5.10: UV-Vis Stacked Spectra of Zirconium Tetrakisethyl Maltol 
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Figure 5.11: Calibration Curve of Ethyl Maltol (368 nm) 
y = 0.05000 x + 0.02484 R-Squared Value = 0.99957 
 
Figure 5.12: Calibration Curve of Tetrakisethyl Maltol (312 nm) 
y = 0.02511 x - 0.00592 R-Squared Value = 0.99995 
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Figure 5.13: UV-Vis Stacked Spectra of Deferiprone 
 
 
Figure 5.14: UV-Vis Stacked Spectra of Zirconium Tetrakisdeferiprone 
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Figure 5.15: Calibration Curve of Deferiprone (217 nm) 
y = 0.09596 x + 0.05576 R-Squared Value = 0.99995 
 
Figure 5.16: Calibration Curve of Tetrakisdeferiprone (227 nm) 
y = 0.07898 x + 0.08495 R-Squared Value = 0.99907 
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5.3.1 UV Analysis of Oxine & Zirconium Tetrakisoxine 
 
UV-Vis spectroscopy was used to analyse both the oxine ligand and the zirconium 
tetrakisoxine complex. The analysis of the ligand and complex using this technique 
provided unique spectra which allowed for their identification. The oxine ligand has 
absorption peaks at 237 nm and 308 nm. The zirconium tetrakisoxine complex has 
peaks at 244 nm and 380nm. 
 
The ligand and the complex both show absorbance between a range of 200 nm – 461 
nm at 256 ppm. Between 369 nm and 461 nm at 256 ppm there is an absorbance for 
the complex only. However this absorbance range is at the tail end of the overall 
absorbance for the complex and is fairly weak. When analysing the complex and 
ligand via HPLC apparatus the detector was set to a range where by both the ligand 
and complex have a large absorbance value and retention times were used to 
differentiate between the ligand and the complex. 
 
The ligand and complex are stable in a solution of acetonitrile at concentrations of 
1.28, 6.40, 12.80, 25.60, 51.20, 76.80, 102.40, 128.00 and 256.00 ppm. R-Squared 
value of oxine = 0.99997 and the R-Squared value of the complex = 0.99998 
indicating a strong relationship between the absorbance of the ligand and complex 
and the concentration. The absorption spectrum of zirconium tetrakisoxine in 
acetonitrile has an absorption at 380 nm (previously reported in toluene at 387 nm)134 
assigned to a π→π* transition in the ligand by comparison with related complexes.181 
Molar absorptivity of the complex at 380 nm ( ε 9480 + 30 dm3 mol-1 cm-1 ) is 
approximately four times that observed for the ligand at 308 nm, ε 2570 +  10 dm3 
mol
-1
 cm
-1
 and is in accordance with the chromophore being ligand based rather than 
involving the Zr. 
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5.3.2 UV Analysis of Tropolone & Zirconium Tetrakistropolone 
 
The analysis of both the tropolone ligand and the zirconium tetrakistropolone 
complex was undertaken with the use of UV-Vis spectroscopy. The analysis of the 
ligand and complex using this analytical technique provided unique spectra which 
allowed for the identification of both the ligand and the complex. The tropolone 
ligand has absorption peaks at 320 nm, 353 nm and 370 nm. The zirconium 
tetrakistropolone complex has peaks at 334 nm and 369 nm. 
 
The ligand and the complex both show absorbance in the range of 250 nm – 403 nm 
at 254 ppm. Between 404 nm and 425 nm at 254 ppm there is an absorbance for the 
zirconium tetrakisethyl maltol complex only. This absorbance range is at the tail end 
of the overall absorbance for the complex and is extremely weak. This has not been 
able to be used to uniquely identify the compound from the  ligand via the use of the 
UV-Vis detector attached to the HPLC apparatus.  Hence it is not possible to 
uniquely identify only the ligand or the complex. When analysing the complex and 
ligand via HPLC apparatus the detector was set to a value where by both the ligand 
and complex have a large absorbance value and retention times were used to 
differentiate between the ligand and the complex. 
 
The ligand and complex are stable in a solution of methanol at concentrations of 
1.27, 6.35, 12.70, 25.40, 50.80 and 76.20 ppm. R-Squared value of tropolone = 
0.99961 and the tropolone complex = 0.99926 indicating a strong relationship 
between the absorbance of the ligand and complex and the concentration. Electronic 
absorptions for free tropolone in methanol were in accord with those previously 
observed in DMSO182 The absorptions are due to π-π* transitions and analogous 
transitions are observed in zirconium tetrakistropolone with increased extinction 
coefficients attributed to the presence of four tropolone rings with enhancement by 
the contribution of a charge transfer transition.182 Molar absorptivity for the complex 
(ε 63000 + 5000 dm3 mol-1 cm-1) at 333 nm is approximately 10 times that observed 
for  the ligand at 320 nm (ε/dm3 mol-1 cm-1 6500 + 600). The complex at 369 nm has 
an molar absorptivity  of  ε 33000 +  1000 dm3 mol-1 cm-1  and the ligand  at 354 nm 
an molar absorptivity of  ε  5900 +  200 dm3 mol-1 cm-1. 
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5.3.3 UV Analysis of Ethyl Maltol & Zirconium Tetrakisethyl maltol 
 
The analysis of both the ethyl maltol ligand and the zirconium tetrakisethyl maltol 
complex was undertaken with the use of UV-Vis spectroscopy. The analysis of the 
free ligand and complex using this analytical technique provided unique spectra 
allowing the identification of both the free ligand and the complex. Ethyl maltol 
ligand absorption peaks at 205 nm and 278 nm. The complex has peaks at 224 nm, 
and 312 nm. The ligand and the complex both show absorbance between a range of 
190 nm – 362 nm at 254 ppm. Between 319 nm and 362 nm at 254 ppm there is an 
absorbance for the zirconium tetrakis complex only. However this absorbance range 
is at the tail end of the overall absorbance for the complex and is extremely weak. 
This has not been able to be used to uniquely identify the compound from the ligand 
via the use of the UV-Vis detector attached to the HPLC apparatus at UKC. As this is 
the case it is not possible to set the UV-Vis detector attached to the HPLC apparatus 
to a unique range to identify only the ligand or the complex. When analysing the 
complex and ligand via HPLC apparatus the detector was set to a range where by 
both the ligand and complex have a large absorbance value.  
 
The ligand and complex are stable in a solution of acetonitrile at concentrations of 
1.27, 6.35, 12.70, 25.40, and 50.80 ppm. R-Squared value of ethyl maltol = 0.99957 
R-Squared value of the ethyl maltol complex = 0.99995 indicating a strong 
relationship between the absorbance of the ligand/complex and the concentration.An 
electronic absorption for ethyl maltol in methanol was recorded as 268 nm, observed 
previously in toluene at 286 nm and interpreted as a π-π* transitions of the α, β 
unsaturated enone.138 In the complex this band disappears due to the loss of 
conjugation of the enone, demonstrating complexation by the carbonyl group. 
Absorption bands appear in UV spectrum at 224 and 312 nm, the latter may be 
attributed to a ligand-to-metal charge transfer from a π ligand orbital to the d0 orbital 
of the zirconium. Molar absorptivity for the complex is (ε 64000 + 5000 dm3 mol-1 
cm
-1
) at 224 nm and at 312 nm (ε/dm3 mol-1 cm-1 21000 + 1000). The ligand at 268 
nm has a molar absorptivity of ε 10200 +  300 dm3 mol-1 cm-1. 
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5.3.4 UV Analysis of Deferiprone & Zirconium Tetrakisdeferiprone 
 
The analysis of both the deferiprone ligand and the zirconium tetrakisdeferiprone 
complex was undertaken with the use of UV-Vis spectroscopy. The analysis of the 
free ligand and complex using this analytical technique provided unique spectra 
which allowed for the identification of both the free ligand and the complex. The 
deferiprone ligand has absorption peaks at 217 nm and 283 nm. The zirconium 
tetrakisdeferiprone complex has peaks at 227 nm and 296 nm. 
 
The ligand and the complex both show absorbance between a range of 200 nm – 344 
nm at 254 ppm. Between 328 nm and 344 nm at 254 ppm there is an absorbance for 
the zirconium tetrakisdeferiprone complex only. This absorbance range is at the tail 
end of the overall absorbance for the complex and is fairly weak. This has not been 
able to be used to uniquely identify the compound from the ligand via the use of the 
UV-Vis detector attached to the HPLC apparatus at UKC. As this is the case it is not 
possible to set the UV-Vis detector attached to the HPLC apparatus to a unique range 
to identify only the ligand or the complex. When analysing the complex and ligand 
via HPLC apparatus the detector was set to a range where by both the ligand and 
complex have a large absorbance value.  
 
The ligand and complex are stable in a solution at concentrations of 1.27, 6.35, 12.70 
and 25.40 ppm. At concentrations of above 25.40 ppm the absorbance for the ligand 
becomes greater than the upper detection limit of 4.00 absorbance units for the 
apparatus. The deferiprone complex can be detected up to a concentration of 25.40 
ppm as is the case of the deferiprone ligand. R-Squared value of deferiprone = 
0.99995 and the R-Squared value of the complex = 0.99907 indicating a strong 
relationship between the absorbance of the ligand and complex and the 
concentration. The intense absorptions in the 280-300 nm region of the UV spectrum 
can be assigned to both hydroxyl and carbonyl Zr(IV) ligand to metal charge transfer 
(MLCT).144 Molar absorptivity for the complex is (ε 78000 + 6000 dm3 mol-1 cm-1) 
at 227 nm and at 296 nm, ε 32000 + 1000 dm3 mol-1 cm-1 The ligand at 283 nm has a 
molar absorptivity of ε 14240 +  90 dm3 mol-1 cm-1. 
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5.4 Conclusion 
 
5.4.1 UV-Vis Analysis of Zirconium Tetra Chloride & Potassium Zirconium 
          Tetrakisoxalate 
 
The analysis of zirconium tetra chloride and potassium zirconium tetrakisoxalate was 
under taken with a UV-Vis spectrometer at a range of concentrations. It was found 
that there was not any noticeable absorbance within the range of 200 to 900 nm.  
These results are clearly problematic when developing a HPLC method at UKC as 
the HPLC apparatus in the research lab is fitted with a UV-Vis detector and as such it 
will not be possible to detect these complexes. 
 
5.4.2 Spectra 
 
Unique UV-Vis spectra were obtained for both the ligands and the zirconium tetrakis 
complexes. In each case the complex had a greater wavelength range with the same 
beginning wavelength value as the ligand. This absorbance range is at the tail end of 
the overall absorbance for the complex and was consistently weak 
 
5.4.3 Calibration Curves 
 
The ligand and complex were shown to be stable at range of concentrations. 
Calibration curves were plotted and indicate a strong relationship between the 
absorbance and the concentration of the ligand and zirconium tetrakis complexes. 
 
5.4.4 Absorbance 
 
It was found that there was always an increase in the molar absorptivity of the 
zirconium complex when compared to its related ligand. However it was seen that 
this increase is not always simply four times the molar absorptivity of the ligand. 
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5.5 High Performance Liquid Chromatography Analysis 
 
HPLC is used in the fields of chemistry and biochemistry to assist devising methods 
to synthesise chemical compounds, for purification purposes, analysing and 
separating mixtures, isolating natural products and predicting physical properties of 
compounds.183 HPLC can also be used in quality control processes such as ensuring 
the purity of raw materials and synthesised compounds, determining the stability and 
monitoring the dissociation of compounds and quantifying the amount of synthesised 
compounds.183 
 
The HPLC analysis of analytes involves the injection of a minute amount of sample 
in solution into a moving stream of liquid known as the mobile phase. The mobile 
phase passes through a column that is packed with particles of a stationary phase 
such as silica. The separation of a mixture into its constituent components depends 
on the different levels of retention of each component in the column.184 The 
partitioning of a component between the stationary phase and the mobile phase 
determines its retention in the column.183 The stationary/solute phase and mobile 
solute/phase interactions directly affect the partitioning between the two. Even 
minute changes in the composition of mobile phases will cause an exceptional effect 
on the separation of analytes. The components of the analytes will have in the 
majority of cases different rates of mobility. Because of this different components 
should exit the column at different times so that they will have different retention 
times.184 Detectors sense anything that is not considered part of the mobile phase and 
transforms this information into an electrical signal, this is in turn is converted into a 
chromatogram via the use of integrated system software. 
 
Radiochemical analysis and quality control for research in nuclear medicine and PET 
is extremely important. Radiochemical purity can be defined as a fraction of the total 
amount of activity in the desired chemical form contained within a sample. It is 
important that impurities are identified as they can cause altered bio distribution.185 
HPLC can be used to identify and quantify the components of a sample by both 
detecting and counting the amount of radiation in each separated fragment of the 
sample or by identifying the amount of absorbance by a UV detector.185 
 158 
 
5.6 Experimental Method 
 
5.6.1 Sample Preparation 
 
A range of solutions were prepared at various concentrations in parts per million of 
both the ligands (oxine, tropolone, ethyl maltol and deferiprone) and the zirconium 
tetrakis complexes from each of the ligands. These were obtained by dissolving the 
appropriate weight of each of the compounds separately into either 250 mL of 
acetonitrile, water or methanol depending on solubility of the complex or the ligand. 
2 mL of each of the solutions was separately filtered using a single use filter and the 
resulting filtrate was placed into 2 mL screw cap glass vials. 
 
5.6.2 HPLC Instrument Preparation 
 
Firstly the instrument and PC were been switched on and the appropriate software 
was loaded (Chromeleon 7.1.0.898). Utilising the Chromeleon software the pump 
and UV-Vis lamps were switched on and parameters such as the flow rate, 
wavelength and attenuation was set to the required values. The instrument was 
allowed to warm up for a period of 30 minutes. The stability of the base line was 
checked and observations were made for any large changes in the absorbance values. 
Mobile phase solvents degassed automatically via the HPLC apparatus to ensure that 
there is not a build-up of gas in the system that will affect the retention times of the 
analytes. 
 
5.6.3 HPLC Analysis of Zirconium Tetrachloride & Potassium Zirconium 
          Tetrakisoxalate 
 
The UV-Vis spectrometer analysis of zirconium tetra chloride and potassium 
zirconium tetrakisoxalate was as expected, there was not any noticeable absorbance 
within the range of 200 nm to 900 nm. Unfortunately the HPLC spectrometer at the 
University of Kent at Canterbury is only equipped with a UV-Vis detector and 
analysis of these compounds is not possible with the current apparatus. 
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5.7 Method Development 
 
5.7.1 Oxine and Zironium Tetrakisoxine 
 
Methods adapted to fit the available equipment and to identify oxine and zirconium 
tetrakisoxine include the identification of aluminium chelates of oxine utilising 
HPLC, Hambali et al186, Fluorescence properties of metal-complexes of 8-
hydroxyquinoline-5-sulfonic acid and chromatographic applications, Krystyna Sorok 
et al187, Extraction with toluene and HPLC determination of aluminium in the form 
of an 8-hydroxyquinoline derivative, Hongzhen Lian et al188 and Reverse-phase high-
performance liquid chromatographic determination of halogenated 8-
hydroxyquinoline compounds in pharmaceuticals and bulk drugs, Wojtowicz et al.189 
 
5.7.2 Tropolone and Zirconium Tetrakistropolone 
 
There are currently no published papers reporting a HPLC protocol for the 
identification of zirconium tetrakistropolone. The method developed to separate and 
identify tropolone and zirconium tetrakistropolone was based on the methods used to 
analyse oxine and zirconium tetrakisoxine.  
 
5.7.3 Ethyl Maltol and Zirconium Tetrakisethyl maltol 
 
There are currently no published papers reporting a HPLC protocol for the 
identification of zirconium tetrakisethyl maltol. The method to separate vanilla 
compounds reported by Jean-Paul Larcinese190 was adapted to fit the equipment 
available and subsequently identify ethyl maltol. 
 
5.7.4 Deferiprone and Zirconium Tetrakisdeferiprone 
 
There are no published papers reporting a HPLC method to identify zirconium 
tetrakisdeferiprone. The method to identify deferiprone was adapted from work 
reported by Mateen Abbasto et al191 to study deferiprone in human plasma and 
adapted to fit the equipment available. 
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5.8 Results and Discussion for HPLC Analysis with a Mobile Phase of 
      Acetonitrile and Water and a Eclipse XDB-C8 Column 
 
5.8.1 Oxine  
 
Oxine was dissolved in acetonitrile and HPLC conditions for the identification of 
oxine at a concentration of 12.8 ppm with the use of a XDB-C8 Eclipse column and a 
mobile phase of acetonitrile and water are as follows;  
 
Column: Eclipse XDB-C8 Mobile Phase: 75/25 
Acetonitrile/Water 
Column Pressure: 125 bar Wavelength: 380 nm 
Flow Rate: 1 mL min
-1
 Concentration: 12.8 ppm. 
Injection Volume: 10 µL Temperature: 22
o
C 
Figure 5.17: HPLC Chromotogram of Oxine (Acetonitrile/Water)  
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5.8.2 Zirconium Tetrakisoxine 
 
Zirconium tetrakisoxine was dissolved in acetonitrile and HPLC conditions for 
attempted identification of the zirconium tetrakisoxine with the use of a XDB-C8 
Eclipse column and a mobile phase of acetonitrile and water are as follows; 
 
Column: Eclipse XDB-C8 Mobile Phase: 75/25 
Acetonitrile/Water 
Column Pressure: 125 bar Wavelength: 380 nm 
Flow Rate: 1 mL min
-1
 Concentration: 12.8 ppm. 
Injection Volume: 10 µL Temperature: 22
o
C 
 
 
Figure 5.18: HPLC Chromotogram of Zirconium Tetrakisoxine 
(Acetonitrile/Water) 
 
No 
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Height 
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Relative 
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Identification 
1 2.501 0.37 0.85 87.64 Unknown 
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5.8.3 Zirconium Tetrakisoxine with Excess Ligand 
 
Zirconium tetrakisoxine was dissolved in acetonitrile and HPLC conditions for the 
identification of zirconium tetrakisoxine (12.8 ppm) with the use of a XDB-C8 
Eclipse column and excess ligand (concentration 1000 ppm) in the mobile phase of 
acetonitrile and water are as follows; 
 
Column: Eclipse XDB-C8 Mobile Phase: 75/25 
Acetonitrile/Water 
Column Pressure: 125 bar Wavelength: 380 nm 
Flow Rate: 1 mL min
-1
 Concentration: 12.8 ppm. 
Injection Volume: 10 µL Temperature: 22
o
C 
 
 
Figure 5.19: HPLC Chromotogram of Zirconium Tetrakisoxine 12.8ppm 
(Acetonitrile/Water + Excess Ligand) 
 
No 
Retention 
Time (min) 
Area 
mAU* min 
Height 
mAU 
Relative 
Area % 
Identification 
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5.8.4 Zirconium Tetrakisoxine with Excess Ligand 
 
Zirconium tetrakisoxine was dissolved in acetonitrile and HPLC conditions for the 
identification of zirconium tetrakisoxine (128 ppm) with the use of a XDB-C8 
Eclipse column and excess ligand (concentration 1000 ppm) in the mobile phase of 
acetonitrile and water are as follows; 
 
Column: Eclipse XDB-C8 Mobile Phase: 75/25 
Acetonitrile/Water 
Column Pressure: 125 bar Wavelength: 380 nm 
Flow Rate: 1 mL min
-1
 Concentration: 128 ppm. 
Injection Volume: 10 µL Temperature: 22
o
C 
 
 
Figure 5.20: HPLC Chromotogram of Zirconium Tetrakisoxine 128ppm 
(Acetonitrile/Water + Excess Ligand) 
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5.8.5 Oxine 
 
It was possible to identify the oxine ligand utilising the Eclipse XDB-C8 HPLC 
column and a mobile phase of acetonitrile and water. The most efficient ratio of the 
mobile phase was found to be 75 % acetonitrile and 25 % water. An increase or 
decrease of acetonitrile caused the complex peak to become less pronounced. 
 
5.8.6 Zirconium Tetrakisoxine 
 
The resulting chromatogram at a wavelength of 380 nm for the Eclipse HPLC 
column showed two major peaks which would suggest that the complex is 
dissociating in to its constituent parts. As such the column is not suitable to analyse 
the zirconium tetrakisoxine complex with a mobile phase of acetonitrile and water. 
 
5.8.7 Zirconium Tetrakisoxine at 12.8 ppm and 128 ppm with Excess Ligand 
 
An excess of ligand in the mobile phase (concentration 1000 ppm) was added in the 
attempt to stabilise the Zr complex during the HPLC analysis with success. 
Concentrations of 12.8 ppm and 128 ppm of the complexes were run to ensure an 
increase in area and peak height to confirm the presence of the Zr complex. However 
an excess of ligand in the mobile phase would result in problems when trying to 
quantify the complex and any remaining unbound ligand for quality control purposes 
and as such further methods that have been undertaken are reported. 
 
5.8.8 A Mixture of Oxine and Zirconium Tetrakisoxine 
 
Separation of the oxine ligand and zirconium tetrakisoxine complex was not possible 
with the Eclipse HPLC column and a mobile phase of acetonitrile and water. 
Methanol was exchanged for acetonitrile in the following experiments in the attempt 
to separate the two analytes of interest. 
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5.9 HPLC Analysis with a Mobile Phase of Methanol and Water and a Eclipse 
      XDB-C8 Column 
 
5.9.1 Oxine 
 
Oxine was dissolved in acetonitrile and HPLC conditions for the identification of 
oxine with the use of a XDB-C8 Eclipse column and a mobile phase of methanol and 
water are as follows; 
 
Column: Eclipse XDB-C8 Mobile Phase: 75/25 
Methanol/Water 
Column Pressure: 125 bar Wavelength: 308 nm 
Flow Rate: 1 mL min
-1
 Concentration: 12.8 ppm. 
Injection Volume: 10 µL Temperature: 22
o
C 
 
 
Figure 5.21: HPLC Chromotogram of Oxine 
(Methanol/Water) 
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5.9.2 Zirconium Tetrakisoxine 
 
Zirconium tetrakisoxine was dissolved in acetonitrile and HPLC conditions for the 
identification of the zirconium tetrakisoxine with the use of a Luna 3 column and a 
mobile phase of methanol and water is as follows; 
 
Column: Lunar 3 Silica Mobile Phase: 75/25 
Methanol/Water 
Column Pressure: 125 bar Wavelength: 380 nm 
Flow Rate: 1 mL min
-1
 Concentration: 12.8 ppm. 
Injection Volume: 10 µL Temperature: 22
o
C 
 
 
 
Figure 5.22: HPLC Chromotogram of Zirconium Tetrakisoxine 
(Methanol/Water) 
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1 1.897 0.51 6.39 91.12 
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5.9.3 Zirconium Tetrakisoxine (Excess Ligand) 
 
Zirconium tetrakisoxine was dissolved in acetonitrile. HPLC conditions for the 
identification of zirconium tetrakisoxine with a Luna 3 column and excess ligand 
(concentration 1000ppm) in the mobile phase of methanol and water is as follows; 
 
Column: Eclipse XDB-C8 Mobile Phase: 75/25 
Methanol/Water 
Column Pressure: 143 bar Wavelength: 380 nm 
Flow Rate: 1 mL min
-1
 Concentration: 12.8 ppm. 
Injection Volume: 10 µL Temperature: 22
o
C 
 
 
 
Figure 5.23: HPLC Chromotogram of Zirconium Tetrakisoxine 
(Methanol/Water + Excess Ligand) 
        
No 
Retention 
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Area 
mAU* min 
Height 
mAU 
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Area % 
Identification 
1 4.037 0.28 1.46 88.91 
Zirconium 
Tetrakisoxine 
2 4.897 0.79 0.07 0.002 Unknown 
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5.9.4 Oxine 
 
A range of columns were tested with the oxine ligand and it was found that the 
Eclipse XDB-C8 column and a mobile phase of methanol and water could be used to 
identify the oxine ligand. A Luna 3 silica column was also tested under the same 
conditions with the zirconium tetrakisoxine complex unsuccessfully. 
 
5.9.5 Zr Tetrakisoxine 
 
It was not possible to analyse the zirconium tetrakisoxine complex with the Eclipse 
XDB-C8 column with a mobile phase of methanol and water as the complex 
dissociates under these conditions. It was however possible to identify the oxine 
ligand utilising a Luna 3 silica without an excess of ligand in the mobile phase.  
 
It was not possible to use this column to separate and identify the zirconium tetrakis 
complex and any remaining unbound ligand as the ligand itself breaks apart using 
this column. This column would have been ideal to separate a mixture of both the 
ligand and complex, as the complex does not dissociate with the Luna 3 silica 
column and does not require an excess of ligand in the mobile phase. 
 
5.9.6 Zirconium Tetrakisoxine with Excess Ligand 
 
Utilising the Eclipse XDB-C8 column and an excess of ligand in the mobile phase 
(concentration 1000 ppm) it was possible to stabilise the zirconium complex during 
the HPLC analysis. An excess of ligand in the mobile phase results in problems when 
trying to quantify the complex and any remaining unbound ligand for quality control 
purposes and as such further methods that have been undertaken are reported.  
 
The following experiments were conducted to use a single HPLC column to separate 
the free oxine ligand and complex without an excess of ligand in the mobile phase. 
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5.10 HPLC Analysis with a Mobile Phase of Acetonitrile and Water anda Alima   
        C18 Micron Column 
 
5.10.1 Oxine 
 
Oxine was dissolved in acetonitrile and HPLC conditions for the identification of 
oxine with the use of an Altima C18 column and a mobile of water + 0.1% formic 
acid and acetonitrile is as follows; 
 
Column: Altima C18 
Micron 
Mobile Phase: 50/50 
Acetonitrile/Water 
Column Pressure: 120 bar Wavelength: 245 nm 
Flow Rate: 2 mL min
-1
 Concentration: 128 ppm. 
Injection Volume: 10 µL Temperature: 23
o
C 
 
 
Figure 5.24: HPLC Chromotogram of Oxine 
(Acetonitrile/Water, Altima C18 Column) 
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5.10.2 Zirconium Tetrakisoxine 
 
Zirconium tetrakisoxine was dissolved in acetonitrile and HPLC conditions for the 
identification of zirconium tetrakisoxine with the use of an Altima C18 column and a 
mobile of water + 0.1% formic acid and acetonitrile is as follows; 
 
Column: Altima C18 
Micron 
Mobile Phase: 50/50 
Acetonitrile/Water 
Column Pressure: 124 bar Wavelength: 245 nm 
Flow Rate: 2 mL min
-1
 Concentration: 128 ppm. 
Injection Volume: 10 µL Temperature: 23
o
C 
 
 
 
Figure 5.25: HPLC Chromotogram of Zirconium Tetrakisoxine 
(Acetonitrilel/Water + Altima C18 Column) 
 
No 
Retention 
Time (min) 
Area mAU* 
min 
Height 
mAU 
Relative 
Area % 
Identification 
1 0.997 1.12 267.50 100.00 
Zirconium 
Tetrakisoxine 
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5.10.3 Oxine and Zirconium Tetrakisoxine (Mixture) 
 
Oxine and zirconium tetrakisoxine was dissolved in acetonitrile and HPLC 
conditions for the separation and identification of oxine and zirconium tetrakisoxine 
with the use of an Altima C18 column and a mobile phase of acetonitrile and water is 
as follows; 
 
Column: Altima C18 
Micron 
Mobile Phase: 50/50 
Acetonitrile/Water 
Column Pressure: 124 bar Wavelength: 245 nm 
Flow Rate: 2 mL min
-1
 Concentration: 64 ppm. 
Injection Volume: 10 µL Temperature: 23
o
C 
 
 
 
Figure 5.26: HPLC Chromotogram of Oxine and Zirconoum Tetrakisoxine (Mixture) 
(Acetonitrile/Water + Altima C18 Column) 
No 
Retention 
Time (min) 
Area mAU* 
min 
Height 
mAU 
Relative 
Area % 
Identification 
1 0.997 0.0226 128.077 16.06 
Zirconium 
Tetrakisoxine 
2 1.267 0.1183 585.400 83.94 Oxine 
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5.10.4 Formic Acid 
 
Formic acid has been added to the mobile phase in several experements to alter the 
pH of the water portion of the mobile phase to ~3.5. This greatly reduces interactions 
between the ligand and the complex which results in reduced peak tailing. 
 
5.10.5 Oxine 
 
It was possible to identify the oxine ligand utilising the Altima C18 Micron HPLC 
column and a mobile phase of acetonitrile and water. The most efficient ratio of the 
mobile phase was found to be 50 % acetonitrile and 50 % water. An increase or 
decrease of acetonitrile caused the complex peak to become less pronounced. 
 
5.10.6 Zirconium Tetrakisoxine 
 
It was possible to separate and identify both the zirconium tetrakisoxine complex and 
the oxine ligand utilising the Altima C18 Micron HPLC column and a mobile phase 
of acetonitrile and water. The most efficient ratio of the mobile phase was found to 
be 50 % acetonitrile and 50 % water. The complex is stable with a mobile phase of 
acetonitrile and water with an Altima C18 Micron HPLC column so it was not been 
necessary to add an excess of the oxine ligand into the mobile phase. This in turn will 
allow the separation, identification and quantification of the ligand and complex for 
quality control purposes. 
 
5.10.7 A Mixture of Oxine and Zirconium Tetrakisoxine 
 
A mixture of oxine and zirconium tetrakisoxine was successfully separated using the 
Altima C18 Micron HPLC column and a 50:50 ratio of water and acetonitrile mobile 
phase. As such this column and mobile phase can be used to separate the oxine 
ligand and zirconium tetrakisoxine complex.  The HPLC UV-Vis detector was set to 
a wavelength of 245 nm for the analysis of the oxine ligand, zirconium tetrakisoxine 
complex and a mixture of the two. This wavelength encompasses both the ligand and 
the complex and as such this single wavelength can be used to identify both. 
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5.11 Oxine and Zirconium Tetrakisoxine Discussion  
 
5.11.1 Oxine 
 
Detection of the ligand can be conducted under a variety of conditions with excellent 
results. The majority of the columns used throughout these experiments could be 
used to identify the ligand with peaks that show the complex in a stable condition. 
The main column that caused problems with the analysis of the ligand was a 
Phenomenex Luna 3 silica. The XDB C8 and Altima C18 columns are the best 
choice for the analysis of the ligand, and the UV-Vis detector shows the best 
responses at settings of 308 nm for oxine and 245 or 380 nm for zirconium 
tetrakisoxine. 
 
5.11.2 Zirconium Tetrakisoxine 
 
The Phenomenex Luna 3 silica and Altima C18 column are the best choices for the 
analysis on the complex without any excess ligand in the mobile phase. The UV-Vis 
detector shows the best response at a setting of 380 nm. The wavelengths were 
chosen for the identification of the complex without excess ligand as they provided 
the clearest chromatogram of the complex at various concentrations. To ensure that 
the ligand was not being detected a range of experiments were conducted under the 
same conditions with only the free ligand. The resulting chromatograms were 
different in both retention times and smoothness of the peaks. It would appear that 
the free ligand has problems passing through the Luna 3 silica column perhaps due to 
the nature of it being un-bound. The chromatogram using an Altima C18 column 
shows one peak indicating the complex is stable with this column. In the majority of 
the experiments conducted without excess ligand, with a variety of columns and 
conditions it was found that the complex itself was prone to dissociate. A number of 
peaks indicated a result of the complex breaking apart into its constituent ligands.  
 
However this was rectified with addition of excess ligand to the mobile phase or the 
use of an Altima C18 column. The excess ligand stabilises the complex so accurate 
and reproducible retention times can be determined using the DBX C8 column. 
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5.11.3 Zirconium Tetrakisoxine (Excess Ligand in Mobile Phase) 
 
The addition of excess ligand in the mobile phase proved to be very problematic. 
Problems such as inconstant baselines and problems running blanks occurred. 
(Baseline problems are common when using inconsistent or contaminated solvents). 
The ligand constantly passing through the detector caused problems when setting the 
base line or running a blank due to inconsistent detection parameters.  
 
Variables were altered to take into consideration the excess of ligand in the mobile 
phase. A blank was run in-between every attempted analysis of the zirconium 
tetrakisoxine with excess ligand to try and reduce detection problems. In many cases 
this resulted in peaks which were unexpected.  
 
These unexpected peaks suggest that the zirconium ion and ligand have an affinity 
for a variety of columns and as such it is imperative that each of the columns is 
thoroughly flushed with a strong solvent between runs. It is suggested that 
approximately 10 columns worth will ensure the column has had any unwanted 
analytes removed.  
 
When analysing the zirconium tetrakisoxine with an excess of ligand in mobile phase 
(x10 concentration of complex) it was found that the best column for analysis was 
the DBX C8. The optimum wavelength for analysis of the complex with excess of 
ligand was 380 nm once a number of blanks had been run.  
 
Retention times for the ligand and the complex (with excess ligand in the mobile 
phase) differed with the ligand having a retention time of 1.960 minutes and the 
complex having a retention time of 2.960 minutes when utilising the following 
conditions; DBX C8 HPLC column, 75/25 acetonitrile/water, 22
o
C, and a flow rate 
of 1mL per minute. However as there was an excess of ligand in the mobile phase it 
was not possible to separate and quantify the amount of ligand and complex in a 
sample hence another method was found to rectify this problem.  
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5.11.4 Mixture of Oxine and Zirconium Tetrakisoxine 
 
It was not possible to separate the oxine ligand and zirconium tetrakisoxine complex 
with the Eclipse HPLC column and a mobile phase of acetonitrile and water. It was 
also not possible to separate these two analytes utilizing the Luna 3 silica column. 
 
Using an Altima C18 column with the addition of a buffer (formic acid 0.1%), 
altering the pH of the water portion of the mobile phase to ~3.5 greatly reduced 
interactions between the ligand and the complex resulting in reduced peak tailing. 
This method also allowed the separation of both the ligand and complex without the 
addition of excess ligand in the mobile phase illustrated in figure 5.2.10. 
 
5.11.5 Column Types 
 
A number of HPLC columns were tested against the oxine ligand and the zirconium 
tetrakisoxine complex. The Eclipse XDB-C8 HPLC column has a solid support of 
fully porous silica and a stationary phase of C8.192  It was not possible to analyse the 
complex with this column without an excess of ligand in the mobile phase but it was 
possible to analyse the ligand. This is possibly due to the Zr being stripped from the 
ligands as there seems to be an affinity with Zr and this column. 
 
The Luna 3 Silica HPLC column has a solid support of fully porous silica and 
stationary phase of ultra-pure unbonded silica193 with high column bed stability 
which is enhanced by partial shape uniformity.194 Used in the separation of polar 
compounds it would be expected that the analysis of the ligand would be possible 
with this column as it is polar and the complex which is not polar would be 
problematic. However the reverse is true and at this time is not fully understood.  
 
The Altima C18, 5u Micron HPLC column uses a pH stable silica of high purity and 
low metal and is ideal for analysis of complex hydrophobic mixtures.195 The Altima 
HPLC column was manufactured to eliminate activated silanols that cause peak 
tailing on silica-based columns.196 The elimination of the activate silanols may 
prevent the Zr complex from breaking apart into its substituents. 
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5.12 Results: Tropolone and Zirconium Tetrakistropolone   
 
5.12.1 Tropolone  
 
Tropolone was dissolved in methanol and HPLC conditions for attempted 
identification of tropolone with the use of a Luna 3 Silica column and a mobile phase 
of acetonitrile and water are as follows: 
 
Column: Luna 3 Silica Mobile Phase: 90/10 
Acetonitrile/Water 
Column Pressure: 125 bar Wavelength: 333 nm 
Flow Rate: 1 mL min
-1
 Concentration: 12.7 ppm. 
Injection Volume: 10 µL Temperature: 22
o
C 
 
Figure 5.27: HPLC Chromotogram of Tropolone (Acetonitrile/Water) 
 
No 
Retention 
Time (min) 
Area 
mAU* min 
Height 
mAU 
Relative 
Area % 
Identification 
1 2.040 1.967 24.077 95.51 Tropolone 
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5.12.2 Zirconium Tetrakistropolone 
 
Zirconium tetrakistropolone was dissolved in methanol and HPLC conditions for 
attempted identification of the Zr tetrakistropolone with the use of a Luna 3 Silica 
column and a mobile phase of acetonitrile and water are as follows: 
 
Column: Luna 3 Silica Mobile Phase: 90/10 
Acetonitrile/Water 
Column Pressure: 125 bar Wavelength: 333 nm 
Flow Rate: 1 mL min
-1
 Concentration: 12.7 ppm. 
Injection Volume: 10 µL Temperature: 22
o
C 
 
 
 
Figure 5.28: HPLC Chromotogram of Zirconium Tetrakistropolone 
(Acetonitrile/Water) 
 
No 
Retention 
Time (min) 
Area 
mAU* min 
Height 
mAU 
Relative 
Area % 
Identification 
1 1.780 59.835 1339.00 99.26 
Zirconium 
Tetrakistropolone 
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5.12.3 Mixture of Tropolone and Zirconium Tetrakistropolone 
 
Tropolone and zirconium tetrakistropolone was dissolved in methanol and HPLC 
conditions for the separation and identification of tropolone and zirconium 
tetrakistropolone from a mixture using a Luna 3 Silica column and a mobile phase of 
water and acetonitrile are as follows; 
 
Column: Luna 3 Silica Mobile Phase: 90/10 
Acetonitrile/Water 
Column Pressure: 125 bar Wavelength: 333 nm 
Flow Rate: 1 mL min
-1
 Concentration: 6.35 ppm. 
Injection Volume: 10 µL Temperature: 22
o
C 
 
 
Figure 5.29: HPLC Chromotogram of Tropolone and Zirconium 
Tetrakistropolone (Mixture), (Acetonitrile/Water) 
 
No 
Retention 
Time (min) 
Area 
mAU* min 
Height 
mAU 
Relative 
Area % 
Identification 
1 1.773 28.644 670.361 90.63 
Zirconium 
Tetrakistropolone 
2 2.037 1.389 17.395 4.39 Tropolone 
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5.13 Discussion of Results 
5.13.1 Tropolone 
 
The majority of the columns used throughout these experiments could be used to 
identify the ligand. The Luna 3 silica HPLC-RP column is the best choice for the 
analysis of tropolone. Optimum conditions to obtain a retention time of 1.967 
minutes were obtained with a flow rate of 1mL a minute, 22
o
C column temperature, 
10% Water and 90% Acetonitrile. In the chromatogram under these conditions a 
negative peak can bee seen just after the peak of tropolone. This is because the less 
absorbing solvent has passed the detector in which the tropolone has been dissolved. 
 
5.13.2 Zirconium Tetrakistropolone 
 
The HPLC analysis of zirconium tetrakistropolone was undertaken and was found to 
be problematic. Results show that various HPLC columns strip the ligand from the 
Zr metal. For example a commonly used HPLC column such as the Eclipse XDB-C8 
will strip the ligand from the Zr metal resulting in a retention time of only the free 
ligand. This is under a variety of temperatures, flow rates, pressures and mobile 
phase constituents. Various HPLC columns were used to resolve the stripping of the 
ligand from the complex. The optimum column for the analysis of the zirconium 
tetrakistropolone was found to be a Phenomenex Luna 3 SILICA (2), 150 X 4.60 
mm, 3 MICRON, 00F-4162-E0 with a retention time of 1.780 minutes, flow rate of 
1mL a minute, 22
o
C column temperature, 90% Water and 10% Acetonitrile. 
 
5.13.3 Mixture of Tropolone and Zirconium Tetrakistropolone 
 
Utilising the Phenomenex Luna 3 SILICA (2), 150 X 4.60 mm, 3 MICRON, 00F-
4162-E0 HPLC-RP column it is possible to separate the tropolone ligand and the 
zirconium tetrakistropolone complex. A retention time of 1.773 minutes was 
achieved for the zirconium tetrakis complex and 2.037 minutes for the tropolone 
ligand. Figure 5.2.13 indicates a clear separation of both the ligand and the complex 
when in a mixture. Conditions for this separation are a flow rate of 1mL a minute, 
22
o
C column temperature, 90% Water and 10% Acetonitrile. 
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5.14 Results Ethyl Maltol and Zirconium Tetrakisethyl Maltol  
 
5.14.1 Ethyl Maltol 
 
Ethyl maltol was dissolved in acetonitrile and HPLC conditions for the identification 
of ethyl maltol with the use of an Altima C18 5 micron column and a mobile phase 
of water with 0.1% formic acid buffer and acetonitrile are as follows. 
 
Column: Altima C18 
Micron 
Mobile Phase: 80/20 
Water/Acetonitrile 
Column Pressure: 118 Bar Wavelength: 278 nm 
Flow Rate: 2 mL min
-1
 Concentration: 12.7 ppm. 
Injection Volume: 10 µL Temperature: 35
o
C 
 
 
 Figure 5.30: HPLC Chromotogram of Ethly Maltol (Acetonitrile/Water) 
 
No 
Retention 
Time (min) 
Area 
mAU* min 
Height 
mAU 
Relative 
Area % 
Identification 
1 0.967 1.70 28.97 1.48 Unknown 
2 2.887 92.90 177.16 80.99 Ethyl Maltol 
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5.14.2 Zirconium Tetrakisethyl Maltol  
 
Zirconium tetrakisethyl maltol was dissolved in acetonitrile and HPLC conditions for 
the identification of the zirconium tetrakisethyl maltol with the use of an Altima C18 
5 micron column and a mobile phase of water with 0.1% formic acid buffer and 
acetonitrile are as follows; 
 
Column: Altima C18 
Micron 
Mobile Phase: 80/20 
Water/Acetonitrile 
Column Pressure: 118 bar Wavelength: 278 nm 
Flow Rate: 2 mL min
-1
 Concentration: 127 ppm. 
Injection Volume: 10 µL Temperature: 35
o
C 
 
 
Figure 5.31: HPLC Chromotogram of Zirconium Tetrakisethyl Maltol 
(Acetonitrile/Water) 
No 
Retention 
Time (min) 
Area 
mAU* min 
Height 
mAU 
Relative 
Area % 
Identification 
1 0.973 1.69 13.79 0.58 Unknown 
2 2.910 49.08 254.32 89.28 
Zirconium 
Tetrakisethyl maltol 
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5.14.3 Mixture of Ethylmaltol and Zirconium Tetrakisethyl Maltol  
 
Ethyl maltol and zirconium tetrakisethyl maltol was dissolved in acetonitrile and 
HPLC conditions for the attempted separation and identification of ethyl maltol and 
zirconium tetrakisethyl maltol from a mixture using an Altima C18 5 micron column 
and a mobile phase of water and acetonitrile are as follows; 
 
Column: Altima C18 
Micron 
Mobile Phase: 80/20 
Water/Acetonitrile 
Column Pressure: 118 bar Wavelength: 278 nm 
Flow Rate: 2 mL min
-1
 Concentration: 127 ppm. 
Injection Volume: 10 µL Temperature: 35
o
C 
 
 
Figure 5.32: HPLC Chromotogram of Ethylmaltol and Zirconium Tetrakisethyl 
Maltol (Mixture), (Acetonitrile/Water) 
 
No 
Retention 
Time (min) 
Area 
mAU* min 
Height 
mAU 
Relative 
Area % 
Identification 
1 0.750 4.03 27.38 4.48 Unknown  
2 0.967 1.51 23.82 1.68 Unknown 
3 2.887 67.28 259.75 74.72 Mixture 
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5.15 Discussion of Results 
5.15.1 Ethyl Maltol 
 
When analysing ethyl maltol an addition of a buffer (formic acid 0.1 %) is required 
to ensure its stability. The majority of the columns used throughout these 
experiments could not be used to identify the ligand with peaks indicating that the 
complex had broken apart. The Altima C18 5 Micron HPLC-RP column is the best 
choice for the analysis of the ethyl maltol ligand. Optimum conditions to obtain a 
retention time of 2.877 minutes was obtained with a flow rate of 2mL a minute, 35
o
C 
column temperature, 80% water + 0.1% formic acid and 20% acetonitrile. 
 
5.15.2 Zirconium Tetrakisethyl maltol 
 
Results show that the retention time for the supposed zirconium tetrakisethyl maltol 
complex 2.910. This retention time is extremely close to the retention time of the 
ethyl maltol ligand and as such it is not possible to identify the complex using a UV 
detector. A variety of columns, temperatures, flow rates, pressures and mobile phase 
constituents were screened in an attempt to increase the differences in the retention 
times of both the ligand and the complex without success. It is possible that the 
ligands are being stripped from the Zr metal resulting in the detection of just the 
ligands. With a HPLC mass spectrometer system it may be possible to determine 
whether the retention time of 2.910 relates to the complex or the ligand. The 
optimum column for the possible identification of the complex is Altima C18 5 
Micron with a retention time of 2.910 minutes, flow rate of 2mL a minute, 35
o
C 
column temperature, 80% water + 0.1% formic acid and 20% acetonitrile. 
 
5.15.3 Mixture of Ethylmaltol and Zirconium Tetrakisethyl maltol 
 
It has not been possible to separate the two with the equipment that is currently 
available. Other HPLC columns with different types of stationary phase and different 
size of partials may rectify this problem and allow the separation of the two analytes. 
A column that may rectify this problem is a Cadenza CW-C18, specifically used in 
the food industry for analysis of maltol and ethyl maltol.197 
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5.16 Results: Deferiprone and Zirconium Tetrakisdeferiprone 
        
5.16.1 Deferiprone 
 
Deferiprone was dissolved in water and HPLC conditions for the identification of 
deferiprone using an Altima C18 column and a mobile phase of water with 0.1% 
formic acid buffer and acetonitrile are as follows; 
 
Column: Altima C18 
Micron 
Mobile Phase: 50/50 
Acetonitrile/Water 
Column Pressure: 124 bar Wavelength: 282 nm 
Flow Rate: 2 mL min
-1
 Concentration: 127 ppm. 
Injection Volume: 10 µL Temperature: 23.5
o
C 
 
Figure 5.33: HPLC Chromotogram of Deferiprone (Acetonitrile/Water) 
 
No 
Retention 
Time (min) 
Area 
mAU* min 
Height 
mAU 
Relative 
Area % 
Identification 
1 0.630 20.96 463.93 99.08 Deferiprone 
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5.16.2 Zirconium Tetrakisdeferiprone 
 
Zirconium tetrakisdeferiprone was dissolved in water and HPLC conditions for the 
identification of zirconium tetrakisdeferiprone using an Altima C18 column and a 
mobile phase of water with 0.1% formic acid buffer and acetonitrile are as follows; 
 
Column: Altima C18 
Micron 
Mobile Phase: 50/50 
Acetonitrile/Water 
Column Pressure: 123 bar Wavelength: 282 nm 
Flow Rate: 2 mL min
-1
 Concentration: 127 ppm. 
Injection Volume: 10 µL Temperature: 23.5
o
C 
 
 
Figure 5.34: HPLC Chromotogram of Zirconium Tetrakisdeferiprone 
(Acetonitrile/Water) 
 
No 
Retention 
Time (min) 
Area 
mAU* min 
Height 
mAU 
Relative 
Area % 
Identification 
1 0.649 7.55 60.31 95.86 
Zirconium 
Tetrakisdeferiprone 
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5.16.3 Mixture of Deferiprone and Zirconium Tetrakisdeferiprone 
 
Deferiprone and zirconium tetrakisdeferiprone was dissolved in water and HPLC 
conditions for the attempted separation and identification of deferiprone and 
zirconium tetrakisdeferiprone from a mixture using an Altima C18 column and a 
mobile phase of water with 0.1% formic acid buffer and acetonitrile are as follows; 
 
Column: Altima C18 
Micron 
Mobile Phase: 50/50 
Acetonitrile/Water 
Column Pressure: 123 bar Wavelength: 282 nm 
Flow Rate: 2 mL min
-1
 Concentration: 63.5 ppm. 
Injection Volume: 10 µL Temperature: 23.5
o
C 
 
 
Figure 5.35: HPLC Chromotogram of Deferiprone and Zirconium 
Tetrakisdeferiprone (Mixture), (Acetonitrile/Water) 
 
No 
Retention 
Time (min) 
Area 
mAU* min 
Height 
mAU 
Relative 
Area % 
Identification 
1 0.640 13.11 235.87 95.57 Mixture 
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5.17 Discussion of Results 
5.17.1 Deferiprone 
 
Analysis of deferiprone requires the addition of formic acid at a concentration of 
0.1% into the water component of the mobile phase to ensure its stability. The 
Altima C18 5 Micron HPLC-RP column is the best choice for the analysis of the 
deferiprone ligand. Optimum conditions to obtain a retention time of 0.630 minutes 
was obtained with a flow rate of 2mL a minute, 23.5
o
C column temperature, 50% 
Water + 0.1% formic acid and 50% Acetonitrile. 
 
5.17.2 Zirconium Tetrakisdeferiprone 
 
The retention time for the supposed zirconium tetrakisdeferiprone complex is 0.649 
minutes. This retention time is extremely close to the retention time of the 
deferiprone ligand and hence it is not possible to confidently identify the complex 
using a UV detector. There is a greater amount of tailing, comparing the ligand to the 
complex which suggests different compounds. Various columns, temperatures, flow 
rates, pressures and mobile phase constituents were used in an attempt to increase the 
differences in the retention times of both the ligand and the complex without success. 
By using a HPLC mass spectrometer system it may be possible to confirm that it is 
the complex that is exiting the HPLC column at 0.649 and not the ligand. The 
optimum column for the possible identification of the complex is an Altima C18 5 
Micron with a flow rate of 2mL a minute, 23.5
o
C column temperature, 50% Water + 
0.1% formic acid and 50% Acetonitrile. 
 
5.17.3 Deferiprone and Zirconium Tetrakisdeferiprone 
 
The relatively short retention times of the analytes suggests that there is minimal 
interaction of both the ligand and complex with the stationary phase in the column. 
As the retention times of the ligand and the supposed complex are very similar it has 
not been possible to separate the two with the equipment that is currently available. 
Utilising other HPLC columns with different types of stationary phase and different 
size of partials may rectify this problem and allow the separation of the two analytes. 
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5.18 HPLC Variables 
 
A range of variables were investigated to provide a means of identifying each of the 
ligands and their respective zirconium tetrakis complexes. Variables were altered in 
the process of determining the best protocol for identifying the ligand, complex and 
complex with excess ligand (if necessary). Column type, mobile phase, temperature, 
flow rate, concentrations and injection volumes were all investigated.  These are 
standard variables for HPLC method development. 
 
5.18.1 Column Type 
 
A range of columns were tested against the complexes during the experiments and 
the following columns yielded the best results; Alltech Nucleosil C18 5 Micron, 
Agilent Eclipse XDB-C8, Altima C18 5u, Phenomenex Luna 3 Silica, and 
Phenomenex Luna 5u Phenyl-Hexyl.  
 
5.18.2 Mobile Phase  
 
It is preferable to use a solvent to dissolve the compounds which will be used as a 
mobile phase during the HPLC analysis.198 This will reduce interference and 
unwanted peaks during the analysis. Acetonitrile, methanol and water were the 
optimum mobile phases used during the experiments. Tetrahydrofuran was tested as 
a mobile phase with the oxine ligand and complex unsuccessfully. 
 
5.18.3 Temperature  
 
Increasing the temperature will decrease the retention time of a solute (k). In the 
majority of systems a decrease in retention time will not be greater than 50% of the 
analytes reduced retention time at ambient temperature.198 It was seen with the 
ligands and Zr tetrakis complexes that once the column had been stabilized under an 
elevated temperature stabilization of retention times occurred. Controlled 
temperatures resulted in the improvement of peak shapes and faster experimental run 
times without impacting the efficiency of the experiments conducted. 
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5.18.4 Flow rate   
 
Increasing the flow rate of the mobile phase decreases the time taken for analytes to 
pass through the HPLC apparatus resulting in sharper improved peaks. However 
when analysing a ligand and suspected complex the flow rate was decreased to the 
minimum possible in an attempt to separate the retention times between the two. 
 
5.18.5 Concentrations   
 
Increasing the concentrations of the ligand and complex resulted in an increase in 
peak height and area with the same retention time being upheld. By using a range of 
concentrations it was confirmed that it was the ligand and complex being identified 
 
5.18.6 Buffers and pH 
 
An addition of formic acid at a concentration of 0.1% into the water portion of the 
mobile phase resulted in greater stability of the complexes but had little effect on the 
analysis of the ligands. The buffer reduces the interaction of the complex with any 
residual silanol groups/active sites on the stationary phase of the HPLC column. 
 
5.18.7 Injection Volumes 
 
When the injection volume was increased from 10 µl to 20 µl the peak-width 
increased greatly and a significant increase in tailing occurred indicating interactions 
with the analytes and stationary phase of the HPLC column. To reduce this 
interaction it was decided to analyse all analytes with an injection volume of 10 µl. 
 
5.18.8 UV-Vis Detector Settings 
 
By using the UV-Vis data of the ligand and the complex reported in section 5.1 it 
was possible to set the detector at the optimum wavelengths to identify the ligands 
and complexes. The baseline was observed before the injection and following it to 
monitor the quality of the mobile phase and the condition of the column. 
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5.18.9 Ligand and Complex Peak Identification 
 
It was determined that the optimum method of proving the peak was actually the 
complex and not an anomaly was to run a serial dilution of the complex through the 
HPLC apparatus. An increase in the concentration of complex will result in an 
increase in peak height and area with the same retention time being upheld. It was 
decided to run a range of concentrations of both the ligands and the complex. The 
results from this experiment allowed the ligand and complex peak to be identified 
and verified. From the positive results from the serial dilution experiments it was 
possible to identify the most useful wavelengths in partnership with the UV-Vis data 
and to identify the ligand and complex depending on the mobile phase and column 
used as well when there is an excess of ligand in the mobile phase as is required 
when analysing Zr tetrakisoxine. 
 
 
Figure 5.36: Concentration vs Peak Area of Zirconium Tetrakisoxine 
y=0.00881x0.01207  R-Squared Value = 0.99835 
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5.19 Conclusion 
5.19.1 Oxine & Zirconium Tetrakisoxine 
 
The optimal column for the analysis of both oxine and zirconium tetrakisoxine was 
found to be an Altima C18 HPLC-RP column. Using this column it was possible to 
separate both the ligand and complex. When analysis of the zcomplex was 
undertaken with a range of other columns it was essential to have an excess of ligand 
in the mobile phase. There are currently no published papers reporting a HPLC 
protocol for the identification of zirconium tetrakisoxine.  
 
5.19.2 Tropolone & Zirconium Tetrakistropolone 
 
The optimal column for the analysis of both tropolone and zirconium 
tetrakistropolone was found to be a Luna 3 Silica column. Using this column it was 
possible to separate both the ligand and complex from each other. When analysis of 
the tropolone ligand or the zirconium tetrakistropolone complex was undertaken with 
a range of other columns the stability of the complex was not consistent.   
 
5.19.3 Ethyl Maltol 
 
It was not possible to identify the complex or separate it from the ligand in a mixture 
of the two using the currently available equipment. This may be rectified using a 
HPLC system connected to a mass spectrometer. It may be possible to use a gamma 
counter to ascertain whether it is the complex that exits the column at a retention 
time of 2.910 minutes when analysing the
 
zirconium-89 tetrakisethyl maltol complex.  
 
5.19.4 Deferiprone 
 
It was not possible to successfully identify the complex or separate it from an amount 
of ligand in a mixture of the two using the currently available equipment. It may be 
possible to rectify this using a HPLC system connected to a mass spectrometer. It 
may also be possible to use a gamma counter detector to ascertain whether it is the 
complex that exits the column.  
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5.20 Instant Thin Layer Chromatography 
5.20.1 Introduction 
 
In the field of nuclear medicine it is standard practise to synthesise the majority of 
complexes close to the time of being dispensed. Each complex must be tested before 
any dose is administered. The use of instant thin layer chromatography (ITLC) can 
ensure a quick and accurate test that provides information about the radiochemical 
composition of the kit that was prepared.199 Once the radiochemical purity of the 
complex has been established it can then be safely administered to patients.  
 
In the case of any complexes that are being synthesised there is a need to ensure that 
certain impurities have been removed from the solution containing the 
radiopharmaceutical before it can be administered to the patient.199 The impurity that 
is a concern with the Zr complexes is any remaining free 
89
Zr. This free 
89
Zr can 
either be in the form of zirconium-89 tetrakisoxalato or zirconium-89 tetra chloride. 
Any unbound Zr may be harmful to the patient. A range of stains, visualisation 
methods and mobile phases were investigated for the use in ITLC analysis. 
 
ITLC analysis involves a small amount of the compound to be analysed, spotted onto 
an ITLC strip.200 The ITLC strips are comprised of glass fibre impregnated with 
either silica gel (SG) or polysilicic acid (SA). Chromatography is undertaken by 
placing the spotted ITLC strip into a suitable solvent contained in a chamber. The 
solvent travels up the ITLC strip and during this process there is a spreading of the 
different constituents of the analyte of interest. The different constituents are 
distributed between the absorbent stationary phase (SG) and the solvent mobile 
phase, which is dependent on their individual distribution coefficients.200 The 
electrostatic forces of the stationary phase normally slow down various components 
whilst the mobile phase transports them along. This along with the polarity of the 
solvent mobile phase affects the amount of distance each of the components on the 
analyte travels along the ITLC strip.201 Each of the components is then allocated an 
Rf value, defined as the distance travelled by the component divided by the distance 
travelled by the solvent.200 
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5.20.2 Experimental Method 
 
A 20 mM citrate solution (pH 4.0) was made by the addition of 0.262 g of citric acid 
and 0.193 g of tri sodium citrate to 100 mL of millipore water. An amount of this 
solution was added to a glass 250 mL beaker to a depth of 0.5 cm. A filter paper was 
then folded and added so that it lined the walls and was immersed in the citrate 
solution. The beaker was then sealed and left for ~20 minutes to allow the 
atmosphere in the beaker to become saturated with solvent. The compounds to be 
tested were dissolved into a solvent at a concentration of 1mg/mL. The ITLC-SG 
plates were then marked with a pencil and a drawn out capillary tube was used to 
spot the samples of complexes on to the ITLC-SG plates. The plates were placed in 
to the development chamber and the solvent was allowed to travel to within 1 cm of 
the top of the plate which was then removed and allowed to dry at ambient 
temperature. A UV lamp was used to visualise the compounds and images were 
taken using a Foster and Freeman video spectral comparator and document imaging 
software (suite V 1.3), Rf values were then calculated for each of the compounds. 
 
5.21 Results and Discussion 
 
Reagent indicators were obtained to match the functional groups of the compounds 
being investigated. 
 
        
4
   
Figure 5.37: Zirconium Tetrakisoxalate & Similar Functional Groups 
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The following reagent indicators were tested against the complex with poor or absent 
indication/visualisation of the potassium zirconium tetrakisoxalate complex;  
 
Indicator Group/s Detected Observation 
Ferric Chloride Phenols Very Faint Outline of Complex 
Iodine Range of Organic 
Compounds 
None Detectable 
Potassium 
Permanganate 
Oxidisable Functional 
Groups 
None Detectable 
Bromocresol  Green Carboxylic Acids Complex observable for a few 
seconds 
Table 5.3.1: ITLC Indicators 
 
5.21.1 Developing ITLC Quality Control Protocol without Visualising Free 
89
Zr 
 
The process of developing a quality control protocol to detect unbound 
89
Zr in the 
form of zirconium tetrakisoxalato as a cold chemistry experiment has proven 
problematic. This is due to the lack of ability to visualise the complex reliably as 
reported above. In order to develop an ITLC quality control method for both the 
zirconium tetrakisoxine and tetrakistropolone complexes it was necessary to conduct 
the experiments without the ability to visualise free 
89
Zr in the form of zirconium-89 
tetrakisoxalate. To do this successfully research was undertaken to establish the Rf 
value of zirconium-89 tetrakisoxalate under certain mobile phase conditions.  
 A range of mobile phases were investigated and it was found that the optimum 
mobile phase composition to be used to identify the Zr complexes was a 20mM 
sodium citrate solution or alternatively ethyl acetate can be used as the mobile phase. 
The mobile phase of sodium citrate has been previously reported to identify the Rf 
value of the unbound zirconium-89 tetrakisoxalate complex by radio ITLC. It has not 
been possible to visualise the zirconium oxalate complex via stains/light sources so 
this information is essential in developing a quality control protocol. The image 
below is an ITLC-SG chromatogram (counts per second) of the zirconium-89 
tetrakisoxalate complex which is a result of the work undertaken by David J. Berry: 
King’s College London. Division of Imaging Sciences and Biomedical Engineering, 
The Rayne Institute, St Thomas’ Hospital, London. 
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Figure 5.38: Radio ITLC-SG Scan of Zirconium-89 Tetrakisoxalate 
Mobile phase 20 mM citrate: Rf  Value: 0.90
Solvent front 80 mm 
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Compound Ref Solvent System Visualization Experimental Observation Rf Value 
Zirconium Tetra Chloride A 20 mM Sodium Citrate AgNO3 Travels with the solvent front. 1.0 
Zirconium Tetrakisoxalate N/A 20 mM Sodium Citrate 
89
Zr Travels close to the solvent front. 0.9 
Zirconium Tetrakisoxalate N/A Ethyl Acetate 
89
Zr Complex remains at origin 0.0 
Oxine B 20 mM Sodium Citrate UV 254 nm Streaking of free ligand. 0.8 
Zirconium Tetrakisoxine C 20 mM Sodium Citrate UV 254 nm Complex remains at origin. 0.0 
Oxine N/A Ethyl Acetate UV 254 nm Ligand streaks slightly. 0.2 
Zirconium Tetrakisoxine N/A Ethyl Acetate UV 254 nm/
89
Zr Travels close to the solvent front. 0.9 
Tropolone D 20 mM Sodium Citrate UV 254 nm Ligand travels with the solvent front. 1.0 
Zirconium Tetrakistropolone E 20 mM Sodium Citrate UV 254 nm Complex remains at origin. 0.0 
Table 2: ITLC Protocols and Results 
             
Figure 5.39: ITLC-SG Results 
A D C B E 
 197 
 
 
5.22 Conclusion 
5.22.1 Visualisation and Staining 
 
The most common method for visualisation of compounds analysed on TLC plates is 
the use of visible or UV light. However the precursor complexes; zirconium tetra 
chloride and potassium zirconium tetrakisoxalate are not visible with these light 
sources. A range of stains were investigated based on their ability to react with the 
complexes and provide a coloured indicator of their location and subsequently Rf 
values could be obtained. The visualisation methods that have been tested to identify 
the precursor complexes and the compounds will not be used to analyse the 
complexes when using the radioactive 
89
Zr isotope. Instead radio ITLC methods will 
be used as the standard method for quality control purposes. 
 
5.22.2 Zirconium Tetrachloride 
 
A range of possible stains to visualise zirconium tetrachloride were tested 
unsuccessfully such as potassium permanganate solution and iodine vapour. It was 
determined that the reagent silver nitrate indicates the presence of zirconium 
tetrachloride. It has a reported detection limit range of between 20 and 100 ng per 
zone of complexes containing either chlorine or bromine. For rapid visualisation of 
the zirconium tetrachloride complex the plate should be illuminated with UV light at 
256 nm immediately after being dipped in the silver nitrate reagent or after drying. 
 
5.22.3 Zirconium Tetrakisoxalate  
 
A range of indicator reagents were tested against the zirconium tetrakisoxalate 
complex, chosen on their ability to indicate various functional groups which were 
either present in the complex or were of a similar nature. It was not possible to 
visualise this complex with any UV light at a frequency of 256 nm or 365 nm or any 
of the staining methods. It is known that the zirconium tetrakisoxalate complex has 
an Rf value of 0.90 with a mobile phase of sodium citrate solution hence the location 
of this complex without visualisation can be known. Alternatively eluting zirconium-
89 tetrakisoxalate with a mobile phase of ethyl acetate results in an Rf value of 0. 
 198 
 
 
5.22.4 Oxine and Zirconium Tetrakisoxine 
 
The visualisation of both oxine and zirconium tetrakisoxine is possible with the use 
of a UV lamp. Visualisation is clearest at a short wavelength of 254 nm but the 
compounds are also visible at a wavelength of 365 nm. The oxine ligand has an Rf 
value 0.80 and results show streaking along the ITLC strip. Using a mobile phase of 
sodium citrate the zirconium tetrakisoxine complex does not move from the point of 
spotting and has an Rf value of 0.  Radio ITLC results of unbound zirconium 
tetrakisoxalate complex show an Rf value of 0.9 and as such it will be possible to 
separate and analyse these three components using ITLC-SG. Alternatively eluting 
with a mobile phase of ethyl acetate results in an Rf value of 0.2 for the oxine ligand. 
An Rf 0.9 for the zirconium tetrakisoxine complex is obtained for both zirconium 
tetrakisoxine and zirconium-89 tetrakisoxine. 
 
5.22.5 Tropolone and Zirconium Tetrakistropolone 
 
The visualisation of both tropolone and zirconium tetrakistropolone is possible with 
the use of a UV lamp. As is the case with oxine and zirconium tetrakisoxine 
visualisation is clearest at a short wavelength of 254 nm but the compounds are also 
visible at a wavelength of 365 nm. The tropolone ligand has an Rf value 1.00 
traveling with the solvent front. The complex itself does not move from the point of 
spotting and has a Rf value of 0.0.  Radio ITLC results of unbound zirconium 
tetrakisoxalate complex show an Rf value of 0.90 and as such it will be possible to 
separate and analyse these three components using ITLC-SG. 
 
5.22.6 Ethyl Maltol and Zirconium Tetrakisethyl maltol 
 
The visualisation of ethyl maltol and zirconium tetrakisethyl maltol was not possible 
with the use of a UV lamp. Stains to visualise these complexes such as potassium 
permanganate solution, ferric chloride, bromocresole green and iodine vapour were 
unsuccessful. It may be possible to use vanillin to stain these compounds. 
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5.22.7 Deferiprone and Zirconium Tetrakisdeferiprone 
 
The visualisation of both deferiprone and zirconium tetrakisdeferiprone was not 
possible with the use of a UV lamp. Stains to visualise these complexes such as 
potassium permanganate solution and iodine vapour were unsuccessful.  
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CHAPTER 6 
The In Vitro and In Vivo Analysis of Zirconium Compounds 
 
6.1. Introduction 
 
Chapter six of this thesis is concerned with the in vitro analysis of zirconium 
tetrakisoxine, tropolone and ethyl maltol and in vivo analysis of zirconium 
tetrakisoxine. The zirconium deferiprone complex is not a suitable candidate for 
pursuing in cell labelling experiments at this time. This is due to the fact that it is not 
possible to synthesise the complex successfully from potassium zirconium 
tetrakisoxalato reported in chapter 4. Tables of equipment, equipment settings and 
reagents used throughout this chapter can be located in the appendix section of this 
thesis 
 
6.1.1 In Vitro 
 
In Vitro (Latin: within the glass) experiments do not involve the use of live animals 
but involve reactions or processes taking place outside or isolated from a living 
organism26. Experiments using the components of the living organism can be 
conducted within culture dishes, test tubes or anywhere else outside of an organism.26 
 
The findings of cell labelling experiments of the Zr tetrakisoxine, tropolone and ethyl 
maltol complexes will be reported in this chapter. The following cell lines were used 
throughout these experiments; HCT116: Colon Cancer, J774: Mouse Macrophage 
and MDA-MB-231: Breast Cancer.   
 
6.1.2 In Vivo 
 
In Vivo (Latin within the living) experiments involve the utilisation of a living animal 
where a clinical condition has been induced which in turn can be studied with 
pharmaceuticals/ radiopharmaceuticals undergoing development.26 In these 
experiments zirconium tetrakisoxine was tested in vitro with white blood cells and 
GFP-5T33: Mouse Myeloma cells. 
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6.2 In Vitro Experimental Method 
 
The following experimental work was conducted primarily by Putthiporn 
Charoenphun, Kings College London. Work undertaken by the author was 
undertaken alongside Putthiporn Charoenphun. Further details of experimental work 
and subsequent work following this research can be found in [
89
Zr]-Zr(oxinate)4 for 
in vivo cell tracking by positron emission tomography. 
 
6.3 Synthesis of 
89
Zr Tetrakis Complexes 
 
The synthesis of the 
89
Zr tetrakis complexes was undertaken utilising the chloroform 
extraction method reported in chapter 4 of this thesis. Sodium carbonate (0.1 M) was 
used to neutralise 20 – 90 MBq (1.36 x 10-11 – 6.12 x 10-11 moles) of 89Zr 
tetrakisoxalate in oxalic acid (1M). The pH at this stage was measured to be at a 
value of ~7. The solution was then diluted with millipore water to a total volume of 
500 µL. Oxine, ethyl maltol or tropolone (500 µg) was dissolved in chloroform (500 
µL) and this solution was mixed together utilising a centrifuge (1000 RPM) with the 
neutralised solution containing 
89
Zr in a new unused clean glass vial with a glass 
pasteur pipette for 15 minutes. The two phases were then allowed to separate. The 
chloroform phase containing the 
89
Zr tetrakis complex was transferred into a new, 
unused glass vial. The chloroform was removed by slow evaporation utilising a 
heating block at a temperature of ~50
o
C to 60
o
C. The now dried 
89
Zr complex was 
re-dissolved in DMSO (10-20 µL) and was ready for the cell uptake and efflux 
experiments. The radiochemical purity was determined by utilising the chloroform 
extraction method. The zirconium tetrakis complexes are found in the chloroform 
layer whereas the free 
89
Zr is found the aqueous layer. 
 
6.4 Cell Cultures 
 
To determine the percentage uptake and efflux of zirconium tetrakisoxine, tropolone 
and ethyl maltol the following cell lines were used; HCT116: colon cancer, J774: 
mouse macrophage and MDA-MB-231: breast cancer. Cell lines were cultured as 
adhesion cells at 37
o
C with CO2 at 5 % under a humidified atmosphere. 
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6.5 Uptake Experiments 
 
89
Zr tetrakis; oxine, tropolone or ethyl maltol was diluted to an activity of 0.05 MBq 
in 50 µL of a serum free medium. This was then added to glass test tubes containing 
the cell line under investigation (~1 x 10
6 
cells) in 500 µL of a serum free medium. 
The percentage of uptake was determined in triplicate at 1, 15, 30, 45 and 60 minutes 
after adding the 
89
Zr tetrakis tracer to the cell line under investigation. Percentage 
uptake was determined at each of the time points by centrifuging the sample for 5 
minutes at 2500 RPM. This separated the solution into a supernatant and cell pellet. 
450 µL of supernatant was collected using a micro pipette and placed into a clean 
glass vial. The (cpm) of supernatant (S) and cell pellet (C) were placed separately 
into a gamma counter to calculate the percentage of radioactivity in the labelled cells 
in cpm (Activity in the cell pellet corrected for residual 50 µL of supernatant). This 
was calculated by the equation; (C / (C + S)) x 100. Controls included uptake of 
neutralised 
89
Zr in sodium carbonate into the cells and the determination of the 
degree of binding of the tracers to the glass test tubes. 
 
6.6 Efflux Experiments 
 
Following the method reported above the 
89
Zr tracers were allowed 30 minutes for 
uptake to occur in the respective cell lines. Efflux was measured at time points of 1, 
2, 3, 20 and 24 hrs depending on the tracer. Samples were centrifuged at ~ 2000 
RPM for 5 minutes. 450 µL of supernatant was then removed from the glass reaction 
vial. Cell pellets were washed with phosphate buffered saline (PBS) 500 µL x 2 to 
remove any excess tracer. Fresh media (with serum, 500 µL) was added to each 
reaction vial. Samples were incubated at 37
o
C until the required time point. At the 
required time point the sample was centrifuged at 3000 rpm for 5 minutes to obtain a 
cell pellet. Supernatant (~400-500 µL) from each reaction vial was placed into a new 
vial and matched to its cell pellet and both were analysed for radioactivity utilising a 
gamma counter. The calculations used in the uptake experiments were used to 
determine the percentage of efflux of the various tracers. Percentage of retention of 
the tracers in the labelled cells was calculated by the comparison of the total activity 
in the cells and the supernatant. 
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6.7 In Vitro Results and Discussion 
6.7.1 Zirconium-89 Tetrakisoxine & MDA-MB-231 Breast Cancer 
 
Radioactive zirconium arrives from the supplier in the form zirconium-89 
tetrakisoxalate, a non-neutral complex was tested alongside the neutral oxine 
complex. 
 
 
Figure 6.1: MDA-MB-231 Uptake of Zirconium-89 Tetrakisoxine 
 
Uptake of zirconium-89 tetrakisoxalate into breast cancer cell line; MDA-MB-231 
was 5.5 % over a period of 60 minutes. The uptake of zirconium-89 tetrakisoxine in 
to the cells was found to be between 16.5% to 23.9% for the breast cancer cell line. 
 
Figure 6.2: MDA-MB0231 Retention of Zirconium-89 Tetrakisoxine 
 
The retention percentage of the zirconium-89 tetrakisoxine complex in cell line 
MDA-MB-231 was found to be high with 84.0 % and 82.0 % over 20 and 24 hours 
respectively. 
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6.7.2 Zirconium-89 Tetrakisoxine & J447 Mouse Macrophage 
 
Figure 6.3: J447 Mouse Macrophage Cell Uptake of Zirconium-89 
Tetrakisoxine 
 
Uptake of zirconium-89 tetrakisoxalate was less than 4.9% % over 60 a period of 
minutes. The uptake of zirconium-89 tetrakisoxine in to the cells was between and 
21.3% to 24.0% for mouse macrophage cells; J447 over a period of 60 minutes. Both 
MDA-MB-231 and J774 the non-neutral complex zirconium-89 tetrakisoxalate have 
an uptake less than that of zirconium-89 tetrakisoxine. 
 
 
Figure 6.4: J447 Mouse Macrophage Retention of Zirconium-89 Tetrakisoxine 
 
The retention percentage of the zirconium-89 tetrakisoxine complex in cell line J774 
was found to be high at 92.0 % and 91.0 % over 20 and 24 hours respectively. This is 
the highest retention percentages out of both of the cell lines tested with the 
zirconium-89 tetrakisoxine complex. As such the zirconium-89 tetrakisoxine 
complex is a plausible candidate for in vivo studies of J447. 
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6.7.3 Zirconium-89 Tetrakistropolone & J447-Mouse Macrophage 
 
Figure 6.5: J447 Mouse Macrophage Cell Uptake of Zirconium-89 
Tetrakistropolone 
 
The uptake of zirconium-89 tetrakistropolone in to J447; mouse macrophage cells 
was found to be 21.9% over a period of 60 minutes. This uptake percentage is similar 
to that of zirconium-89 tetrakisoxine in the same cell line over the same period of 
time. 
 
 
Figure 6.6: J447 Mouse Macrophage Retention of Zirconium-89 
Tetrakistropolone 
The retention percentage of the zirconium-89 tetrakistropolone complex in cell line 
J447 was found to be 51.2% and 48.9% over 20 and 24 hours respectively. Whereas 
the uptake of this tracer is similar to zirconium-89 oxine its retention in the cells is 
significantly less. In comparison the retention rate of the zirconium-89 tetrakisoxine 
complex in cell line J774 is 40.8% percent greater over 20 hours and 42.1 % greater 
over 24 hours.  
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6.7.4 Zirconium-89 Tetrakisethyl maltol & HTC-116 Colon Cancer 
 
 
Figure 6.7: HCT-116 Cell Uptake of Zirconium-89 Tetrakisethyl Maltol 
 
The uptake of zirconium-89 tetrakisethyl maltol was found to be 43.2% after one 
hour for HTC-116; colon cancer cells. This is an excellent uptake of the tracer 
however it cannot be compared to the other tracers because they were tested against 
different cell lines.  
 
 
Figure 6.8: HCT-116 Retention of Zirconium-89 Tetrakisethyl Maltol 
 
The retention percentage of the zirconium-89 tetrakisethyl maltol complex in cell 
line HTC-116 colon cancer was found to be 36.0 %, 26.2 % and 26.2 % over 1, 20 
and 24 hours respectably. These results show that the tracer is quickly being removed 
from the cells and as such it is not a suitable candidate for further studies in in vivo 
experimental work. 
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6.7.5 Radiochemical Purity 
 
The radiochemical purity of a radiopharmaceutical synthesis is the percentage of the 
radionuclide present in its desired chemical form. In this case this is the amount of 
radionuclide percentage present in the desired tetrakis complex. Radiochemical 
purity of all the tetrakis complexes was greater than 95% .This was determined from 
solvent extractions in the case of zirconium-89 tetrakisoxine, tropolone and ethyl 
maltol. The radiochemical purity of the zirconium-89 tetrakisoxine complex was also 
determined by radiochromatography. 
 
6.7.6 Retention of Tracers on Glass Reaction Vials 
 
As a control the amount of the zirconium-89 tetrakis complexes binding to the glass 
reaction vials without cells was determined.  
 
Table: 6.2.1: Percentage of Activity Found to be Bound to Reaction Vials 
 
In the case of zirconium-89 tetrakisoxine less than 0.57% of activity was found to be 
attached to the glass reaction vials. The tracer zirconium-89 tetrakistropolone has 
less than 0.27% of activity attached to the glass reaction vials. In both of these tracers 
it can be seen that there is a low affinity of the tracer for the glass reaction vial. 
Unfortunately the zirconium-89 ethyl maltol tracer has a high affinity for the glass 
reaction vial with nearly 33% of activity being detected on the glass vial after a 
period of 60 minutes. The activity that has been found to be attached to the reaction 
vials and not the cells themselves has been deducted from overall cell labelling 
uptake percentages as in figure 6.2.7. 
Time 
(Minutes) 
Zirconium-89 
Tetrakisoxine (%) 
Zirconium-89 
Tetrakistropolone 
(%) 
Zirconium-89 
Tetrakisethyl maltol 
(%) 
1 0.13 + 0.04 0.16 + 0.00 3.70 + 0.31 
15 0.38 + 0.19 0.24 + 0.03 10.63 + 0.48 
30 0.24 + 0.14 0.14 + 0.04 18.54 + 0.13 
45 0.25 + 0.11 0.17 + 0.07 26.12 + 3.88 
60 0.29 + 0.09 0.12 + 0.08 30.61 + 1.44 
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6.8 In Vivo Experimental Method 
 
The following experimental work was conducted by Levente Meszaros, Kings 
College London utilising synthesis methods developed by the author. Work 
involving 5T33 Murine Multiple Myeloma cells in the following paper; [89Zr]-
Zr(oxinate)4 for in vivo cell tracking by positron emission tomography. 
 
6.8.1 Zirconium-89 Tetrakisoxine and Labelled White Blood Cells 
 
Male Lewis rats were injected in the left back ankle subcutaneously with 35 µg of 
lipopolysaccharide in 40 µL of saline solution. The injections took place 4 hours 
before images were taken. For a control 40 µL of saline solution was injected into 
each of the Lewis rat’s right back ankle. The rats were then injected intravenously 
with zirconium-89 tetrakisoxine (activity; 4 MBq) labelled white blood cells. Images 
were then taken at 2, 24 and 44 hours post injection. 
 
6.8.2 Zirconium-89 Tetrakisoxine and GFP-5T33 Murine Multiple Myeloma       
         Model 
 
The following animal experiments were undertaken in full compliance with the 
Animal Scientific Procedures ACT (1986) and Home Office (UK) guidelines. Male 
C57BL/KaLwRij mice were inoculated with 1.7 MBq (In111 tris oxine) or 0.6 – 0.8 
MBq (zirconium-89 tetrakisoxine) radiolabelled cells (~ 10
7
 cells) and imaged for 7 
days in preclinical SPECT/CT and PET/CT scanners. The mice were inoculated with 
0.5 MBq 
111
In tris oxine or zirconium-89 tetrakisoxine labelled 5T33 cells for ex 
vivo tissue counting and culled 7 days post inoculation.  
 
PET/CT images were acquired in a nanoScan PC in vivo pre-clinical PET/CT imager 
(Mediso Hungary). SPECT images were acquired in a nanoSPECT/CT Plus system 
(Mediso Hungary) equipped with four 1 mm high resolution pinhole collimators. 
Mice were anesthetised, cannulated and injected via the cannula with the 
radiolabelled cells as described above. 
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6.9 In Vivo Results and Discussion 
6.9.1 Zirconium-89 Tetrakisoxine & Labelled White Blood Cells 
 
PET images below of Lewis rats with zirconium-89 tetrakisoxine labelled white 
blood cells, imaged at 2 (fig 6.9), 24 (fig 6.10) and 48 (fig 6.11) hrs. 
   
     Figure 6.9: 2 Hrs               Figure 6.10:  24 Hrs   Figure 6.11: 48 Hrs 
 Post Inoculation 
89
Zr            Post Inoculation 
89
Zr  Post Inoculation 
89
Zr 
 
There is a good accumulation of the zirconium-89 oxine tracer at the 2 hr time point 
in the left back ankle. This is reduced greatly over time, seen in the PET image at 24 
hrs. In the PET image taken at 48 hrs the skeleton of the Lewis rat can be seen 
indicating that there is mostly skeletal uptake of zirconium-89 tetrakisoxine. This 
indicates that the tracer has left the cells and fallen apart. Unfortunately the quantity 
of white blood cells obtained from one rat is small compared to the required amount, 
hence it is not an easy or particular viable experiment. 
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6.9.2 Zirconium-89 Tetrakisoxine and 5T33 Murine Multiple Myeloma Model 
 
The SPECT image (figure: 6.12) below is indium-111 tris oxine acquired 7 days post 
inoculation.  PET images below are zirconium-89 tetrakisoxine 7 days (figure 6.13) 
and 14 days (figure 6.14) post inoculation.  
   
  Figure 6.12: 7 Days     Figure 6.13: 7 Days  Figure 6.14: 14 Days            
Post Inoculation 
111
In             Post Inoculation 
89
Zr  Post Inoculation 
89
Zr 
 
The imaging results of indium-111 oxine and zirconium-89 oxine labelled 5T33 cells 
at 30 mins – 2 hrs showed an initial accumulation in the lungs. The labelled myeloma 
cells rapidly migrated to the liver, spleen and skeleton of the C57Bl/KaLwRij mice 
as illustrated above. The tissue distribution of indium-111 oxine and zirconium-89 
oxine labelled cells was found to be very similar in turn suggesting that zirconium-89 
oxine is a suitable substitute for indium-111 oxine. The ex vivo results confirmed that 
the tissue distribution of radiolabelled GFP-5T33 cells was not affected by the tracers 
that they carried. 
 211 
 
 
6.10 Conclusion 
 
6.11 In Vitro 
 
6.11.1 Neutralised Zirconium-89 
 
Neutralised zirconium-89 in sodium carbonate was used as a control for the 
zirconium-89 uptake into the cell lines. Neutralised zirconium-89 was shown to have 
the lowest uptake of all of the zirconium-89 complexes at 4.9 % for J774; mouse 
macrophage cells and 5.5 % for MDA-MB-231; breast cancer cells. 
 
6.11.2 Zirconium-89 Tetrakisoxine 
 
Results of the uptake and retention experiments for the zirconium-89 tetrakisoxine 
complex were promising. There was a good level of uptake of the complex into the 
breast cancer cell line MDA-MB-231 and mouse macrophage cell line J447. 
Retention % of the zirconium-89 tetrakisoxine complex over a period of 24 hours 
was very high at 91% in cell line J774 and 82% in cell line MDA-MB-231. As the 
zirconium-89 tetrakisoxine complex had the highest retention % in the in vitro 
experiments its potential as a new radiotracer will be established in a range of in vivo 
experiments. 
 
6.11.3 Zirconium-89 Tetrakistropolone 
 
The uptake of this tracer was similar to zirconium-89 tetrakisoxine in cell line J447 
with 21.9 %. However its retention in these cells was significantly less, therefore 
zirconium-89 tetrakisoxine is the most suitable candidate out of the two for further 
studies in vivo. 
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6.11.4 Zirconium-89 Tetrakisethyl maltol  
 
The uptake percentage of zirconium-89 tetrakisethyl maltol was the highest out of all 
of the tested tracers, however direct comparison cannot be undertaken as different 
cell lines were used due to availability. The retention rate of this tracer was low and 
as such it is not a suitable candidate for further studies in in vivo experimental work. 
 
6.12 In Vivo 
 
6.12.1 Zirconium-89 Tetrakisoxine & Labelled White Blood Cells 
 
There is an accumulation of zirconium-89 tetrakisoxine labelled white blood cells in 
the lesion of the Lewis rat. This is seen in the bottom left of the PET image at 2 hrs 
(figure 6.3.1). At 24 hrs (figure 6.3.2) there is still a small amount of accumulation of 
the zirconium-89 tetrakisoxine labelled white blood cells but as can be seen in the 
image there is mostly skeletal uptake at this time point. At 48 hrs (figure 6.3.3) there 
is minimal accumulation of the zirconium-89 tetrakisoxine labelled white blood cells 
and there is a high skeletal uptake. This indicates that the tracer has not stayed within 
the cell for reasons unknown and is possible that the labelled cells have denatured 
releasing the zirconium-89 which accumulated in the bones of the Lewis rat. 
 
6.12.2 Zirconium-89 Tetrakisoxine & GFP-5T33 Murine Multiple Myeloma Model 
 
Once intravenously administered in animal models, GFP-5T33 cells are known to 
home exclusively in the spleen, liver and skeleton. The zirconium-89 labelled cells 
showed a high in vivo stability and they also have a very similar biodistribution 
pattern to indium-111 oxine labelled GFP-5T33. After inoculation of GFP-533 
myeloma cells PET imaging showed accumulation of the cells in the lungs after 30 
mins, followed by cell migrating and accumulating in the spleen and bone marrow 
after a period of 24hrs. Ex vivo tissue sampling confirmed that the location of 
radioactivity was largely in the liver, spleen and bone marrow. 
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The high renal uptake that can be seen in figure: 6.3.4 is of indium-111 oxine 
labelled cells is probably due to dead cells releasing protein bound indium-111. The 
images of the kidneys in figures: 6.3.5 and 6.3.6 show a lower uptake of the 
zirconium-89 tracer in to the kidneys suggesting that zirconium-89 is being retained 
in the cells more efficiently.  
 
Radiobiological effects of indium-111 and zirconium-89 on labelled GFP-5T33 cells 
needs to be determined. Indium-111 emits Auger electrons which can be deadly to 
cells whereas zirconium-89 emits 900 KeV positrons that possibly go past the 
nucleus resulting in zirconium-89 being less toxic to the cells. Clonogenic assay 
studies need to be undertaken to compare and confirm that indium-111 is more toxic 
to cells than zirconium-89. 
 
In conclusion within the GFP-5T33 murine multiple myeloma model the zirconium-
89 oxine labelled cells showed a higher in vivo stability than those labelled with 
indium-111 oxine.  The new zirconium-89 oxine complex is lipophilic and can be 
used to radiolabel a range of cell types. It may be a replacement for indium-111 to be 
used to image cell migration. Advantages would include improved quantification, 
resolution and sensitivity using PET instead of scintigraphy or SPECT.  
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CHAPTER 7 
Future Work and Conclusion 
7.1 Future Work 
7.1.1 Synthesis of Zirconium Tetrakisdeferiprone  
 
The synthesis of zirconium tetrakisdeferiprone was problematic when attempting 
synthesis from potassium zirconium tetrakisoxalato, with or without an excess of 
acid in the solution. As it has been possible to synthesise zirconium 
tetrakisdeferiprone from zirconium tetrachloride it may be possible to synthesise this 
complex with an excess of acid in solution, by simply neutralising the acid. It is 
possible to obtain 
89
Zr in the form zirconium-89 tetrachloride in an excess of HCl 
and as such the synthesis of this complex is probable. 
 
7.1.2 ITLC and HPLC methods for Zirconium Tetrakisethyl maltol and 
         Deferiprone 
 
The development of ITLC and HPLC methods for quality control purposes is very 
important. It is necessary to ensure a compound is pure so that once administered it is 
effective and does not deliver unnecessary radiation exposure to a patient. ITLC 
methods to identify the two complexes will require the further investigation of 
staining or radio techniques. Development of HPLC protocols for the two complexes 
will require the investigation and utilisation of more suitable HPLC columns. 
 
7.1.3 In Vitro Analysis of Deferiprone and In Vivo Analysis of Complexes 
 
If the difficulties in synthesising the zirconium tetrakisdeferiprone complex from 
potassium tetrakisoxalate or zirconium tetra chloride are overcome, in vitro and in 
vivo analysis of this complex would be of interest. The complex would fulfil some 
criteria required in the development of new 
89
Zr radiopharmaceuticals such as it 
being neutral, but it lacks lipophilic properties. Determining affinity of deferiprone 
for Zr against other metals is important. It has been reported that iron has the greatest 
affinity for deferiprone against other metals such as copper. It is important to 
determine whether deferiprone would release Zr in preference to other metals. 
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7.1.4 Diethyldithiocarbamate 
 
Diethyldithiocarbamate would be a suitable ligand to chelate to Zr and investigate for 
use in PET.  The ligand would attach to the Zr ion in a manner similar to the Zr 
complexes reported in this thesis. Bonding would occur through the sulfur atoms of 
this ligand to the Zr ion and a neutral complex would be formed. If  this complex is 
successfully synthesized it would provide a wide range of tetrakis complexes that 
could be tested in vitro/vivo as the ethyl groups of the ligand could be exchanged. 
 
Sodium diethyldithiocarbamate is an organosulfur complex, formula; NaS2CN 
(C2H5)2 and it has been previously used in a variety of medical applications. It has 
been used to treat acute nickel carbonyl poisoning in various cases with success.202 
 
 
 
 
 
 
 
 
with those of thallium-201 diethyldithiocarbamate (
201
Tl-DDC) which is a compound 
used in cerebral perfusion imaging (CPI). Results of the research in rabbits showed 
that 
99m
Tc-DDC does in fact enter the brain but is not retained as much as the 
201
Tl-
DDC compound.203 201Tl-DDC has also been investigated as an alternative to iodine-
123-N-isopropyl-p-iodoamphetamine [(
123
I) IMP] which is used to monitor cerebral 
blood flow in SPECT. The lipophilic radiopharmaceutical 
201
Tl-DDC is cheaper to 
produce than [(
123
I) IMP] and studies have concluded that the two 
radiopharmaceuticals in comparison are equivalent when studying the blood flow in 
rabbit brains.204 Human tomographic experiments were under taken with two healthy 
subjects and the results obtained with 
201
Tl-DDC show that it may be possible to for 
the radiopharmaceutical to be used in combination with SPECT for clinical 
applications.204 Diethyldithiocarbamate complexes are established and as such 
warrant investigation for possible chelation with Zr and subsequent use in PET. 
Figure: 7.1: 
 Sodium 
Diethyldithiocarbamate 
H2C
H3C
Na+
-
C2H
C3H
 
In the treatment of cancer the compound chelates to zinc. 
This resulting zinc diethyldithiocarbamate complex inhibits 
metalloproteinases. This prevents the breakdown of the 
extracellular matrix which is the first step in cancer 
metastasis and angiogenesis.184 In nuclear medicine the 
ligand has been used in several research areas. The 
properties of technetium-99m diethyldithiocarbamate 
(
99m
Tc-DDC) were compared (both in vitro and in vivo) 
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7.2 Summary of Complexes 
 
7.2.1 Zirconium Tetrakisoxine 
 
Zirconium tetrakisoxine was synthesised from zirconium tetrachloride by the 
reaction of four molar equivalents of oxine. The resulting complex was characterised 
utilising FTIR and Raman spectroscopy. Assignment of functional groups was 
undertaken utilising published work by T. Gavrilko et al163, A Patel et al164, M 
Sekkina et al and 165 Wagner et al.166 Both the 
1
H and 
13
C NMR spectroscopic data 
and CHN elemental analysis were in accord with the formation of the desired 
zirconium tetrakisoxine compound. UV-Vis analysis showed that the molar 
absorptivity of the complex is approximately four times that observed for the ligand 
in accord with the chromophore being ligand based rather than involving the Zr. 
ITLC and HPLC protocols were developed for quality control purposes. Uptake and 
retention of the complex in to cell lines was promising and the complex progressed 
to in vivo testing. In vivo testing with the 5T33 model showed that the zirconium-89 
oxine labelled cells show a higher in vivo stability than cells labelled with indium-
111 oxine. The complex was synthesised from potassium zirconium tetrakisoxalate 
in 0.1M and 1M oxalic acid if the acidic solutions were first neutralised. 
 
7.2.2 Zirconium Tetrakistropolone 
 
Zirconium tetrakistropolone was synthesised adapting the published method of 
synthesis of zirconium tetrakis isopropyltropolone143 
1
H and 
13
C NMR spectra were 
in accord with the proposed product showing ligand resonances perturbed from their 
positions in tropolone.  
1
H NMR spectroscopy and elemental analysis data suggest 
inclusion of CHCl3. FTIR and Raman spectra were assigned by comparison with 
work by Yusaku Ikegami167 and Jianlin et al.168. Electronic absorptions for tropolone 
in methanol were in accord with those observed in DMSO.182 Absorptions observed 
in zirconium tetrakistropolone have increased extinction coefficients attributed to the 
presence of four tropolone rings with enhancement by the contribution of a charge 
transfer transition.182 The complex was synthesised from potassium zirconium 
tetrakisoxalate in 0.1 M and 1M oxalic acid if the acid is first neutralised. 
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 7.2.3 Zirconium Tetrakisethyl maltol 
 
Zirconium tetrakisethyl maltol was synthesised by the reaction of four equivalents of 
ethyl maltol with ZrCl4 in tetrahydrofuran. CHN Elemental analysis data was in 
accord with the desired complex. The 
1
H NMR spectrum shows no resonance due to 
free ligand OH in the region of 8.8 ppm and the shift of the Ha and Hb protons to 
lower frequencies in relation to the ligand demonstrates the loss of aromaticity due to 
the donation of electron density to the metal.  FTIR and Raman spectra were 
assigned by comparing work by J Burges et al169, B S Parajon- Costa et al 171, 172, C Y 
Panicker et al174, K Thompson et al170 and C Wagner et al.173 An electronic 
absorption for tropolone in methanol was recorded as 268 nm having been observed 
previously in toluene at 286 nm.138 In the zirconium tetrakisethyl maltol complex this 
band due to the loss of conjugation of the enone, demonstrating the complexation by 
the carbonyl group. Zirconium tetrakisethyl maltol was also synthesised from 
potassium zirconium tetrakisoxalate in 0.1M and 1M oxalic acid once the acidic 
solution was neutralised. 
 
7.2.4 Zirconium Tetrakisdeferiprone 
 
Zirconium tetrakisdeferiprone dodeca hydrate was synthesised by the reaction of four 
equivalents of deferiprone with zirconium tetrachloride in methanol. Elemental 
analysis data fits with the inclusion of twelve molecules of water. In contrast to the 
other zirconium tetrakis complexes zirconium tetrakisdeferiprone is soluble in water 
and insoluble in chloroform suggesting a lack of lipophilicity. 
1
H NMR spectroscopy 
revealed a shift of the alkenic protons to lower frequency in relation to the ligand as 
expected due to electron density donation to the metal. IR and Raman spectra were 
assigned by comparison with Chromium tris deferiprone dodeca hydrate144 and iron 
tris deferiprone.177 The FTIR spectrum displays a broad band is due to the waters of 
crystallisation and four strong bands in the region 1600-1400 cm
-1
 characteristic of 
coordinated 3-hydroxy-4-pyridinones. The intense absorptions in the 280-300 nm 
region of the UV spectrum can be assigned to both hydroxyl and carbonyl Zr(IV) 
ligand to metal charge transfer.144 Numerous attempts to prepare the complex from 
neutralised acidic solutions failed. 
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7.3 Overall Conclusion 
 
The aim of this PhD research was to produce a range of Zr complexes of the general 
form ZrL4 where L is a bidentate uninegative ligand. These Zr complexes needed to 
be neutral and able to diffuse into cells and dissociate easily. Determining the 
usefulness of these Zr complexes in PET medical imaging applications was the final 
goal of this research. All of these aims were fulfilled and are reported in this thesis. 
 
Methods to synthesise the neutral complexes; zirconium tetrakis; oxine, tropolone, 
ethyl maltol and deferiprone under a range of conditions were developed. 
Characterisation of the zirconium tetrakis complexes was undertaken with 1H and 13C 
NMR, FTIR, Raman spectroscopy, UV-Vis spectroscopy and CHN elemental 
analysis. HPLC and ITLC methods to analyse the zirconium tetrakisoxine and 
zirconium tetrakistropolone complex were developed. These methods can be used for 
quality control purposes in the process of radiolabeling to determine radiochemical 
purity. 
 
Cell uptake and efflux studies showed that zirconium tetrakis; oxine, tropolone and 
ethyl maltol complexes are able to diffuse into cells with varying levels of uptake 
with zirconium-89 tetrakisoxine having the highest retention percentage  in J774; 
mouse macrophage cells. The in vitro evaluation of the three potential radiotracers 
resulted in zirconium tetrakisoxine being investigated as a lead compound to be used 
in in vivo studies.In the GFP-5T33 murine multiple myeloma animal model 
zirconium-89 tetrakisoxine labelled cells demonstrated a higher level of in vivo 
stability than those labelled with indium-111 tetrakisoxine. However radiobiological 
effects still need to be determined. 
 
The use of 89Zr complexes in PET have the benefits of longer time periods for studies 
and no known biological interactions with 89Zr becoming increasingly available. 
Zirconium-89 tetrakisoxine labelled cells have shown high in vivo stability with a bio 
distribution pattern that is similar to that of indium-111 tetrakisoxine. The developed 
complexes and especially zirconium-89 tetrakisoxine have the potential to become 
effective PET imaging agents. 
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Appendix 
A.1 Equipment and Materials 
A.1.1 Chapter 2, Synthesis Methods of Zr Complexes. 
 
The following equipment and materials were used throughout the synthesis of all of 
the zirconium based complexes reported in chapter 2 of this thesis. 
 
 100 mL glass volumetric flask with plastic stopper ± 0.10 mL, manufacturer: 
Volac. 
 150, 250 mL glass conical flasks, manufacturer: Pyrex. 
 50 mL glass measuring cylinder, Class B, ± 0.5 mL, manufacturer: 
Fisherbrand. 
 Air tight glass bottles with plastic lids, sizes: 100 mL, 50 mL, 25 mL, 
manufacturer; Simax.  
  Buchi B465 water bath with power cord; 240 Volt 50-60 Hz 11 Amps 1200 
watts. 
 Buchi Rotovapor R-114 rotary evaporator; 240 Volt 50-60 Hz 35 Watt. 
 Büchner funnel and vacuum conical flask. 
 Electric hot plate with magnetic stirrer function; 250V, 750 watts, 
manufacturer Bibby Stuart. 
 Electric oven, 100 watts, 3.5 amps, 220/240 volts, 50/60Hz, model: 
GP/40CLAV/250/HYD, manufacturer: Scientific Laboratory Supplies. 
 Electromantle MA Solid State Stirrer; EMA025/CE MK5, 230 V, 170 W.  
 Filter paper, 6 cm diameter, for crystalline precipitates, maximum ash per 
circle .000036 grams, No 43, manufacturer WHATMAN. 
 Fisherbrand; Immersion thermometer general purpose/stirring 76 mm 
immersion red spirit filled amber graduations white backed -10°C to 110°C x 
1°C 305mm. 
 Glass spatula, spoon and paddle ends, dimensions; 7 mm x 200 mm. 
 Glass stirring rod 25 cm in length. 
 Grant water bath; Grant Instruments (Cambridge) Ltd, JB2, 3,3A/220-
240V/50-60 Hz. Serial No: 9826. 
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 HI 98103 pH meter (Checker®) with HI 1270 electrode. Manufacturer: 
HANNA instruments. Specifications: range; 0.00 to 14 pH, resolution 0.01 
pH, accuracy ±0.2 pH, environment; 0 to 50°C (32 to 122°F); RH max 95%. 
 Metal spatula, nickel stainless steel rod, dimensions; 4mm x 200mm. 
 Nalgene 180 PVC Metric tubing; Various Lengths. 
 Narrow range pH indicator paper (pH 7-9), manufacturer: WHATMAN-
BHD. 
 Octagon Magnetic Stirrer; 20 mm x 8 mm. 
 Pestle and Mortar; capacity 30 mL. 
 Plastic disposable narrow mouth bottle pipettes, manufacturer: Nalgene. 
 Purified water obtained by reverse osmosis at the School of Physical 
Sciences, University of Kent. 
 PVC Metric tubing, various lengths and diameters. 
 Quickfit; glass cooling column, 19/26, 19/26, 153 cm length. 
 Quickfit; glass round bottomed flask, 250 mL capacity, 24/29. 
 Quickfit; glass size adapter, B19/26, B34/35, DA 25. 
 Quickfit; glass stopper 19/26. 
 Quickfit; soxhlet extractor, 60 mL borosilicate glass 34/35 socket 24/29 cone. 
 Whatman cellulose extraction thimbles. Internal diameter x external length 30 
mm x 100 mm, external diameter x external length 32 mm x 100 mm. 
 
A.1.2 Chapter 2, Nuclear Magnetic Resonance Spectroscopy. 
 
 Dimethyl Sulfoxide-D6 (D, 99.9%), Cambridge Isotope Laboratories, Inc. 
 Deuterium Oxide (>99.8%), Fluka Chemika. 
 Plastipak, 2 mL sterile syringe (PP), Becton Dickson Ireland. 
 7 mL clear neutral squat form vial, Kent University stores. 
 Minisart, single use filter unit, Sterile, 0.45µm, Sartorius stedim biotech. 
 BD Sterile microlance 3, 25G 0.5 X 16mm, BD Drogheda, Ireland. 
 Economy NMR Tube, thin walled, O.D: 5mm, Length 20 cm, ASTM Type 1 
Class B Borosilicate Glass (N51), Goss Scientific Instruments Limited. 
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A.1.3 Chapter 4, Synthesis of Zirconium Tetrakis   
          Complexes under Conditions Compatible with Radiopharmacy. 
  
 Borosilicate glass funnel, 100 mm diameter; Pyrex® 
 Safety control,hot plate magnetic stirrer, 1100 rpm; IKA® RTC IKAMAG™  
 Temperature controller electronic contact thermometer with 3 operating 
modes, stainless steel, 1/cs; IKA
®
 ETS-D5. 
 Laboratory stand and clamp, chemistry retort stand; Griffin & George. 
 500 mL capacity borosilicate glass separating funnel conical, with plain glass 
key and 24/29 glass stopper; Pyrex®. 
 
A.1.4  Chapter 5, Ultraviolet-Visible Spectroscopy. 
 
 1 mL and 10 mL Glass Pipettes; VOLAC® 
 500 mL, 100 mL & 10 mL Volumetric Flasks (Boro) Fisherbrand 
 Acetonitrile: HPLC Gradient Grade, Fisher Chemical 
 Methanol: HPLC Gradient Grade, Fisher Chemical 
 Millipore Water (Prepared utilising Thermo Scientific Easy Pure II) 
 Quartz Absorption Cuvettes, 400 µL, Pathlength 10mm, 25 x 12.5 x 12.5; 
Sciensco 
 
A.1.5 Chapter 5, High Performance Liquid Chromatography Analysis. 
 
 Sterile Syringe (PP), 2 mL, Plastipak, Becton Dickson. 
 Ministart, Single use filter unit, non-pyrogenic, Sartiorius stedim biotech. 
 Sample Vials:   2 mL screw top clear glass vial with PTFE/silicone pre-slit 
grey cap closure, 12 x 13 mm, Perkin Elmer. 
 Methanol: HPLC Grade, Fisher Chemical. 
 Acetonitrile: HPLC Grade, Fisher Chemical. 
 Millipore Water (Prepared utilising Thermo Scientific Easy Pure II). 
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A.1.6 Chapter 5, 1 Instant Thin Layer Chromatography 
 
 250 mL beaker, Fisher Brand 
 Bromocresol Green Indicator; Fisions 
 Micro Capillary Tubes, L = 75 + 1.00 mm x D = 1.15 + 1.00 mm; GMBH 
 Checker Pocket Sized pH Meter, Range: 0-14 pH, Hanna instruments 
 Citric Acid > 99.5 %; Sigma Aldrich 
 Ferric Chloride Hexahydrate 97%, Aldrich Chemicals 
 Filter Paper, 1 Qualitative Circles 70mm, Whatman 
 Handheld UV Lamp, LW/SW, 6W, UVGL-58, 254/365 nm 
 Instant Thin Layer Chromatography Silica Gel (ITLC-SG) Plates; Varian 
 Iodine, 99.8% ACS Reagent; Sigma - Aldrich 
 Millipore Water (Prepared utilising Thermo Scientific Easy Pure II) 
 Potassium Permanganate, > 99.0%; Sigma-Aldrich 
 Tri Sodium Citrate, 99.5%; Fisons Analytical 
 Video Spectral Comparator, VSC4CX; Foster and Freeman 
 
A.1.7 Chapter6, The In Vitro and In Vivo Analysis of Zirconium Compounds. 
 
 Auto Pipette, Volume 0.1 - 2 µL & 100 – 1000; Star Labs 
 Automated Cell Counter, Countess™ & Trypan Blue Solution; Sigma 
Aldrich 
 Centrifuge, FB15024; Fisher Scientific &, Rotina 380R; Hettich Zentrafugen 
 Chloroform (99.8+ %); Fisher Scientific 
 CRC ® -25R Dose Calibrator; Capintech 
 Dimethyl Sulfoxide ≥99.7 %; Fisher Scientific 
 Falcon Tubes, 15 mL; BD Biosciences 
 Fix Test pH Strips 0 - 14, 100 colour fixed; Macherey-Nagel 
 Gamma Counter Personal Computer & Eden Term v1.21 Software 
 Gamma Counter, Compugamma model, 1282; LKB Wallac 
 Glass Sample Bottle and Screw Cap Septum 5 mL; Sigma Aldrich 
 Glass Test Tubes, Glass Borosilicate 12 mm x 50 mm, Pyrex 
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 Graduated Filter Tips, 2 µL & 1000 µl; Star Labs 
 Hanks Balanced Salt Solution (HBBS), (with/without phenol red); Sigma 
Aldrich 
 Interlocking Lead Brick Shielding 40 mm; Britec 
 LB 124 SCINT monitor for α- and β-γ-measurements; Berthold Technologies 
 Lead Cylinder Sample Container 
 Microcentrifudge Tube 1.5 mL Blue; Cliklok 
 Standard Viewing Barrier Pb Glass 30 mm Lead Equivalence; Britec 
 
Cells 
 
HCT116: Colon Cancer Cells.  J774: Mouse Macrophage Cells. 
MDA-MB-231: Breast Cancer Cells.  White Blood Cells. 
GFP-5T33: Mouse-Myeloma Cells. 
 
89Zr 
 
89Zr in 1 M oxalic acid. Radioactive concentration between 740 – 1850 MBq/ mL 
(20 – 50  mCi/ mL), Radionuclide purity >99.9% 89Zr at calibration. Supplier; iba 
Molecular, Belgium or supplied from Perkin-Elmer in 0.1 M in oxalic acid
  
2
2
4
 
 
 
 
Table A1 below contains information regarding the range of compounds used in all of the experiments reported in chapter 2 of this 
thesis. Each compound has a full description, its chemical formula and supplier details. 
 
Compound IUPAC Name 
Chemical 
Formula Supplier 
1,4-Dioxane 1,4-dioxacyclohexane C4H8O2 Sigma Aldrich 
Oxine Quinolin-8-ol C7H9NO Sigma Aldrich 
Chloroform (99.8+ %) Chloroform CHCl3 Fisher Scientific 
Deferiprone (98%) 3-hydroxy-1,2-dimethyl-4(1H)-pyridon C7H9NO2 Aldrich 
Diethyl ether (99+ %) Ethoxyethane C4H10O Fisher Scientific 
Ethanol (99.8%) Ethanol C2H6O Fisher Scientific 
Ethyl maltol (99%) 2-ethyl-3-hydroxy-4-pyranone C7H8O3 SAFC 
Hexane Hexane C6H14 Fisher Scientific 
Piperidine Piperidine C5H11N GPR 
Tetrahydrofuran (99.6%) Oxolane C4H8O2 Fisher Scientific 
Tropolone (98%) 2-hydroxy-2,4,6-cycloheptatrien-1-one C7H6O2 Aldrich 
Zirconium (IV) chloride Zirconium tetrachloride ZrCl4 Aldrich 
Table A1 
. 
 
  
2
2
5
 
Table A2 below contains information regarding the range of compounds used in all of the experiments reported in chapter 4 of this 
thesis. Each compound has a full description, its chemical formula and supplier details. 
 
Compound IUPAC Name Chemical Formula Supplier 
Absolute ethanol (99.9%) Ethanol C2H6O Fisher Chemical 
Ammonia (35%) Azane NH3.H2O Fisher Chemical 
Chloroform (99.8+ %) Chloroform CHCl3 Fisher Scientific 
Deferiprone 3-hydroxy-1,2-dimethyl-4(1H)-pyridon C7H9NO2 Aldrich 
Diethyl ether (99+%) Ethoxyethane (C2H5)2O Fisher Chemical 
Ethanol (99.7%) Ethanol C2H5OH BHD 
Ethyl Maltol 2-ethyl-3-hydroxy-4-pyranone C7H8O3 SAFC 
Hydrochloric acid Chlorane, Hydrogen chloride HCl Sigma Aldrich 
Oxalic acid Ethanedioic acid H2C2O4 Sigma Aldrich 
Oxalic acid dihydrate Ethanedioic acid dihydrate C2H2O4.2H2O Sigma Aldrich 
Oxine Quinolin-8-ol C9H7NO Sigma Aldrich 
Potassium oxalate monohydrate Dipotassium oxalate hydrate C2K2O4.H2O Sigma Aldrich 
Potassium zirconium tetrakisoxalato Potassiumoxalatozirconate(IV) K4(C2O4)4.5H2O Synthesised at UKC 
Sodium hydrogen carbonate Sodium hydrogen carbonate NaHCO3 Sigma Aldrich 
Sodium hydroxide Sodium hydroxide NaOH Fisons 
Tropolone (98%) 2-hydroxy-2, 4, 6-cycloheptatrien-1-one C7H6O2 Aldrich 
Zirconium (IV) chloride Zirconium tetrachloride Cl4Zr Sigma Aldrich 
Zirconyl chloride octahydrate Zirconyl chloride octahydrate Cl2OZr.8H2O Sigma Aldrich 
Table A2 
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A.2 Settings and Specifications 
A.2.1 NMR Settings 
 
ECS 400 NMR Spectrometer 
 
Observation nuclei 1H/19F, 31P to 15N, 39K to 109Ag 
Observation frequency 1H: 400 MHz, 13C: 100 MHz 
Sensitivity for 13C _190 (ASTM) 
Sensitivity for 1H _280 (0.1% ethyl benzene) 
Variable temperature range _100 to 180° C (dependant on probe) 
 
Hardware Configuration 
 
Alternate HF receiver gain limit: 80 [dB] 
Alternate HF receiver gain point: 200000 [Hz]  
Alternate LF receiver gain limit: 60 [dB] 
Alternate LF receiver gain point: 150000 [Hz] 
IRM crossover point:   490000000 [Hz]  
90 [deg] Pulse attenuation default: 79[dB] 
90 [deg] Pulse width default:  1[us] 
Auto shim delay:   3600 [s] 
Lock settle point:   4096 
Optimum lock phase width:  60 [deg] 
Shim drift correction interval: 60 [sec] 
Shim system type:   DM 
 
Dell Personal Computer 
 
Operating System: Windows 7 Professional 
Processor:   Intel® Core ™ i3-2120 CPU @ 3.30 GHz 
Installed Memory: 4.00 GB (3.24 usable) 
System Type:  32-bit Operating System 
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A.2.2 FTIR Settings and Specifications 
 
Shimadzu IRAffinity-1 Fourier Transform Infrared Spectrophotometer 
 
Michelson interferometer (30º incident angle) 
Equipped with dynamic alignment system (JPN patent No.2115670, 3613171) 
Sealed interferometer with auto dryer (JPN registration of utility model No.3116465) 
Wave number range: 7,800 to 350 cm-1 
Resolution:  0.5, 1, 2, 4, 8, or 16 cm-1 
S/N ratio: 30,000:1 or higher (peak-to-peak, 4 cm-1 resolution, in a 
neighbourhood of 2,100 cm-1, 1-minute accumulation) 
Dimensions:  514(W) X 606(D) X 273(H) mm 
Weight:  35 kg 
 
Standard Specac Golden Gate ATR Single reflection diamond ATR accessory 
 
ATR Crystal Diamond: Type IIIa Diamond 45° 2 mm x 2 mm 
Germanium: Ge 45° 4 mm x 4 mm 
Accessory Transmission Range: 6500 -600 cm-1 (with ZnSe lenses), 6500 - 400cm-1 
(with KRS-5 lenses), 5200 – 650 cm-1 (with ZnSe lenses or KRS-5 lenses) 
Refractive Index at 1000 cm
-1
: 2.4 4.0 
ATR Plate: Diamond brazed into Tungsten Carbide Disc Germanium Sampling 
Area: (50% of Transmitted Energy): 0.8 mm diameter 0.8 mm diameter 
Maximum Applied Force: 100 cNm (torque) 160 lbs or 128 lbs, 0.36 KBar. 
Depth of Penetration 2.0μm (For sample of Refractive Index 1.5 @1000 cm-1) 
0.7μm (For sample of Refractive Index 1.5 @1000 cm-1) 
 
Viglen Personal Computer 
 
Operating System: Windows 7 Professional 
Processor:   Intel® Core ™ 2 Duo CPU E7600 @ 3.06 GHz 
Installed Memory: 4.00 GB (3.18 usable) 
System Type:  32-bit Operating System 
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A.2.3 Raman Settings and Specifications 
 
LabRAM HR UV-VIS-NIR Raman Spectrometer 
 
Detector (s):   LN2 cooled CCD detectors 
Measurement mode (s): Raman, photoluminescence 
Laser source:   224, 247 and 325 nm (Opt 532, 633, 785 nm) 
Focal length:   800 nm 
 
Hardware Configuration 
 
Acquisition time (s):  2 
Accumulation:  10 
Range (cm-1):   100-2000 
Windows:   3 
Delay time (s):  0 
ICS correction:  On 
Detector:   Synapse 
Objective:   x 50 LWD NIR 
Grating:   600 
ND filter:   25 % 
Laser:    784.14 
Slit:    100.021 
Hole:    799.986 
Stage XY:   Märzhäuser 
Stage Z:   Märzhäuser 
 
Dell Personal Computer 
 
Operating System: Microsoft XP: Professional Service Pack 3, Version 2002 
Processor:   Pentium® Dual Core E5800 Dual Core CPU @ 3.20 GHz 
Installed Memory: 4.00 GB (3.46 usable) 
System Type:  32-bit Operating System 
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A.2.4 HPLC Settings and Specification 
 
UltiMate
®
 3000 Standard LC systems with UltiMate
®
 3000 Solvent Rack SR-3000 
 
Hardware Configuration 
 
UltiMate
®
 3000 Quaternary Analytical Pump LPG-3400SD 
 
Operating flow rate range:  200 µL min – 10 mL min  
Operating pressures:   Maximum, 620 bar (9000 psi) 
Pump module pressure lower limit: 10 bar 
Pump module pressure upper limit: 350 bar 
Pump module pump flow nominal: 1.000 mL min 
Pump module pressure maximum flow ramp up 6.000 mL/min
2
 
Pump module pressure maximum flow ramp up 6.000 mL/min
2 
 
UltiMate
®
 3000 Autosampler Column Compartment ACC-3000 
 
Pulled-loop injection:  Full & partial-loop injections 
Injection volume ranges: 1–10 mL, partial-loop, 20 μL full-loop. 
Wash speed:   50.000 µL / s 
Wash volume:   150.000 µL 
Sample height:  2.000 mm 
Waste speed:   50.000 µL / s 
Dispense delay:  0.000 s 
Dispense speed:  20.000 µL / s 
Draw speed:   5.000 µL /  
Flush Volume:  80.000 µL 
Column oven ready temp: 1.0 
o
C 
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UltiMate
®
 3000 RS Diode Array Detector DAD-3000RS 
 
Noise:      <±7 µAU 
Drift:     <0.5 mAU/h  
UV 3D Field Min Wavelength: 190.0 nm 
UV 3D Field Max Wavelength: 800.0 nm 
UV Response Time:   1.000 (s) 
UV Data Collection Rate:  5.0 [Hz] 
UV Vis 1 Wavelength:  Variable 
UV Vis 1 Bandwidth:   4 [nm] 
UV Vis 1 Ref Wavelength:  Off 
UV Vis 2 Wavelength:  Variable 
UV Vis 2 Bandwidth:   4 [nm] 
UV Vis 2 Ref Wavelength:  Off 
UV Vis 3 Wavelength:  Variable 
UV Vis 3 Bandwidth:   4 [nm] 
UV Vis 3 Ref Wavelength:  Off 
UV Vis 4 Wavelength:  Variable 
UV Vis 4 Bandwidth:   4 [nm] 
UV Vis 4 Ref Wavelength:  Off 
 
Dell Personal Computer 
 
Operating System: Windows 7 Professional 
Processor:   Intel® Core ™ Duo CPU E7600 @ 3.06 GHz    3.06 GHz 
Installed Memory: 4.00 GB (3.18 usable) 
System Type:  32-bit Operating System 
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A.2.5 UV-Vis Settings and Specifications 
 
Shimadzu UV-1800 
 
Resolution:     1 nm 
 
Hardware Configuration 
 
Wavelength Range (nm):  190-1100 
Scan Speed:    Fast 
Sampling Interval (nm):  0.5 
Scan Mode:    Single 
Repetitions:    2 
Measuring Mode:   Absorbance 
Slit Width (nm):   1.0 Fixed 
Light Source Change Wavelength: 340nm 
S/R Exchange:   Normal 
Attachments:    None 
 
Dell Personal Computer 
 
Operating System: Windows 7 Enterprise 
Processor:   Intel® Core ™ i5-3470 CPU @ 3.20 GHz 
Installed Memory: 4.00 GB (3.41 usable) 
System Type:  32-bit Operating System 
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A.2.6 Melting Point Apparatus Specifications 
 
Stuart SMP3 Melting Point Apparatus 
 
Dimensions:    L 180 mm, H 259 mm, W 300 mm 
Maximum Temperature: 360°C  
Memory Storage:   8 x temperature readings per sample tube tested  
Number of Samples:  3 
Temperature range:   0.1°C  
Temperature resolution: Ambient to 360°C  
Ramp rate:   0.5° to 10°C minute  
Net weight:   8 lbs  
Sensor:    PT100 
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